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CHAPTER I 
INTRODUCTION ANO AIMS OF THE STUDY 

1.1 INTRODUCTION 
The syndrome of infantile autism was first described by Leo Kanner in 
1943 in his famous paper "Autistic disturbances of affective contact" 
(Kanner L., 1943). Kanner considered the core problem of the 11 children 
he originately described:"the inability to relate themselves in the 
ordinary way to people and situations from the beginning of 1 ife". 
Infantile autism is a behavioral syndrome .. It is generally believed that 
it is etiologically heterogeneous. If one considers the sine qua non of 
the syndrome of infantile autism to be the presence of a severe and 
unique distortion of social relating and communication~ the uniqueness of 
the syndrome suggests one underlying pathophysiological mechanism. 
Originally Kanner understood the peculiar indifference to social contact 
and the lack of communicative intent as arising sui generis in the 
autistic child itself and suggested an inherited predisposition (Kanner 
L., 1943, 1944). Later he thought the social and communicative deficits 
were attributed to psychopathological influences in the family environ-
ment (Kanner L., 1949). Subsequently up to the 1960's, psychodynamic 
theories predominated the litterature (e.g. Fraknoi and Ruttenberg, 
1971). But in the early 1970's it appeared that much evidence had 
accumulated pointing in other directions, and reviewers (Ornitz, 1973; 
Cantwell et al., 1978) concluded that extensive clinical investigation 
had provided no compelling evidence of any unusual parental charac-
teristics of family interactions in families of autistic children. 
Encouraged by the rapid advance of basic neuroscience and findings in 
schizophrenia, depression, and other psychiatric disorders new research 
approaches and theories appeared. 
Neurophysiologic hypotheses were put forward in which infantile autism is 
seen as secondary to a disorder of arousal (Hutt et al., 1965; Hutt and 
Hutt, 1968), as secondary to a specific cognitive (language related) 
disorder (Rutter, 1978,1982) and as secondary to a disorder of sensory 
modulation (Ornitz and Ritvo , 1968; Reichler and Schopler, 1971; Ornitz, 
1974, lg83, 1985). These hypotheses suggested an underlying area of 
neurophys i o 1 ogi ca 1 dysfunction. In recent neuroanatomic hypotheses 
infantile autism is considered to be secondary to temporal lobe pathology 
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(Delong, 1978; Delong et al., 1981), to dysfunction of dopaminergic 
mesal imbic cortical and neostriatal structures (Damasio and Maurer, 1978) 
and to dysfunctions of brainstem mechanisms involving (vestibular) 
modulation of sensation and motility (Ornitz, 1974, 1978, 1983). (For a 
review, see Ornitz, 1983.) 
Evidence from neurochemical and neuropharmacological studies of autistic 
children has often been of importance in development and support of these 
newer theories .. Neurochemical studies have been undertaken in order to 
examine aspects of neural transmission in the central and the peripheral 
nervous system. Typically levels of neurotransmitters, their metabolites 
and associated enzymes in blood, urine, or cerebrospinal fluid were 
measured. In neuroendocrine studies the functioning of central monoamine 
neurotransmitters involved in controlling hormone release has been 
assessed by measuring hormone levels after administration of specific 
pharmacological agents. 
Recently research has widened further. Genetic aspects and immunological 
factors are the new targets of research efforts. 
Currently~ infantile autism is viewed as a neuropsychiatric disorder of 
childhood and the scientific efforts to uncover its causes and underlying 
pathophysiologic mechanisms may serve as a model in modern research in 
child psychiatry. 
1.2 AIMS OF THE STUDY 
The topic of this thesis is neurochemical aspects of infantile autism. 
The experimental work is centered around the most robust and consistant 
neurochemical finding in child psychiatry, namely that group mean whole 
blood serotonin (5-Hydroxytryptamine, 5-HT) values are increased 
approximately 50% in autistic populations. Although the elevation has 
been observed many times~ a number of basic questions are unanswered in 
respect of characterizations of this 5-HT elevation~ and the elucidation 
of its causes. 
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In chapter II the behavioral syndrome of infantile autism will be 
described and the basic findings which support an organic etiology will 
be briefly outlined. 
In chapter III the neurochemical findings will be reviewed with an accent 
on research related to the catecholamines and neuroendocrine functioning. 
In chapter IV research in autism related to the serotonergic system will 
be extensively reviewed and critically discussed. This discussion will 
also include an examination of the original findings which are presented 
in the appendix. Findings concerning the "hyperserotonemia" of infantile 
autism will be critically discussed and related to other studies of the 
serotonergic system and further possible lines of research will be 
suggested. 
The appendix is comprised of papers based on original experimental work 
related to "hyperserotonernia" in infantile autism. 
Appendix I deals with whole blood serotonin and tryptophan values in 
autistic individuals and nonnal controls and its relationship to age, 
sex, platelet count and medication. 
Appendix II describes again whole blood serotonin values and platelet 
count in autistic individuals and actresses to their inter-relationship 
and effects of medication and deals with the stability over time of whole 
blood serotonin values in unmedicated and medicated autistic individuals. 
Appendix III adresses to the question whether an increased production of 
serotonin in the gut might be a cause of· hyperserotonemia in autistic 
individuals by measuring the urinary excretion of 5-hydroxyindoleacetic 
acid, the major 5-HT metabolite. 
In Appendix IV an aspect of platelet membrane function is assessed as 
being related to whole blood serotonin by measuring platelet imipramine 
binding in autistic subjects. 
In Appendix V and VI the presence of primitive reflexes in autistic 
subjects and the relationship of the snout reflex and the visual rooting 
reflex to blood serotonin levels are described. 
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CHAPTER ll 
INFANTILE AUTISM: A NEUROPSYCHIATRIC DISORDER OF CHILDHOOD 

2.1 INTRODUCTION AND CLASSIFICATION 
Infantile autism is a syndrome that, since its first description by 
Kanner (1943, 1944), has raised many questions for the childpsychiatrist. 
The symptomatology differs from child to child in seriousness and 
character and may change in the course of time~ There are no anamnestic 
features pointing to one origin of the illness and there are no specific 
bodily symptoms. These facts hamper the diagnosis (Ornitz et al., 1976) 
and this confusion becomes evident in differences in diagnostic 
terminology. The terms childhood autism, primary autism, infantile 
autism, atypical development, childhood schizophrenia, symbiotic 
psychosis and early onset psychosis, all refer to nearly the same 
symptomatology .. The work of the American National Society for Autistic 
children (Ritvo and Freedman, 1978), The American Psychiatric Association 
(DSM-Ill, 1980) and Rutter and coworkers (Rutter, 1978b) brought more 
unity of meaning in the description and definition of this syndrome. 
In clinical practice and for research purposes the criteria found in the 
third edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-lll, 1980) are generally accepted. In the DSM-lll 
infantile autism is brought under the general heading of the Pervasive 
Developmental Disorders of Childhood. These disorders are characterized 
by distortions, deviations and delays in the development of social, 
language and motor behaviors, attention, perception and reality testing. 
The DSM-III distinguises among 5 diagnostic categories within the group 
of Pervasive developmental disorders of childhood: 
- Infantile autism, full syndrome present (299.00) 
- Infantile autism, residual state (299.01) 
Childhood onset pervasive developmental disorder, full syndrome present 
(299.90) 
Childhood onset pervasive develomental disorder, residual state 
(299.91) 
Atypical pervasive developmental disorder (299.8X). 
The criteria for these diagnostic categories are given in Table I. The 
DSM-Ill is a multiaxial system. Mental retardation can be diagnosed if 
present (Axis I) and a concomitant medical condition or disease can be 
diagnosed on Axis Ill. 
19 
Table I 
Diagnostic and Statistical Manual of Mental Disorders (DSM-1 I I), 1980 
Diagnostic Criteria for Infantile Autism 
A. Onset before 30 months of age. 
B. Pervasive lack of responsiveness to other people (autism). 
C. Gross deficits in language development. 
D. If speech is present, peculiar speech patterns, such as immediate 
and delayed echolalia, metaphorical language, pronominal reversal. 
E. Bizarre responses to various aspects of the environment, e.g. 
resistance to change, peculiar Interest in or attachments to animate 
or inanimate objects. 
F. Absence of delusions, hallucinations, loosening of associations, 
and incoherence as in schizophrenia. 
Diagnostic Criteria for Infantile Autism, Residual State 
A. Once had an illness that met the criteria for infantile autism. 
B. The current clinical picture no longer meets the full criteria for 
infantile autism, but signs of the illness have persisted to the 
present, such as oddities of communication and social awkwardness. 
Diagnostic Criteria for Childhood Onset Pervasive Developmental Disorder 
A. Gross and sustained impairment in social relationships, e.g. lack of 
appropriate affective responsivity, inappropriate clinging, asociality, 
1 ack of empathy. 
B. At least three of the following: 
1. Sudden excessive anxiety manifested by such symptoms as 
free-floating anxiety, catastrophic reactions to everyday occur-
rences, inability to be consoled when upset, unexplained panic 
attacks. 
2. Constricted or inappropriate affect, including lack of appropriate 
fear reactions, unexplained rage reactions, and extreme mood 
l abi 1 i ty. 
3. Resistance to change in the environment (e.g. upset if dinner 
time is changed), or insistence on doing things in the same man-
ner every time (e.g. putting on clothes always in the same order). 
4. Oddities of motor movement, such as peculiar posturing, peculiar 
hand or finger movements, or walking on tiptoe. 
5. Abnormalities of speech, such as question-] ike melody, monotonous 
voice. 
6. Hyper- or hypo-sensitivity to sensory stimuli, e.g. hyperacusis. 
7. Self-mutilation, e.g. biting or hitting self, head banging. 
C. Onset of the ful 1 syndrome after 30 months of age and before 12 years 
of age. 
D. Absence of delusions, hallucinations, incoherence, or marked 
loosening of associations. 
20 
Table 1 - continued 
Diagnostic Criteria for Childhood Onset Pervasive Developmental 
Disorder, Residual State 
A. Once had an illness that met the criteria for childhood onset per-
vasive developmental disorder. 
B. The current clinical picture no longer meets the ful 1 criteria for 
the disorder, but signs of the il ]ness have persisted to the present, 
such as oddities of communication and social awkwardness. 
Atypical Pervasive Developmental Disorder 
This category should be used for children with distortions in the 
development of multiple basic psychological functions that are in-
volved in the development of social skills and language and that 
cannot be classified as either infantile autism or childhood onset 
pervasive developmental disorder. 
2.2 DESCRIPTION OF THE SYNDROME 
Infantile autism is a syndrome defined in terms of behavior, the typical 
symptoms of which exist before the age of thirty months. The most 
significant symptoms are: 
- a disturbance in speech- and language development and the non-verbal 
communicative skills: retardation of speech development or mutism; if 
speech exists, 
capability of 
deviations in syntaxis and articulation; 
using symbols; inability of abstract 
absent or poor 
reasoning and 
comprehension; neologisms; echolalia; absence of communicative gestures, 
etc. 
- a disorder in the relationship with people, objects and events: failure 
to develop a speci fie relationship with primary caretakers; absence of 
eye contact, a failure to play with peers and make friends, inadequate 
use of toys, stereotyped use of objects, a particular sensitivity for 
specific sequence of events, in which interruption of it may lead to 
panic, etc. 
-a disturbance in the reaction on sensory stimuli; hyper-, hyporeactive, 
or both alternating: excessive interest in visual details; staring; 
attention for changes in light fall, excessive reactions on noises, or no 
reaction at all, touching, smelling, licking of inedible objects, 
increased pain threshold; attention for self produced sounds; excessive 
rubbing on surfaces; turning and rythmic moving of the body, attention 
21 
for spinning objects. 
In general the motor-, socially adaptive, and 
and 
cognitive development are 
the mutual balance in the seriously retarded, hampered or regressed 
development has been disturbed. There is a serious disturbance of the 
ability of expression, the estimation and appreciation of emotions and in 
the regulation of anxiety and excitement. 
Infantile autism should be distinguished from 
- developmental aphasia, in which there is serious expressive, and often 
less serious receptive language disturbance. In comparison to autistic 
children, aphasic children have a relatively more intact inner language. 
They make use of gestures and mime and are communicatively directed on 
the other. Aphasic children are often hyperactive, and they find it 
difficult to focus their attention on one thing. They often develop 
secondary behavioral problems. Some of these children have autisticlike 
features. In a recent longitudinal study (Paul et al., !983) on 28 
chi1 dren diagnosed as aphasic, ha 1 f of the children evidenced some 
features similar to autism. The overlap of this group with autism may 
present a diagnostic problem. 
- mental retardation. This is diagnosed on the basis of psycho-metric 
examination. The intellectual functioning and the adaptive abilities are 
well below average (IQ < 70). The social and emotional capabilities 
pointing to social attachment, and the development of speech 
are in agreement with the global general level of 
and language 
intellectual 
functioning. Since most autistic children are also mentally retarded, it 
is often necessary to distinguish between mentally retarded children with 
and those without autistic features. This distinction is often difficult 
to make. Many children are mentally retarded and present autistic 
characteristics, in a greater or less degree. 
- childhood onset pervasive developmental disorders (OSM-II!). In such 
children a serious disturbance in social relationships exists with 
peculiar inadequate reactions in social contacts. Furthermore sudden 
anxieties, inadequate expression of emotions and disturbed motor 
functioning are often present. In addition there are often deviations in 
cognitive and thought processes such as disconnected associations, 
bizarre preoccupations, and overly concrete thinking. The disturbance 
developes after the thirthieth month and before the age of twelve. To 
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what extent there are di st i net, qua 1 itati ve differences between this 
group of children and children with the diagnosis of autism is not quite 
clear (Chess et al ., 1977). In psychoses in early childhood there seems 
to be a less serious disturbance in the forming of social relationships 
and more symptom variability than in autism (Prior et al., 1975). 
- degenerative organical brain diseases, such as Schilder's disease and 
the syndrome of Heller. 
- deafness. Because autistic children often are mute or may show 
selective desinterest in spoken language, they are often thought to· be 
deaf. However, deaf children are usually attached to their parents, seek 
their attention and affection and enjoy being held. 
2.3 EPIDEMIOLOGICAL ASPECTS 
Infantile autism occurs with a prevalence of 4 or 5 per 10.000 children 
below the age of 15. If mentally retarded children with autistic features 
are included, the prevalence rises to 20 per 10.000. It occurs 4 times 
more in boys than in girls. The families of autistic children do not 
differ from control groups as to socio-economic status (Wing et al., 
1980). 
2.4 INTELLIGENCE 
About 60% of the autistic children have an IQ below 50, 20% between 50 
and 70, and 20% higher than 70. Since subjects with an IQ below 70 are 
usually considered to be mentally retarded, a majority of autistics meet 
this criteria. Only a very small portion are of average or above average 
intelligence. Severely retarded autistic children may present a somewhat 
different clinical picture from those functioning on a relatively high 
intellectual level. Hyperkinesis, stereotyped behavior, self-injurious 
behavior and seizures are more frequently seen in the lower functioning 
children; obsessi anal phenomena are more frequent in those who are 
functioning higher. The !Q is stable, measured over a longer period of 
time and has a prognostic value: the lower the IQ the worse are the 
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prospects for the total functioning of the child (Rutter and Lockyer, 
1967; DeMyer et al ., 1973). 
2.5 PARENTS AND FAMILY 
The parents of autistics do not differ as a group in frequency of 
psychiatric problems or in parental care~ emotional response or social 
contact (Cox et al ., 1975; McAdoo and DeMyer, 1978; DeMyer et al ., 1972). 
The family interactions are similar to those of nonnal control families 
(Byassee and Murrell, 1975). Psychodynamic causation does not appear 
therefore to be a major contributor to the etiology of infantile autism. 
This does not imply that psychodynamics and interactions with caretakers 
and environment are unimportant. 
2.6 GENETIC FACTORS 
All reports agree that approximately 2 percent of siblings of autistics 
are afflicted by infantile autism;, a rate 50 times greater than in the 
general population (Campbell et al., 1981). Folstein et al. (1977) found 
concordance for autism in 36% of monozygotic twins and in 0% dizygotic 
twins. The concordance for cognitive disturbances was 82% in monozygotic 
twins and 10% in dizygotic twins. So, it was concluded from this study 
that a genetic factor possibly plays a role in a subgroup of autistic 
children and probably does not concern the whole syndrome, but only the 
cognitive language components. 
Recently two studies of Ritvo and coworkers have appeared. In a first 
study they reported a concordance for autism of 95.7% in the monozygotic 
twins (22 out of 23) and 23.5% in dizygotic twins (4 of 17) (Ritvo et 
al., 1985a). They judged the results compatible with autosomal recessive 
inheritance, which predicts 100% concordance in monozygotic pairs and 25% 
in dizygotic pairs. The parents reported developmental language problems 
in 10.3% of their nonautistic children. 
In a second study 46 families were ascertained with multiple incidences 
of autism (41 with 2 and 5 with 3 autistic probants) (Ritvo et al., 
1985b). Of several genetic mechanisms considered only autosomal recessive 
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inheritance was consistent with the data and could not be rejected by 
classical segregation analysis with correction for the ascertainment bias 
introduced by using multiple incidence families. 
The presence of excess male probands indicates that the final answer will 
be more complex and involve either the identification of additional 
etiologic subgroups or a sex-modified expression for the trait. Of course 
the results of this study might only be applicable to families having at 
least two siblings affected with the syndrome of autism. 
It appeared recently that, in a subgroup of autistics (4-10%) the 
tragi 1 e-X syndrome caul d be diagnosed~ a sex-1 inked hereditary disease 
which is transmitted by the mother, and is expressed, among other things, 
in mental retardation in boys (Brown et al., 1982; Levitas et al., 1983; 
Meryash et al., 1982). Blomquist et al. (1985) reported that fragile-X 
syndrome occured even in 15-20% of autistic males, however Goldfine et 
al. (1g85) reported blood samples from 37 autistic children were negative 
for fragile X chromosome. In reverse, nearly 50% of the children 
diagnosed with a fragile-X syndrome are reported to present autistic 
characteristics (Levitas et al ., 1g33). 
Although in a first study of human leukocyte antigens (HLA) and autism no 
statistically significant relationship between HLA and autism has been 
demonstrated (Stubbs and Magenis, 1980), sets of parents of autistic 
children were found to share significantly more often at least one HLA 
antigen compared to sets of parents of a comparison group (Stubbs et al ., 
1985). This is interpreted as of possible significance because differ-
ences rather than similarities at the HLA sites between the father and 
the mother stimulate blocking antibodies which protect the fetoplacental 
unit. In a recent study of Spence et al. (1985) thirty-four families with 
at least two autistic children were subjected to gene linkage analyses 
with 30 standard phenotypic gene markers. No statistically si gni fi cant 
evidence for linkage with a gene marker was found. 
2.7 CONCOMITANT ORGANIC DISORDERS 
In a number of cases it is possible to diagnose an organic disease (see 
Tab 1 e I I). The diseases most frequently mentioned to occur concomitant 
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with autism are phenylketonuria and congenital rubella (Chess et al., 
1977; Coleman, 1979) and fragile X syndrome (see paragraph 2.6). 
Table II 
Selected pathologic conditions associated with autism (Ornitz, 1983) 
Prenatal Conditions 
Down's syndrome 
Congen ita 1 rube 11 a 
Congenital cytomegalovirus 
Mid-trimester bleeding 
Toxemia 
Perinatal Conditions 
Anoxia 
Breech presentation 
Low Apgar score 
High bilirubin 
Ret ro 1 enta 1 fib rap 1 asia 
Respiratory distress syndrome 
2.8 PRE- AND PERINATAL FACTORS 
Conditions Manifest in the 
First Three Years 
I nfanti 1 e spasms 
Other seizures 
Cerebral lipidosis 
Microcephaly 
Oculocutaneous albinism 
Hi sti d i nemi a 
Addison 1 s disease 
Moebius syndrome 
PKU 
Cel lac disease 
Tuberous sclerosis 
Fragile X 
Conditions Manifest in 
Later Years 
Congenital rubella 
Herpes simplex encephalitis 
Seizures 
Temporal lobe pathology 
The more frequent occurence of postmaturity, haemorrhage during the 
pregnancy, and pre- and perinatal complications in autistic subjects are 
mentioned by different authors (Lobascher et al., 1970; OeMyer, 1979; 
O'Moore, 1972; Campbell et al., 1978c). Autistics also have significantly 
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more minor congenital anomalies than their siblings or normal controls 
(Campbell et al ., 1978e; Walker, 1977). 
2.9 PHYSICAL CHARACTERISTICS AND NEUROLOGICAl AND NEUROPHYSIOLOGICAL 
FINDINGS 
Young autistic children (age 2-7 years) have been found to be shorter, as 
a group, than a normal population (Campbell et al., 1980). There is a 
greater incidence of abnormal denmatoglyphic patterns than in the general 
population (Walker, 1976a). 
Several authors have suggested that aspecific neurological findings occur 
in approximately 50% of autistic subjects (Kolvin et al ., 1971; Gubbay et 
al., 1970; DeMyer, 1979; Knobloch and Pasamanick, 1975). Physical and 
neurological assessment of autistic children has yielded an array of 
neurological findings, including hyperactive tendon reflexes, hypotonia, 
and spasticity (Gubbay et al., 1970). Individually, none of these 
symptoms are found in a majority of chi 1 dren. We reported that a 
snoutreflex and a visual rooting reflex occur in a majority of autistic 
children (Minderaa et al., 1985a, Appendix No V). The visual rooting 
reflex is seen significantly more often in mentally retarded children 
with than in mentally retarded children without autistic characteristics 
(Minderaa et al., 1985b). There is a failure of lateralization in the 
majority of young autistic children. They remain ambidextrous at an age 
when cerebral dominance is established in their siblings and other 
normals (Campbell et al., 1984). 
The incidence of epilepsy is increased. The occurence of seizures 
increased during and after puberty (Deykin and Macmahon, 1979). 
EEG-anomal ies also occur with an increased frequency after the onset of 
puberty (!til et al ., 1976; Small, 1975; Waldo et al ., 1978). Although as 
yet there is no EEG finding specific to infantile autism, there is 
suggestion that some abnormalities are indicative of failure of cerebral 
lateralization. In neurophysiological investigations, making use of 
different parameters, such as heartfrequency, vasomotor reactions (Cohen 
et al., 1977b; Lake et al., 1g77) and electrodermal activity (Angus, 
1970; Van Engeland, 1980), possible deviations have been found. By 
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several investigators autistic children have been found to have increased 
brain stem transmission times as detennined by auditory evoked responses 
(Sohmer and Student, 1980; Rosenblum et al., 1980; Tanguy et al., 1982; 
Gilberg et al., 1983b). Others found smaller amplitudes of long-latency 
auditory event-related brain potentials in response to novel auditory 
information (Courchesne et al., 1985). 
On the basis of CT-scan investigations, indications have been found for 
deviations of the left hemisphere (Hier et al., 1978; Hier, 1979) and 
ventricular enlargement (Damasio et al., 1980; Campbell et al., 1982; 
Hoshino et al., 1984) in some autistics. Other investigators have found 
no abnormality compared to normals (Prior et al ., 1984) or in comparison 
with patients with various neurological disorders (Tsai et al., 1982; 
Tsai et al ., 1983). 
2.10 TREATMENT 
In general longlasting coaching of parents and family is indicated. 
Attention should be paid to e.g. coping-problems, daily problems in the 
approach of the a uti sti c chi 1 d, prevention or decrease of secundary 
behavioral problems of the child, looking for a psychic balance of the 
family and advice on questions about chasing a special school, a daycare-
center, or a residential treatment center. Focussing on individual parent 
problems and concerns within a problem solving format is important. 
An approach along the lines of behavior modification, directed towards 
different relevant behavioral aspects of the syndrome is considered to be 
the most useful (DeMyer et al., 1981). 
Adjusted schooling with structured classroom training is important. The 
a uti sti c chi 1 dren require an a 11-day structure and a daily program 
adapted to their special needs. 
In serious behavioral problems medication may sometimes be useful, 
not-sedating antipsychotic medication having appeared the most effective 
(Campbell et al., 1978d; Faretra et al., 1970; Anderson et al., 1984). 
Haloperidol has proved to be an effective and safe drug in many autistic 
chi 1 den who are hyper- or normoacti ve when administered in conservative 
doses over a relative short period of time, up to 3 months (Campbell, 
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1984) .. The main improvements are decreases in hyperactivity, stereo-
typies, withdrawal, fidgetiness, abnormal object relations, irritability 
and labile affect. Furthermore, it seems that haloperidol remains an 
effective drug on a long-term basis. When haloperidol is carefully 
administered~ tardive and withdrawal dyskinesias are not frequent 
(Campbell , 1984). Recently, fenfl urami ne, a drug that increases centra 1 
serotonergic functioning was reported to be effective (Ritvo et al., 
1983; August et al., 1984, 1985). However, critical assessment of 
fenfluramine•s effect in large samples of patients is required to 
validate the preliminary findings. 
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CHAPTER Ill 
NEUROCHEMICAL ASPECTS OF INFANTILE AUTISM: 
CATECHOLAMINE AND NEUROENDOCRINE STUDIES 

3.1 INTRODUCTION 
Neurochemical research in autistic children has mainly focused on the 
metabolism of three monoamine transmitters, namely the catechol ami nes 
dopamine (DA) and norepinephrine ( NE) and the i ndol eami ne serotonin 
(5-HT). 
One of the reasons for the investigation of the functioning of the 
dopaminergic systems is the relative therapeutic effect of neuroleptics. 
Although the phenothiazines and butyrophenones are far from being a cure 
for autism, so far they have appeared to be the most effective medication 
avail ab 1 e. They influence severa 1 symptoms concerning the motor system 
such as hyperactivity, stereotypies, aggression and automutilation. These 
actions of the neuroleptics are thought to be due to their blockade of DA 
receptors. 
Stimulants, such as amphetamines and methylphenidate, worsen autistic 
symptoms in most cases~ leading to increased motor activity~ aggression, 
stereotypies and a general desintegration of behavior. Stimulants release 
dopamine from the presynaptic tenni na 1 and block its re-uptake and 
degradation. 
The important central and peripheral neurotransmitter, NE, has also been 
widely studied in autism. Although little specific neuropharmacological 
evidence, of the type mentioned concerning DA, has been obtained to 
suggest NE functioning might be altered in autism, its crucial role in 
the nervous system has made its study worthwile. 
Central monoaminergic systems are involved in the control of honnone 
release. Therefore, assessment of neuroendocrine parameters might throw 
light on central neurotransmitter functioning. 
In this chapter, we will review the studies on autistic individuals 
dealing with the catechol amine systems (norepinephrine and dopamine), 
neuroendocrine systems (cortisol, prolactin, growth hormone, luteinizing 
hormone, follicle-stimulating hormone and the thyroid hormones, and 
several hormone-releasing hormones) and neuropeptide systems. 
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3.2 NOREPINEPHRINE 
Norepinephrine (NE) is found as a neurotransmitter in the brain as well 
as in the peripheral sympathetic nervous system. Furthermore, NE is 
excreted by the adrenal gland. 
Much evidence suggest that noradrenergic systems play a major role in 
fundamental modulatory processes including arousal, orientation, 
habituation, vigilance, stress responses and memory. Most of the NE cell 
bodies in the brain are located in the locus coeruleus (LC), a nucleus in 
the dorsal tegmentum of the pons. From here they project extensively in a 
diffuse manner to different parts of the brain. Besides NE-LC dendrites 
extend to the spinal cord, affecting autonomic activity via the 
sympathetic nervous system. In the postganglionic sympathetic nervous 
sytem NE serves as a neurotransmitter. 
3.2.1 ASSESSMENT OF NORADRENERGIC FUNCTIONING: SPINAL FLUID MEASURES 
As it is impossible in people to measure concentrations of monoamines and 
their metabolites in the brain directly, use is made of measurements in 
the cerebrospinal fluid (CSF). The amines themselves can not be measured 
in the CSF because, after being released into the synaptic cleft, they 
are retaken up or broken down immediately afterwards. Therefore in order 
to study the metabolism of the amines, the most important metabolites of 
serotonin, dopamine and noradrenaline, in the spinal fluid are measured: 
respectively 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) 
en 3-methoxy-4-hydroxyphenylglycol (MHPG) (see Figures l and 2). The 
concentrations of these metabolites in the CSF give an impression of the 
turnover rate of the ami nes in the brain. Because of the differences 
between lumbar and ventricular CSF circulation, the variability over 
time, and the differences in concentrations between different areas of 
the brain which are not reflected in the CSF, one should be cautious in 
the interpretation (Van Praag et al., 1g73; Garelis et al., 1974). 
Activity of central NE neurons has been assessed by measuring levels of 
MHPG in the spinal fluid. MHPG levels in spinal fluid probably reflect NE 
activity in the brain as well as the spinal cord. Furthermore it appeared 
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that there is a small contribution of blood MHPG to CSF MHPG (Kopin et 
al., 1983). 
MHPG is measured in the CSF of 6 a uti sti c children and appeared to be 
'normal', if compared to the MHPG levels of adult neuropsychiatric 
patients (Young et al., 1981). Gill berg et al. (1g83a) found CSF MHPG 
levels slightly but not significantly increased in autistic individuals 
compared to age- and sex-matched controls. These findings suggest that 
central NE turnover is not grossly altered in autistic individuals. 
Figure 1. 
The synthesis of catecholamines 
from their amino-acid precursor 
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35 
Tyrosine 
I Ty~;ne 
.... hydroxylase 
L-dopa 
! Oops decarboxylase 
Dopamine 
! Dopamine {3 -hydroxylase 
HOP) IHCH2NH2 
HoV OH 
Noradrenaline 
I Phenylethanolemine 
... N-rnethyltrensf'erase 
H HOO -cHCH2N::: I I CH3 
HO ~ OH 
Adrenaline 
3.2.2 ASSESSMENT OF NORADRENERGIC FUNCTIONING: BLOOD MEASURES 
The use of plasma norepinephrine as an index for sympathetic functioning 
is based on the assumption that the plasma levels are for the greater 
part produced by the postganglionary nerve endings. Besides, norepi-
nephrine is also excreted by the adrenal gland (Lake et al., 1976; Taylor 
et al., 1978; Louis et al., 1973). Under nonnal physiological circum-
stances the sympathetic nervous system is probably the most important 
source of the noradrenaline of the plasma, while under stress the adrenal 
contribution of the plasma norepinephrine increases (Popper et al., 1977; 
Micallizzi and Pale, 1979). This is of importance with regard to autistic 
children because in clinical research vegetative disturbances are 
repeatedly reported, as for instance deviations in the vasomotor 
regulation and electrodermal activity. The remarkable responsiveness of 
plasma catecholamines on psychological and bodily stimuli requires that 
procedures to co 11 ect blood are carefully standardized in order to 
minimalize the effect of stimulation by the venapunction .. Although 
norepinephrine in plasma is for the greater part produced by the 
sympathetic nervous system, it may reflect in an indirect way the 
functioning of centra 1 systems.. The 1 ocus coerul eus, the important 
noradrenergi c nucleus, influences sympathetic functions vi a descending 
noradrenergic fibers to the lateral columns of the spincal cord. This 
implicates that peripherally derived norepinephrine and the metabolite 
MHPG are probably correlated with the rate of central noradrenergic 
activity. 
Opinions differ about the question to what extent plasma MHPG, the most 
important metabolite of centrally produced norepinephrine, is produced in 
the brain or in the peripheral systems. Variable estimates have been made 
concerning the actual percentage of MHPG found in plasma that originates 
in brain (Roth, 1983) .. However, as with norepinephrine, plasma MHPG seem 
to be a useful index for the functioning of central noradrenergic systems 
(Leckman et al., 1980; Roth, 1983), even if the lower percentage were 
correct .. 
Lake et al. (1977) found that in a group of 11 autistic children the 
norepinephrine levels in plasma were significantly higher in comparison 
to the control group. Young et al. (1981) found the plasma free MHPG 
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Figure 2. The metabolic pathways of dopamine and noradrenaline. 
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levels in 9 autistic boys within the range which in adults is considered 
to be normal and in agreement with that of a control group consisting of 
8 boys. Minderaa et al. (1985b) didn't find a difference in plasma MHPG 
levels between 17 autistics and a normal control group. These findings 
indicate that longterm overall release of NE is not greatly altered in 
autistic subjects. 
Dopamine beta-hydroxylase (DBH) catalyses the conversion of dopamine into 
norepinephrine (see Figure 1). It is found intracellulary in free and 
membranebound form (in the storage vesicles of the nerve endings) and is 
released, together with norepinephrine, into the synaptic cleft. DBH 
activity is used as a possible index of sympathetic nervous system 
activity in man. Measurements of DBH in serum of autistic children did 
not yield results which can be easily interpreted. Coleman et al. (1974) 
found OBH activity increased in autistic subjects. However, Goldstein et 
al. (1976a) reported DBH serum levels were significantly lower in 
autistic individuals compared to normal controls. Lake et al. (1977) 
confirmed these results and found DBH activity significantly decreased in 
autistics as well as in their relatives. Bel maker et al. (1978) reported 
DBH activity was significantly elevated in children with functional 
psychoses but not in psychotic children with known organic etiology. 
Finally Young et al. (1980) did not find differences in DBH activity 
between autistics and normal controls. 
Catecho l-0-methyl transferase ( COMT) is an enzyme that catalyses the 
transfer of a methyl group from S-adenosyl-methionine to a phenolic group 
of epinephrine, norepinephrine or other catecholamines (see Figure 2). 
Because of the functional similarity of COMT in synaptosomes in the brain 
and in erythrocytes, erythrocyte COMT activity has been examined in 
autistic and normal control groups. O'Brien et al. (1g76) reported no 
difference in COMT activity of erythrocytes in autistics compared to 
normal controls. Walker et al. (1976b) compared institutionalized 
schizophrenic autistic-like children, a heterogenous group of chronica1 
psychotic children and a group of acting-out but nonpsychoti c children. 
The erythrocyte COMT activity was found to be significantly lower in the 
autistic-like schizophrenic children. Belmaker et al. (1978) reported no 
differences in erythrocyte COMT activity between children with functional 
psychosis and children with organic psychosis. Finally Giller et al. 
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(1980) did not find such differences between autistic children and 
children with the Gilles de la Tourette syndrome. These findings indicate 
that COMT activity in red blood cells is probably not altered in autism. 
3.2.3 ASSESSMENT OF NORADRENERGIC FUNCTIONING: URINE MEASURES 
Free or conjugated catecholamines in the urine are produced by peripheral 
systems, namely the adrenal marrow and the sympathetic nervous system.-
The most important metabolite of peripherally fanned norepinephrine is 
vanillyl mandelic acid (VMA) (see Figure 2). VMA and MHPG are found in 
the urine in relatively large quantities (several mg excreted per day). 
The fact that centrally formed norepinephrine is mainly degraded to MHPG, 
means that urine MHPG reflects, at some degree, the brain metabolism of 
NE. Measurements of MHPG in 24-hours urine is a frequently used clinical 
method to investigate the central norepinephrine metabolism. 
In a pilot study of urine MHPG in 6 autistic boys and 9 normal boys a 
significant decrease in the mean urinary excretion of MHPG was found in a 
group of autistics compared to the control group (Young et al., 1979). 
At the same time there was a parallel decrease of the free catecholamines 
in the urine in this group of autistic children. Free catecholamines (NE 
and epinephrine) mainly reflect noradrenergic activity, consisting of 80 
or 90% noradrenaline. However, Minderaa et al. (1985b) found no differ-
ence between a group of 17 unmedicated autistics and a normal control 
group in the urine excretion of MHPG, norepinephrine or epinephrine. 
In addition, the diurnal variation observed in nonnal children was seen 
to be similar in the autistic group, with lower values overnight compared 
to the late afternoon and evening values. 
It might be concluded, based on CSF, blood and urine studies, that 
noradrenergic functioning is not greatly altered in autism. The finding 
in conflict with this conclusion is, above all, the apparent increased 
values of blood NE. However, the noradrenergic system is episodically 
responsive. NE levels, in contrast to MHPG and OBH measures, reflect 
acute sympathetic response and NE has a short chemical halflife. So, 
increased NE levels might reflect a dysfunction in functional respon-
sivity of the noradreneric system, while the overall long term func-
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tioning might be normal. Noradrenergic challenge tests might throw new 
light on these questions in a more dynamic way. 
3.3 DOPAMINE 
Dopamine (DA) is found as a neurotransmitter in the brain and as a 
precursor toNE in the peripheral sympathetic nervous system, it is also 
excreted by the adrenal gland. In the brain most dopamine containing 
neurons lie in the neostriatum, the nucleus accumbens, and the tuberculum 
olfactorium. The central dopaminergic systems are especially important in 
the control of motor function, in cognition and in the regulation of the 
release of hormones. OA-b1ockers such as haloperidol or thioridazine, 
have been observed to be effective in decreasing some symptoms of 
autistic children like stereotyped behavior. Furthermore, drugs which 
enhance dopaminergic functioning, like amphetamines make autistic 
symptoms worse. 
3.3.1 ASSESSMENT OF OOPAMINERGIC FUNCTIONING: SPINAl FLUID MEASURES 
As pointed out homovanillic acid (HYA) is the major metabolite of 
dopamine in the brain (see Figure 2). Measurements of HYA in spinal fluid 
have been used to assess the central dopamine turnover. 
During the 1970's probenecid was widely used to get a better picture of 
the monoamine metabolism in the brain. Probenecid hampers membrane-
transport and thus blocks the egress of the acid metabolites 5HIAA and 
HYA out of the spinal fluid into the blood stream. Therefore the blockade 
by probenecid causes a rise in the concentrations of these metabolites in 
the CSF and thus offers a reflection of the metabolism over a 1 anger 
period of time. Moreover, after administration of probenecid, metabolite 
measures reflect better production instead of steady state va 1 ues which 
are influenced by kinetic aspects of elimination processes. In autistic 
children the CSF concentrations of 5-HIAA (see chapter IV) and HYA are 
tested both without and after administration of probenecid. The values 
are compared to those of contrast groups because normal values in healthy 
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children are not available. 
In an investigation in 6 autistic boys~ without using probenecid, the 
concentrations of HVA and 5-HIAA were relatively low, clustered and 
within the range as found in adults (Cohen et al ., l980b). The several 
transmitter systems seem to play a different role in the organization of 
behavior, and their mutual balance may throw light on certain aspects of 
disturbed behavior. Therefore the ratio between the 5-HIAA and HVA values 
is considered after probenecid loading. In autistic children the 
5-HIAA/HVA ratio is in the low range of those of adult schizophrenic and· 
depressive patients (Cohen et al., 1978). This may partially be explained 
by the fact that HVA concentrations in the CSF of children are higher 
than in adults. Within the group of autistic children there existed a 
subgroup with more increased HVA concentrations, both absolutely and in 
comparison with the 5-HIAA concentrations. This subgroup distinguished 
itself by the great amount of stereotyped and repetitive behavior, and 
increased locomotor activity. In general the most seriously disturbed 
children belonged to this subgroup. Within the group of autistic children 
the authors searched for correlations between CSF metabolite concentra-
tions and behavior ratings. As there exists a relation between the 
concentrations of the metabolites and probenecid in low probenecid 
levels, metabolite concentrations might be reflected in their relations 
to the probenecid concentrations. For 10 autistic children the 
HVA/probenecid ratio was negatively correlated with scores concerning 
social responsiveness and attention. The ratio 5-HIAA/HVA was positively 
correlated with these behavioral aspects. So, autistic children who 
functioned worse in these aspects of behavior, had higher concentrations 
of CSF HVA and lower concentrations of 5-HIAA. 
In another study (Winsberg et al., 1980) the increases in HVA levels in 
spinal fluid after probenecid loading appeared to be normal in autistics. 
Recently, Gill berg et al. (l983a) found that the baseline levels of HVA 
in spinal fluid of autistic subjects appeared to be increased compared to 
an age- and sex-matched control group of neurologically disordered 
children. These findings suggest that the dopami nergi c system might be 
overactive in autism. 
HVA levels in the liquor of autistic children may be related to the 
remarkably more frequent occurence of this disease in boys than in girls, 
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as CSF HVA levels have been reported to be higher in men than in women 
(Leckman et al., 1980; Shaywitz et al., 1980). This may make men more 
vulnerable for diseases in which the dopaminergic system is involved, 
such as autism, chronical multiple tic syndrome and attention deficit 
disorder with hyperactivity. All these disorders occur more frequent in 
boys than in girls (Young, 1982c). 
Another hypothesis cou 1 d be that the HVA e 1 evati on might represent a 
developmental delay in the maturation of dopaminergic systems, as higher 
CSF HVA levels are seen in younger children (Anderson et al., 1985a) and 
in young animals (Shaywitz et al ., 1985). 
3.3.2 ASSESSMENT OF OOPAMINERGIC FUNCTIONING: BLOOD MEASURES 
Most of the DA and HVA measured in peripheral body fluids is derived from 
the adrenal gland and the sympathetic nervous system. The relationship of 
these measures to centra 1 dopami nergi c function is unclear. Dopamine 
measured in urine is estimated to be almost comp1 etely derived from 
peripheral sources. HVA measured in blood or urine might be of 
approximately 25% (Mars et al ., 1980) central origin. 
We know of only one study dealing with plasma HVA levels in autistic 
subjects (Minderaa et al., 1985c). In this study no differences have been 
observed between autistics and normal controls. No studies of the levels 
of dopamine itself in autistics have been reported. 
Boullin and O'Brien (1971) measured in vitro uptake and loss of 
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C-dopamine by blood platelets. No differences were found between 
autistic subjects and normal age-matched controls. 
3.3.3 ASSESSMENT OF DOPAMINERGIC FUNCTIONING: URINE MEASURES 
Several investigators found increased urine HVA levels in autistic 
children (Lelord et al., 1978; Garreau et al., 1980; Martineau et al ., 
1981; Martineau et al., 1984). In one study (Garreau et al., 1980) 
urinary HVA excretion was correlated with the severity of autistic 
symptoms. Martineau et al. (1981) showed urinary HVA levels decreased 
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with treatment with Vitamin B6 and magnesium, while Lelord et al. (lg78) 
reported a reduction of urinary HVA excretion after administration of 
Vitamin B6. However, we have found no difference between unmedicated 
autistics and normal controls in total urinary DA or HVA excretion 
(Minderaa et al ., lg85c). 
3.4 ADRENOCORTICOTROPIC HORMONE, CORTISOL AND RELATED COMPOUNDS 
Adrenocorticotropic hormone (ACTH) is secreted by the anterior lobe of 
the pituitary gland and acts primarily on the adrenal cortex. It 
stimulates the release of cortical steroid hormones, the principal one of 
which is cortisol. Levels of cortisol in plasma vary with the time of the 
day, and are increased in the early morning. The release of ACTH is 
regulated by the hypothalamic corticotropin-releasing factor (CRF). 
Urinary levels or cortisol and of the other glucocorticoids, the 
17-hydroxy corticosteroids are useful indices of adrenocortical function. 
Metapyrone is used for testing pituitary reserve of ACTH. The effect of 
metapyrone is a decreased secretion of cortisol which thereby causes an 
increase in ACTH release. 
Another way to assess the pituitary-adrenal function is by use of the 
dexamethason suppression test. Dexamethason, a potent analogue of 
cortisol, suppresses cortisol production by inhibiting ACTH release of 
the pituitary. 
Brambilla et al. (1g6g) studied three children with early onset 
psychosis. They found reduced levels of urinary 17-hydroxy- and !?-keto-
steroids but normal plasma levels of ACTH. After stimulation of ACTH with 
metapyrone a blunted response was seen. 
Hill et al. (1977) reported plasma levels of cortisol being decreased in 
six autistic subjects. 
However, Hoshino et al. (lg84a) and Jensen et al. (1985) reported normal 
4 PM baseline cortisol levels in autistic subjects compared to mentally 
retardeds and normal controls, and 8 AM baseline cortisol values in 
autistics similar compared to those of normal adults respectively. 
Maher et al. (1975) found an increased elevation of cortisol after 
insulin loading in 11 autistic children compared to mentally retarded 
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controls. 
Yamazaki et al. (1975) reported a normal increase in 11-hydroxy 
corticosteroids after pyrogen stress, but deviant diurnal variations in 
levels of these compounds in autistic individuals. 
A dexamethasone suppression test (DST) has been performed with autistic 
subjects by Hoshino et al. (1984a) and Jensen et al. (1985). The first 
group of investigators found no suppression of plasma cortisol after 
dexamethasone administration in all of six autistics with low IQ 
(IQ < 60). The second group performed a dexamethasone suppression test in 
a group of low-functioning autistic subjects (IQ <; 30) and found 10 out 
of 12 autistics did not suppress cortisol release. 
In conclusion, it can be said that baseline levels of cortisol are not 
probably abnonnal in autistic subjects, and that low functioning 
autistics do suppress cortisol secretion after dexamethasone loading to a 
lesser extent than controls. 
3.5 HUMAN GROWTH HORMONE AND PROLACTIN 
Human growth hormone (hGH) and prolactin (PRL) are secreted by the 
anterior pituitary. Release of hGH is regulated by hypothalamic secretion 
of growth hormone-releasing factor (GRF) and somatostatin (somatotropin 
release-inhibiting factor, SRIF). Hypothalamic release of dopamine 
stimulate secretion of GRF and, in turn, of hGH. Prolactin is controlled 
primarily by prolactin-inhibiting factor (P!F) and perhaps by a prolactin 
releasing factor (PRF). Dopamine blockers increase and dopamine agonists 
decrease serum prolactin, presumably by altering dopamine release by the 
tubero-i nfundibul ar neurons. Serotonergi c mechanisms apparently play a 
modulatory role in prolactin secretion. Thyrotropin-releasing factor also 
increases prolactin levels, probably via a direct action on the 
pituitary. 
Hoshino et al. (1983, 1984b) assessed baseline levels of plasma human 
growth honnone and prolactin and after loading with the precursor of 
serotonin, L-5-hydroxytryptophan (L-5-HTP) in six autistic children and a 
group of normal controls. The baseline hGH levels as well as the hGH 
elevation after L-5-HTP loading were similar in the autistic subjects, 
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compared to the normal controls. Th-e autistics did show lower baseline 
levels of PRL and a blunted response of prolactin after L-5-HTP 
challenge. These results are interpreted as possible indicating a 
diminished central serotonergic functioning or an enhanced dopaminergic 
activity of the tuberoinfundibular system. 
In contrast Minderaa et al. (1985c) found normal baseline levels of 
prolactin in a group of unmedicated autistics and apparently normally 
increased levels of prolactin in neuroleptic medicated autistic subjects. 
Several investigators measured plasma prolactin levels after challenge 
with thyrotropin-releasing hormone (TRH). Campbell et al. (1978a) 
reported a normal response of prolactin to TRH in 10 psychotic children. 
Suwa et al. (1984) found a increased response of PRL to TRH in one out of 
four autistic children. Hoshino et al. (1983) however, found a blunted 
response of PRL to TRH in 6 autistic children. 
3.6 THYROID HORMONE AND THYROID STIMULATING HORMONE 
Thyroxine (T4) and triidothyronine (T3) are the hormones secreted by the 
thyroid gland. The thyroid is stimulated by the thyroid-stimulating 
hormone (TSH), a glycoprotein produced and secreted by the anterior 
pituitary. TSH synthesis and release is stimulated by thyroid-releasing 
hormone (TRH), which is synthesized in the hypothalamus and secreted into 
the pituitary. The precise way the release of TRH is regulated is not 
known, but monoamines like dopamine, serotonin, norepinephrine and 
opiates like B-endorphin and metenkephalin seem to play an important role 
in the regulation of the activity of tub-era-infundibular neurones. 
Kahn (1970) reported diminished values of T3 uptake in more than 70% of a 
group of 62 autistic subjects. However, Abbassi et al. (1978) and Cohen 
et al. (1980a) found normal levels of T3, T4, and thyroid stimulating 
hormone (TSH) in autistic children. 
Several investigators have performed thyrotropin-releasing hormone (TRH) 
tests in autistic children. Campbell et al. (1978a) found after TRH 
challenge an elevated response of TSH and a delayed or blunted response 
of T3 in a group of 10 psychotic children. Hoshino et al. (1983) reported 
an increased response of TSH to TRH in 6 autistic children as well. 
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Finally Suwa et al. (1984) found an enhanced response of TSH to TRH in 3 
out of 4 autistic children. 
So rather good agreement does exist about the finding of an enhanced 
reaction of TSH secretion after TRH stimulation in autistic subjects. 
3.7 LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) 
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are the 
gonadotropic hormones produced by the anterior pituitary. The 
hypothalamic control of these gonadotropic hormones is performed by the 
decapeptide luteinizing hormone-releasing hormone (LRH). 
Hoshino et al. (1983) adminstered LH-RH intravenously and measured plasma 
release of luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH) (LH-RH test) in 6 autistic male subjects. The elevations of both LH 
and FSH release was decreased after LH-RH loading. 
3.8 NEUROPEPT!DES 
The behavioral effects of the neuropeptides are the result of a direct 
action on the central nervous system, and consist of influences on memory 
processes, motivation, attention and arousal, pain perception, appetite 
and sexual behavior. 
Panksepp and coworkers (Panksepp et al., 1979, 1980) demonstrated the 
importance of the endogenous opiate system for the establishment of 
social bonds, the regulation on the neurobiological level of 
attachment-behavior, imprinting processes, experienced contact comfort 
and separation distress reactions. Based on animal work they hypothesized 
that hyperactivity of endogenous opiate systems would contribute to a 
state of progressive social isolation and social withdrawal which seems 
similar to the symptoms of autistic children in social behavior. 
So far there are few studies to test this interesting hypothesis. 
Coid et al. (1983) found significantly increased plasma levels of the 
short chain opioid metenkephalin in a group of adult habitual 
self-mutilators compared to a group of former self-mutilators who were 
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discharged. B-endorphi n and 1 i potropi n 1 evel s were similar in these 
groups. However, Weizman et al. (1984) found significantly lower levels 
of humoral-endorphin in plasma in autistic individuals compared to normal 
controls~ 
Naxolone, a blocker of opoid systems, has been succesfully used in 
mentally retarded individuals with self abusive behavior (Sandman et al ., 
1983). So far as known, this drug has not been used with autistic 
subjects. 
No quantitative studies about urinary excretion of peptides in autistic 
subjects are known. However, qualitatively deviations in urinary 
excretion of these substances have been described. Gillberg et al. (1982) 
concluded that half of the autistic patients showed different urinary 
excretion patterns of peptides compared to normal children and only 8% _of 
the autistic subjects exhibited the normal pattern seen in 97% of the 
controls. 
3.9 DISCUSSION 
Up to the present time the neurochemical research on catecholamines in 
children suffering from infantile autism has not yielded any specific 
biochemical characteristic.. However, there are i nd icati ons that 
noradrenergic and dopaminergic systems in the brain are involved in the 
syndrome .. These indications are among other things: therapeutic effects 
of medication i nfl uenci ng these transmitter systems, increased baseline 
HVA levels in spinal fluid and a subgroup with relatively raised HVA 
values in the CSF after probenecid loading, and a raised norepinephrine 
level in plasma .. Furthermore abnormalities have been found in neuro-
endocrine functioning and in the peptide excretions .. The most robust 
finding of which is an increased release of TSH after stimulation with 
TRH .. It is not clear whether these findings are of a primary or secondary 
nature .. There is no clarity either about the nature and localisation of 
the pathogenetic substrate. It has not yet been ascertained whether there 
are correlations of neurochemical variables with syndromal subgroups or 
specific behavior characteristics, but there are indications that a 
subgroup with high CSF HVA concentrations is characterized by a more 
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serious degree of stereotypy, repetitive behavior and locomotor activity, 
and in general a more severely disturbed behavior. In the very first 
place it will be necessary to replicate the recent findings with larger 
groups of children. It will be of importance that factors as age, sex, 
level of intelligence and level of activity are put under experimental 
control. A great number of practical problems will play a role. Although 
the parents are often very willing to co-operate, it is often difficult 
to gain the co-operation of the children in a number of procedures, so 
that reliable results are not easily obtained. The burden of a spinal tap 
for child and family is great and requires intensive support. Medication 
and other therapeutic 
to interprete data. 
variables should be 
interventions often complicate the possibilities 
Scoring procedures of emotional and behavior 
accurately attuned to the specific problems of 
autistic children and are difficult to perfonn. Replication of findings 
is required, and investigations should focus for example on finding 
correlations of HVA values in the CSF with behavior variables measured 
with more objective behavior observation instruments. Research on the 
therapeutic and metabolic effect of medication influencing the monoamine 
metabolism will yield data which can be both of practical and theoretical 
significance. Further research is required on the relation between the 
dopaminergic functioning in the brain and abnormal motility and behavior 
phenomena. Pharmacological provocation of the system (as with stimulants 
and neuroleptics) can throw new light in this field as well, when it is 
related to clinical and metabolic variables. Moreover, it is of impor-
tance to investigate the relation between adrenergic functioning and 
clinical phenomena such as excitement and anxiety. In this case the 
system can be loaded by pharmacological means (for instance clonidine, a 
partial noradrenergic agonist) or by functional means, such as an 
intellectual task or a physical exertion. Stress-situations of every-
day-life can also be used as an experimental loading. Correlations can be 
investigated with neurophysiological parameters. A different line of 
research can be the investigation of maturation changes of biogenic 
amines and the substances related to their metabolism. Oopaminergic 
activity appears to decrease during youth, noradrenergic activity appears 
to increase and serotonergic activity is stable or decreases. These 
age-related changes may have fundamental effects on behavior. The balance 
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of the monoamine systems and their relative rates of development, can be 
of importance for the development of the child (Young et al., l982c). 
When the profile of neurotransmitter maturation in different tissues and 
bodily flu ids has been determined with more certainty, it wi 11 be 
possible to trace an abnormal development on a molecular level if it 
occurs and to relate it to clinical pathology. 
As autism and other neuropsychiatric syndromes such as 1 attention deficit 
disorder' (ADD) and the syndrome of Gilles de la Tourette are 3 or 4 
times more frequent in boys than in girls, differences in monoamine 
functioning between men and women are also of importance. 
More direct information about receptor functioning can be obtained by the 
investigation of the binding characteristics of specific receptors with 
radioactive ligands. 
Another approach would be to assess neurochemical parameters within 
families to look after deviations under genetic control. 
On the basis of investigations of the basic functioning of the nervous 
system, and a clinical neurochemical research and by the strong progress 
in the neurochemical analytical techniques there are many hypotheses 
which are waiting to be tested. It will be the task of the future to 
translate this knowledge and these skills into practical and workable 
clinical experiments, so that new insight will be acquired into the 
syndrome of infantile autism. 
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CHAPTER IV 
CHILDHOOD AUTISM AND THE SEROTONERGIC SYSTEM: 
"HYPERSEROTONEMIA" AND RELATED SUBJECTS 

4.1 SEROTONIN 
4.1.1 INTRODUCTION 
About 100 years ago a substance was discovered in serum with 
vasoconstrictive properties. This substance~ called serotonin, was 
isolated about 40 years ago and characterised as 5-hydroxytryptamine 
(5-HT) by Page and coworkers (For review, see Page, 1968). 
In the same period a substance called enteramine found in 
enterochromaffi n ce 11 s of the gut, and known to be ab 1 e to constrict 
smooth muscular tissue,· particularly of the gut, appeared to have the 
same chemical structure (For review, see Erspamer, 1961). 
Shortly afterwards in the early 1950s, 5-hydroxytryptamine was 
demonstrated to be present in the mammalian brain by Page (1968) and by 
Gaddum (1953). 
In the human body about 90% of the 5-HT is found in the gut, 8-10% in the 
blood platelets and only 1-2% in the brain. 
The precursor of serotonin is tryptophan (see Figure 1). 
4.1.2 TRYPTOPHAN 
Tryptophan is an amino acid that is primarily derived from the diet. In 
animals elimination of dietary tryptophan can profoundly lower the levels 
of brain serotonin. 
A portion of the dietary tryptophan is drawn off by the intestinal flora 
for bacterial protein synthesis. The rest is absorbed and carried to the 
1 i ver in the hepatic portal b 1 ood. The transportation of tryptophan 
across the mucosal membrane is an active process occurring against a 
concentration gradient. After a protein meal, the concentrations of amino 
acids in portal plasma are elevated but the increases are much smaller in 
venous plasma because of active uptake by the liver and other tissues. 
Less is known about the ways these processes are regulated and about its 
effects on regulation of brain tryptophan. In the liver tryptophan and 
other amino acids are used for protein synthesis. When the protein is 
broken down the component amino acids become available again. 
53 
Figure 1. 
The metabolic pathway of tryptophan 
to 5-hydroxytryptamine, tryptamine, 
and their acid metabolites 
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Another important fate of tryptophan in the 1 iver is its catabol isation 
by tryptophan pyrrolase. Quantitatively most tryptophan is metabolized by 
this enzyme to kynurenine and then to a variety of other metabolic 
products (Figure 2). This process, the 11 kynurenine pathway 11 is 
irreversible. Tryptophan pyrrolase is primarily found in the liver and 
induced by tryptophan and cortisol. Thus an increased plasma tryptophan 
concentration results in enzyme induction and therefore a more rapid 
metabolism of the amino acid. The kynurenine pathway leads to the 
formation of nicotinamide adenine dinucleotide (NAD). 
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Figure 2. Metabolic pathway of tryptophan metabolism (kynurenine pathway) 
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There is a strong evidence that an increase in the rate of tryptophan 
catabolism by induction of tryptophan pyrrolase in the 1 iver in some 
circumstances might alter tryptophan metabolism in the brain and 
influence 5-HT production. The decline in the free tryptophan pool owing 
to excess metabolism along the kynurenine pathway may be partly set off 
by compensatory protein catabolism. 
Large amounts of tryptophan and other amino acids are held for longer 
periods of time in the free form in muscle. 
Tryptophan is carried in the plasma largely (~ 85%) bound in a loose form 
at sites on serum albumine. These sites may be shared with free fatty 
acids (and certain drugs). The proportion of tryptophan in plasma that is 
in free solution depends not only on the albumin concentration but on 
that of the nonesterified fatty acids. The percentage of free tryptophan 
in human plasma is positively and significantly correlated with the 
concentration of the nonesterified fatty acids. A variety of 
pharmacological agents displace tryptophan from albumen; these agents 
include salicylates, probenecid, chlorpromazine, 
tal but amine and benzodi azepi nes. There has been 
diphenylhydantoin, 
a great deal of 
controversy regarding the relative importance of "free" versus *'total 11 
tryptophan as a determinant of brain tryptophan concentration. It is now 
generally accepted that it is the nonal bumin-bound tryptophan, and not 
the total plasma tryptophan that controls the content of tryptophan in 
the brain. 
Tryptophan shares a transport system with other large neutral amino 
acids, including leucine, isoleucine, valine, phenylalanine and tyrosine. 
These amino acids can inhibit tryptophan transport across the blood brain 
barrier and across the brain cell membrane. Accordingly, when rats ingest 
protein containing food, there is no change in the content of brain 
tryptophan, despite a large increase in the concentration of plasma 
tryptophan, for the protein containing food also elevates the 
concentration of the amino acids in plasma that compete with tryptophan 
for uptake into the brain. The level of brain tryptophan is correlated 
with the ratio of the concentration of plasma tryptophan to the sum of 
the concentrations of the other large neutral amino acids in plasma. 
(For review: see Young and Sourkes, 1977). 
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4.1.3 SYNTHESIS AND CATABOLISM OF SEROTONIN 
In those cells that synthesize serotonin tryptophan is hydroxylated by 
tryptophan hydroxylase to yield 5-hydroxy tryptophan (5-HTP) (Figure 1). 
Tryptophan hydroxylase requires e 1 ementary oxygen and tetra 
hydrobi opteri n as a cofactor. The hydroxylation of tryptophan is the 
rate-1 imiting step in the biosynthesis of 5-HT. In vivo tryptophan 
hydroxylase is not normally saturated with tryptophan. This means, in 
animal experiments, that an increase in tryptophan availability results 
in an increase of serotonin levels and vice versa. The way that the 
activity of the tryptophan hydroxylation in the brain is further 
modulated is not known. 
5-Hydroxytryptophan is than decarboxyl a ted into 5-hydroxytryptami ne 
(serotonin) by 5-HTP decarboxylase which is present in cells in vast 
excess. 5-HTP decarboxylase requires pyridoxal phosphate as a cofactor. 
The enzyme that is primarily responsible for catabolizing 5-HT is 
monoamine oxidase A (MAOA). This enzyme oxidizes the primary amine group 
of serotonin to form 5-hydroxyindoleacetaldehyde. This aldehyde is 
rapidly dehydrogenated to yield 5-hydroxyindoleacetic acid (5-HIAA), the 
major metabolite of serotonin. 
In the cell MAO is probably located on the outer mitochondrial membrane. 
The enzyme has 1 imited substrate specificity and oxidyzes tyramine, 
norepinephrine, epinephrine and dopamine as well. 
4.1.4 SEROTONIN IN THE GUT 
The enterochromaffin cells in the gastrointestinal mucosa contains a 
large proportion of the body's store of serotonin (Erspamer, 1958). 
Little is known about the control of serotonin release from these cells. 
The enterochromaffi n cells typically span the mucosa. In genera 1 , the 
apical pole of each cell borders the intestinal lumen and is striated 
with microvilli (Forsberg and Miller, 1983). The polimorphous secretory 
granules that contain the amine are most commonly found in the widened 
base of the cell but occasionally are found in the apical portion. 
Presumably, dietary stimuli induce responses in the apical portion and 
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endocrine or nerve-derived factors induce responses in the basal portion. 
Muscarinic cholinergic receptors appear to mediate serotonin release from 
(rabbit) duodenal enterochromaffin cells in vitro (Forsberg and Miller, 
1983). Neurones from the enteric nervous system (ENS) may act to 
stimulate the enterochromaffin cells to release 5-HT in response to 
acetylcholine. Conversely, the 5-HT released from enterochromaffin cells 
may act to stimulate sensory neurons to provide an important neural input 
into the ENS (Gershon and Erde, 1981). The cell bodies of the ENS lie 
within the myenteric and submucous plexuses. These neurones interconnect 
with each others to form an integrated network responsible for regulating 
gut function (motility, blood flow, transport, etc.). The ENS receives an 
extrinsic cholinergic input from the vagal nerve and an adrenergic input 
from the sympathetic nerve. The neuronal processing in the ENS is carried 
out by a great variety of neurotransmitters and neuropeptides 1 ike 
norepinephrine, acetylcholine, vasoactive intestinal peptide (VIP), 5-HT 
and others. 
In vivo studies indicate that the enterochromaffin cells have the ability 
to secrete serotonin from their apical or basal sites, leading to 
increases in either luminal or blood concentrations of serotonin. Low 
luminal pH (Resnick and Gray, 1962), intraluminal sucrose solutions 
(Ohara et al., 1959), intraluminal pressure (Bulbring and Crema, 1959) 
and vagal nerve stimulation (Ahlman et a1 ., 1981) were shown to increase 
serotonin levels within the intestinal lumen (Forsberg and Miller, 1g83). 
On the other hand, vagal nerve stimulation (Pettersson et al., 1979), 
splanchnic nerve stimulation (Larsson et al., 1979), intra arterial 
nicotine, morphine, catechol ami nes and acetylcholine (Burks and Long, 
1966a, 1967a,b), intraluminal glucose (Drapanas et al., 1962) and low 
luminal pH (Kellum and Jaffe, 1976) increased serotonin levels in the 
portal blood. 
4.1.5 SEROTONIN IN THE BLOOD PLATELET 
Almost all the serotonin is released from the enterochromaffin cells into 
the blood system and broken down by MAO in the lung and the liver or 
transported into the circulating platelets. Lacking nuclei, platelets 
58 
have no DNA and very little ability to synthesize proteins. Once the 
platelets are released from the marrow, they age slowly in the circu-
lation and die in about 10 days, if they are not consumed before "in the 
line of duty" (Zucker, 1980). In the circulation, blood platelets appear 
as disc-shaped bodies with an outer membrane enclosing a cytoplasm 
differentiated into organells, such as granules, lysosomes, mitochondria, 
glycogen particles, microtubules and microfilaments. 
Serotonin is accumulated from the blood by an active transport mechanism 
1 ocated in the ce 11 membrane. In addition to this membrane transport" 
system b 1 ood plate 1 ets possess an efficient i ntrace 11 ul ar storage 
mechanism which permits the accumulation and retention of high 
concentrations of 5-HT, thus protecting the amine from metabolism by 
cellular enzymes such as monoamineoxidase. Platelet MAO is localized in 
mitochondria of which there are about ten per human platelet. The 
mitochondria supply the energy required for the platelet functions. 
Platelets behave as a multitransmitter storage site, in the sense that 
they have the ability to store several transmitter-like substances 
including, besides 5-HT, histamine, catecholamines, octopamine and the 
norepinephrine metabolite normetanephrine. 
The 5-HT organelles in platelets are bounded by a typical unit membrane. 
Platelets have a high content of 5'-phosphonucleotides, mainly adenosine 
triphosphate (ATP), adenosine diphosphate (ADP), guanosine triphosphate 
(GTP) and uri dine triphosphate (UTP). About 65% of the adenine 
nucleotides in human platelets is stored in the 5-HT organelles. High 
resolution nuclear magnetic resonance spectoscopy (NMR) investigations 
have revea 1 ed that the interaction between the i ntragranul ar components 
is very strong in human platelets. In rabbits ATPase of the 5-HT 
2+ 
oroanelles is selectively activated by Mg and partially inhibited by 
; 2+ 
Na and ca • This ATPase probably generates the proton gradient across 
the 5-HT organelle membrane driving inwardly directed electrogenic proton 
pump. This ATPase dependant proton translocation is intimately linked to 
the 5-HT uptake. The phosphonucleotides in the 5-HT granules do not 
further take part in the metabolic activity of the platelet. 
Uptake studies with isolated 5-HT organelles of rabbit platelets and 
chromaffin granules show that both organelles transport 5-HT and 
catechol amines quite efficiently. The concentration ratio between 
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platelet 5-HT and plasma 5-HT is probably more than 100.000. The 
concentration of 5-HT is about 200 times more concentrated in the 5-HT 
organelles than in whole platelets. 
In a more general subcellular distribution actin has been found in 
platelets. In contrast, selective localisation of alpha actinin in 
membranes of electron microscopically pure fractions of 5-HT organelles 
has been demonstrated. Alpha-actinin could serve as an anchoring protein 
for mi crofi laments of the platelet contractile system attached to 5-HT 
organelle membranes, and such an alpha-actinin-actin microfilamentous 
system could be involved in the exocytosis and in the expulsion of the 
granular contents. A circumferential band of long microtubules just 
inside the external membrane serves as a skeletal frame that maintains 
the roughly discoid shape of the platelet. There are numerous open 
vesicles, or membranous chanels, some of which are connected with one 
another and with the surface of the platelet, much like channels of a 
sponge, to form what is called the surface connected system (Da Prada, 
1981). The platelet serotonin stored in the nucleotide-containing 
granular vesicles can be released by drugs such as reserpine, 
tetrabenazine and amphetamine (Paasonen et al ., 1965; Pletscher, 1978). 
Serotonin, secreted from the dense granules, is a weak aggregating agent 
and also a vasoconstrictor that narrows the blood vessel locally, whether 
they are cut or intact, and thereby helps to restrict bleeding (Zucker, 
1980). 
In normal circumstances the platelets are undersaturated with 5-HT and an 
excess storage capacity of platelets does exist. 
It is not clear which aspect of 5-HT physiology is most important in 
setting blood level s in normal subject (Anderson et a l • , 1985d) • Steady 
state levels of whole blood 5-HT are apparently determined by the rate of 
gut production and the bal a nee between platelet uptake, storage and 
metabolism by monoamine oxidase. That these factors may influence blood 
5-HT levels is evident. In carcinoid syndrome (Crawford et al ., 1967) and. 
eel iac disease (Pimpakar et al ., 1961) and after monoamine oxidase 
inhibition (Weissbach et al., 1961, Marshall et al ., 1960) an increase of 
5-HT levels in blood is seen. 
After administration of imipramine (Marshall et al ., 1960), chloripramine 
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(Ross et al., 1976), fenfluramine (Ritvo et al., 1983) or reserpine 
(Hanley et al ., 1977) a decrease of 5-HT levels has been observed. 
4.1.6 SEROTONIN IN THE BRAIN 
In the brain serotonin serves as a neurotransmitter. Serotonin does not 
pass into the brain from the periphery, but it is synthesized in special 
nerve cells, stored in synaptic vesicles in the nerve endings and 
released by an exototic process. 
The distribution of serotonin in the brain is uneven with relatively high 
concentrations in the hypothalamus, the midbrain and the brainstem. 
The primary source of most of the serotonin in the brain are several 
clusters of neurons in the midline, the raphe of the pons, and 
mesencephalon. The more rostrally placed cellgroups project to the 
telencephalon and diencephalon. The more caudally placed cellgroups 
project to the medulla and the spinal cord. Serotonergic cells in the 
median raphe nucleus innervate preferentially structures of the 1 imbic 
system. The cells in the dorsal raphe nucleus project primarily to the 
cerebral cortex, the neostriatum, the thalamus and the cerebellum. 
Another important place serotonin is manufactured is the pineal body, 
where it is metabolized into melatonin. 
Both serotonergic and nonserotonergic neurons have serotonin receptors. 
On serotonergic neurons, serotonin receptors ("autoreceptors") provides 
the mechanism for feedback inhibition of neuronal activity that is 
coupled to release of the transmitter. So:o activation of the serotonergic 
autoreceptors reduces the neuron's rate of spontaneous firing. 
The action of 5-HT receptors on nonserotonergi c ce 11 s is predominantly 
inhibition of firing:o although some excitatory serotonin receptors have 
been described (Brownstein, 1981). 
Serotonin has been implicated in many central processes, i ncl ud ing 
regulation of the anterior pituitary:o sleep, appreciation of pain, 
thermoregulation, control of blood pressure, appetitive behavior, 
drinking, res pi ration, heart rate, rhythmic behavior and memory 
(Brownstein, 1981). 
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4.2 INFANTILE AUTISM AND SEROTONIN LEVELS IN BLOOD: HYPERSEROTONEM!A 
4.2.1 INTRODUCTION 
In 1961 Schain and Freedman were the first persons who reported an 
elevated serotonin level in the blood of some autistic children {Schain 
and Freedman, 1961). Of a group of 23 autistics the serotonin was 
elevated in 6 children. The mean level of the whole group was 
significantly higher than that of a contrast group consisting of mildly 
retarded children without autistic characteristics .. Schain and Freedman 
also compared their group of autistics with a group of severely mentally 
retarded children. On an average these children had higher serotonin 
values than the slightly retarded children, but lower than the autistics. 
However, the latter difference was not significant. 
After the publication by Schain and Freedman the finding of an elevated 
serotonin level in the blood of autistic children has been confirmed by 
many investigators. Thus, Ritvo et al. (1970), Yuwiler et al. (1971, 
1975), Goldstein and Coleman (1976), Takahashi et al. (1976), Hanley et 
al. (1977), Hoshino et al. (1979b), Hoshino et al. (1984c), Anderson et 
al. (1985b, Appendix No. I) and Minderaa et al. (1985d, Appendix No. !!) 
were among those who have found that the serotonin values in the blood 
were elevated. In total, more than 300 autistic children were involved in 
these investigations. There are not any results of investigations contra-
dicting these findings. Only some investigators found the differences 
were not significant (Boullin et al., 197la; Campbell et al., 1974a). 
Thus there is good agreement among investigators that mean whole blood 
5-HT levels are elevated in autistic subjects. However, considerable 
overlap does exist for platelet 5-HT values among individuals in the 
autistic groups with those among normal control subjects. 
It is difficult to compare the results of the different investigators. In 
the very first place there exists the problem of the diagnostic marking 
of the limits of the syndrome. The symptomatology differs from child to 
child and can change with time. Consequently, the view of the symptom-
atology has been evolved in the course of decades. This has 1 ed to a 
great variety of different diagnostic terminologies, which hamper com-
parison of the results of the investigations. In the literature the terms 
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childhood autism, primary autism, infantile autism, atypical development, 
childhood schizophrenia, symbiotic psychosis and early onset psychosis 
refer all to nearly the same symptomatology. It is possible that there 
exist diagnostic differences in the groups that were investigated. 
Furthermore, it is important to note that in comparing the results of 
investigations on the serotonin levels various measurement techniques has 
been applied in the course of years. Schain and Freedman (1961) extracted 
the serotonin from homogenised blood by means of acetone. Serotonin was 
measured with a bioassay with heart of clams or rat uterus. Later various 
fluorometric methods were applied (Yuwiler et al., 1975; Goldstein and 
Coleman, 1976; Takahashi et al., 1976; Hanley et al., 1977; Hoshino et 
al ., 1979b; Ritvo et al ., 1970; Sankar et al ., 1962). Recently Anderson 
(1985b) has employed high performance liquid chromatography (HPLC). 
Another factor which plays a part is that by some the serotonin level was 
determined in serum (Ritvo et al ., 1970; Hoshi no et al ., 1979b), by 
others in whole blood (Ritvo et al., 1970; Yuwiler et al., 1975; 
Goldstein and Coleman, 1976; Hanley et al., 1977), in platelet rich 
plasma (Hoshino et al., 1979b) or in platelet pellets (Takahashi et al., 
1976). 
As to the measurement in serum it is difficult to know which percentage 
of 5-HT stored in the platelets was released and was measured. In 
isolating platelet rich plasma or platelet pellets an important factor is 
that heterogeneous platelet populations can be acquired by centrifuging. 
Younger blood platelets are heavier and are characterized by a greater 
metabolic activity such as greater enzyme activity and more granules 
storing serotonin (dense granules) (Karpatkin, 1978; Murphy et al., 
1978). Consequently, the isolation of platelets by centrifuging can lead 
to variable serotonin values (Young et al., 1982). Lastly the concentra-
tion of 5-HT has been expressed by some investigators per ml blood, and 
by others per number blood platelets or per mg protein. 
In consequence, there are considerable differences between observed mean 
group values of autistic children and control groups (Anderson et al ., 
1985b, Appendix No. I Table I). The above mentioned problems concerning 
diagnostic procedures, measurement techniques and ways of expression can 
be causal aspects in this matter. With regard to control groups there are 
found blood 5-HT (ng/ml) elevations in groups of autistics of 137% 
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(Hanley et al., 1977), 117% (Schain and Freedman, 1961), 51% (Anderson et 
al., l985b, Appendix No. I), 49% (Yuwiler et al., 1971), 41% (Minderaa et 
al., l985d, Appendix No. II), 40% (Hoshino et al., l984c), 33% (Yuwiler 
et al., 1975), 22% (Ritvo et al., 1970) and 18% (Goldstein and Coleman, 
1976). Our findings of 51% and 41% (Anderson et al., 1985b, Appendix No. 
I) and 41% and 33% (Minderaa et al., 1985d, Appendix No. II) for ng/ml 
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and ng/10 platelet respectively are approximately in the middle of this 
range. 
Some investigators defined hyperserotonemia as a whole bood 5-HT level in 
the upper 5% of a normal control group. Using this criteria Hanley et al. 
(1977) found a percentage of 30% while our findings are 38% (Anderson et 
al., l985b, Appendix No. I) and 29% (Minderaa et al., 1985d, Appendix No. 
II), percentages approximating each other. 
4.2.2 STABILITY OF WHOLE BLOOD SEROTONIN OVER THE TIME 
Only few studies dealt with the stability over the time of serotonin 
values in the blood. Yuwiler did not find any indications pointing to 
circadium rythmicity in nonnal nor in autistic children. In a normal 
control group Ritvo et al. (l97la) found constant 5-HT values in the 
blood over the period of a week. Yuwiler et al. (1971) also found a 
slight intra-individual variance in the 5-HT values obtained from male 
val unteers. However, the peri ad between the b 1 ood drawings was not 
mentioned in this investigation. 5-HT values repeatedly measured over one 
year period of time, were also stable in 2 male control subjects. Hanley 
et al. (1977) reported several hyperserotonemic children were repeatedly 
confirmed to have high blood 5-HT levels over the one-year period of 
time. 
In our own investigation (Minderaa et al., 1985d, Appendix No. II) 5-HT 
values appeared to be very stable over one year period with a very high 
significant intraclass correlation and a low mean percentage of change in 
10 unmedicated autistics. In a series of articles Wirz-Justice described 
a variable pattern of 5-HT values over the day and a bimodal annual rythm 
in a group of nonnal volunteers (Wicz-Justice et al., 1977,1978, 1979). 
However, the variation of 5-HT over time shown in these studies is very 
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modest. It might be concluded that blood 5-HT is stable over the time. 
4.2.3 AGE 
The relation between age and the serotonin level in -the blood is unclear, 
both in control subjects and in autistics. After investigating a control 
group (N=164) in the age of 1-40 Ritvo et al. (1971a) found that the 
whole blood serotonin values (llg/ml) decreased from the first year of 
life up to puberty and remained constant afterwards. The number of blood 
platelets decreased in the same way with the climbing of age. In our 
study (Anderson et al ., 1985b, Appendix No. I) no connection was found 
between whole blood serotonin levels and the age in a group of normal 
children (6 years and older) and young adults. Both Ritvo et al. (1970) 
and Takahashi et al. (1976) found differences between autistics and 
control groups to be the greatest in the younger age group up to the 
age of 6. This finding was confirmed by us, but only in young boys 
(Anderson et al., 1985b, Appendix No. I). 
4.2.4 SEX 
Ritvo et al. (1970) found no sex differences in their control group. In 
our investigation (Anderson et al., 1985b, Appendix No. I) significantly 
higher serotonin values were found in the blood of boys in the younger 
age group (1-6 years of age) of the control children in comparison with 
girls. 
4.2.5 INTELLIGENCE 
In his original study Schain and Freedman (1961) examined three groups: a 
group of mentally retarded children (IQ 60-80), a group of autistics 
functioning at a severely retarded level, and a group of seriously 
retarded non-autistic children with an IQ below 20. The serotonin levels 
of the first group were significantly lower than those of the second 
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group. However, the difference in serotonin values between the autistics 
and the most severely retarded children was not significant. 
Hanley et al. (1977) employed a similar grouping. They defined hyper-
serotonemia as those values which were more than 1.65 times the standard 
deviation higher than the average serotonin values of the control group. 
According to this criteria 30% of the autistics had elevated serotonin 
levels, and 52% of the group seriously retarded children. Consequently, 
more than half of the seriously mentally retarded children without 
specific (manifest), metabolic or neurological disorders had hyper-
serotonemia. Surveying the studies which had been published up till then, 
they arrived at the impression that children with IQ values below 20 tend 
to have hyperserotonemia, whereas children with IQ values above 60 tend 
not to have it. 
In a group of 11 seriously disturbed children (11 "schizophrenic" 
children, 2 autistics and 2 children with a "withdrawal reaction 11 ) 
Campbell et al. (1974a) tried to find a relation between serotonin values 
and intellectual functioning. She found that low intellectual functioning 
was the only parameter which seemed to correlate clearly with higher 
serotonin levels. In a later study Campbell et al. (1975) measured 
serotonin values in 23 children with "childhood schizophrenia'' and 16 
control children. The mean serotonin values in the autistics were 
elevated, although this was not significant. However, the serotonin 
values were significantly higher in a subgroup of children with floride 
psychoses, and with lower IQ's than of children in remission, partly 
remission or with higher IQ's. 
The importance of these findings becomes more clear when one realises 
that in the 1 i terature 85% of a uti sti c children are described as being 
mentally retarded. This 1 eads to the question whether hyperserotonemia 
doesn't say more about mental retardation than about autism. 
4.2.6 HYPERACTIVITY 
Schain and Freedman (1961) examined the symptomatology of the 6 autistics 
with the highest serotonin values from their group of 23 and found no 
difference as to activity with the other autistics. In the group of 30 
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autistics of Takahashi et al. (1976) there were 21 with a high score for 
hyperactive behaviora However, the serotonin values of these children 
were only slightly higher than those of the whole group of autistics. In 
their contrast group of non-autistic psychiatrically disturbed children 
hyperactive children did have significantly higher serotonin levels than 
the rest of the children in this group. Neither Hoshino et al. (197gb) 
and Hanley et al. (1977} could find a connection between hyperactivity 
and elevated serotonin levels in autistic children. 
4.2.7 NEUROLOGICAL EXAMINATION AND MEDICATION 
Hanley et al. (1977) found no connection between results of neurological 
examination and the serotonin levels in the blood of their group of 
autistics. However, Schain and Freedman (1961) reported that none of the 
6 hyperserotonemi c a uti sti c children in their group suffered from epi-
lepsy, although this frequently occurred in the other autistics. Further-
more, it is reported that anti-epileptics did not seem to influence the 
serotonin values. Anderson et al. (1985b; Appendix No. I) recently found 
that autistics with anticonvulsive medication had significantly lower 
serotonin values than those without medication. In a follow-up study 
about this subject, the decrease seen was not statistically significant 
(Minderaa et al., 1985d, Appendix No. II). According to Schain and 
Freedman (1961) phenobarbital and chlorpromazine didn't have any 
influence on the serotonin level of the autistics either. Hoshi no et al. 
(1979a) also reports that medication (methylphenidate and haloperidol) 
did not change the serotonin percentage in serum. However~ Anderson et 
al. (1985b, Appendix No. I) also found significantly lowered serotonin 
values in autistics with neuroleptics in comparison with the unmedicated 
autistics. Minderaa et al. (1985d, Appendix No. II) found significantly 
decreased 5-HT values after the start of neuroleptic medication in 4 
autistic individuals. In the same study in a group of 10 autistics with 
neuroleptic and anticonvulsive medication the 5-HT values were signifi-
cantly higher for the second blood drawing compared to the first blood 
drawing when measured a year apart. But only a nonsignificant trend was 
found for a group time effect of the medicated group compared to the 
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unmedicated autistic individuals. 
In some groups of mentally retarded children with a defined syndrome 
(e.g.: congenital rubella) elevated serotonin levels have also been found 
{Pare et al., 1960; Coleman, 1978}, as well as lowered serotonin values 
as in Down's syndrome (Boullin et al., 1971b) and phenylketonuria (Pare 
et al., 1957, 1958). In the groups of mentally retarded children in which 
hyperserotonemia is found, autistic behavior characteristics have some-
times been described too .. The percentage of hyperserotonemia did not 
differ when these subgroups were included or excluded from a group of 
autistics (Young et al., 1982c). Oikawa et al., (1978) found the degree 
of mental retardation in retarded adults correlated with the serotonin 
levels. Common symptoms in the individuals with increased serotonin 
levels included aggressiveness, seizures and hearing or visual defects. 
Finally, Minderaa et al. (1985f, Appendix No. VI) reported that a small 
group of unmedicated autistics with a visual rooting reflex showed 
significantly higher 5-HT values compared to those without a visual 
rooting reflex. This finding needs replication. 
4.3 NUMBER OF BLOOD PLATELETS 
The serotonin percentage circulating with the blood is almost completely 
situated in the blood platelets. Only a small part is situated in the 
plasma (l-5%). This gives rise to the question whether in hyperseroto-
nemic autistics the number of blood platelets is elevated. This could be 
a possible explanation for elevated serotonin levels in blood. Thus, 
Boullin et al. (1971a) found that in 5 autistics the number of blood 
platelets per ml plasma was significantly elevated in comparison with 
control children. 
Similarly, Ritvo et al. (1970) found that in 24 autistic children the 
number of blood platelets was elevated in comparison with a control group 
of same age .. Although the serotonin level given per ml blood was 
significantly higher in the group of autistics, the serotonin values 
given per number of blood platelets did not differ with that of the 
control group. However, Yuwiler et al. (1975) found that in 12 autistics 
the serotonin values were elevated both when the concentration was given 
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per ml blood and per number of blood platelets. 
Hanley et al. (1977) compared 4 autistics with high serotonin values with 
4 mentally retarded children with normal serotonin values. The difference 
in number of blood platelets was small and could not account for the 
difference of serotonin values between the two groups. In our investi-
gation (Anderson et al ., 1985b, Appendix No. I, Minderaa et al ., 1985d, 
Appendix No. II) there wasn't found any difference either in number of 
blood platelets between 21 unmedicated autistics and the normal children 
in the control groups (N= 87). In this study the serotonin level in 
autistics was elevated both when the concentration was given per ml 
blood and per number of blood platelets. So, the more recent findings 
point in the direction of an elevated serotonin level, both absolutely 
and per number of blood platelets. Consequently, it seems very unlikely 
that an elevated number of blood platelets should be the cause of 
elevated serotonin values in autistics. 
Hanley et al. (1977) found a positive correlation between serotonin 
levels (ng/ml) in the blood and the number of blood platelets in 
autistics. In our first report (Anderson et al., 1985b, Appendix No. I) 
no correlation was found between the 5-HT (ng/ml) levels in the blood and 
the platelet count in unmedicated autistics. On the contrary, in the 
second report (Minderaa et al., 1985d, Appendix No. II) a correlation was 
found between whole blood 5-HT (ng/ml) levels and p
9
1atelet count. 
Together with a lack of correlation between 5-HT ng/10 platelets and 
platelet count in unmedicated autistics this suggests that platelet count 
or function might play a causal role in hyperserotonemia. 
4.4 FUNCTION OF BLOOD PLATELETS 
Much work has been done on the in vitro capability of autistics• blood 
platelets to take up and store serotonin. The results are contradictory 
and controversial. In a series of articles Sankar (Sankar et al ., 1962; 
Sankar, 1970; Sankar, 1971) demonstrated that the ability of blood 
platelets to take up serotonin is decreased in autistic and mentally 
retarded children. The lower the IQ, the greater the decrease seen. In 
normal children there was an increase of the serotonin-uptake of blood 
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platelets in vitro with climbing age. This was not found in autistic 
children. More recently this finding was replicated again and the author 
concluded that the defect is associ a ted with the platelet and not with 
the plasma (Sankar, 1977). 
On the other hand Boullin et al. (1971a) found a slight, not significant 
increase of the ability of blood platelets in vitro to take up serotonin. 
This was attended with an also slight increase in the adenosine tri-
phosphate (ATP) level of blood platelets. 
Lucas et al. (1971b) did not find any difference in the serotonin-uptake 
ability between 16 male "schizophrenic patients", with an average age of 
12.9 and a control group with children with serious personality 
disturbances. 
In 1975 Yuwiler et al. investigated 12 autistic children and 15 
hospitalized otherwise psychiatrically disturbed children. The aim was in 
particular to measure the serotonin-uptake ability according to 2 
different methods and to compare these methods with each other. In one 
method manupulation of the fragile trombocytes was prevented as_ much as 
possible. In the other method centrifuging and resuspensing was applied 
with an increased change of cell damage. With the first method the 
serotonin uptake of blood platelets in the autistics appeared to be 
slightly but not significantly decreased. In the second method the uptake 
was somewhat higher, but there were not any differences between the 
groups either. Finally, Rotman et al. (1980) investigated 2 subgroups of 
"autistics". They called the four children of the first group 
"affectively centripetal chi1dren 11 • These children resisted contact and 
preferred to be left alone. Accardi ng to the authors they were most 
similar to the original autistics described by Kanner. The 6 children of 
the second group were called "affectively centrifugal children". These 
children were directed on the outer world and were considered to be more 
aphasic or specific brain-organically disturbed. Rotman found the 
serotonin-uptake ability of blood platelets of the first group to be 
significantly higher than those of the second group. These findings are 
interesting in particular because an elevated uptake ability of 5-HT of 
blood platelets could be a factor in elevated serotonin values in the 
blood. However, in this investigation whole blood 5-HT values are not 
mentioned. Furthermore, 8 out of 10 children used psychoactive drugs. 
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Although the authors indicate that psychopharmacological medication had 
no significant effect on 5-HT uptake in vitro, the results should be 
viewed with cautiona 
The outcome of the investigation on the release of serotonin from blood 
platelets, is as contradictory as the results of the investigations 
mentioned above. In the investigation of 5 autistic children Boullin et 
al. (1970) found that the the ability of the blood platelets to store the 
radioactively labeled serotonin, was decreased. In a following study 
(Boullin et al ., 1971) they were able to blindly predict, on the basis of 
experimental data concerning the serotonin efflux of blood platelets, 
which six out of ten psychotic children were autistic and which not, 
according to a specific scoring procedure. The criterium was that the 
efflux had to be three time the control value in order to predict the 
presence of autism according to the scores. In the vesicles in the blood 
platelets 5-HT forms a binding with adenosine-tri-phosphate. The ATP 
values in blood platelets were not abnormal and the ATP-5-HT ratio was 
normal in autistics. In consequence, a possible shortage of ATP could not 
be an explanation for the decreased ability of the blood platelets to 
store 5-HT. However, Yuwil er et a 1. (1975) could not confirm these 
spectacular findings. These investigators found no differences in 
serotonin efflux from blood platelets between a uti sties and control 
children. Later, the latter investigation was attacked in detail by 
Rimland (1976), one of the coworkers of the investigation of Boullin. The 
essence of the criticism is that Yuwiler used wider inclusive criteria 
for the experimental group. Soul lin selected by means of score of +20 or 
higher on the Rimland E-2 Diagnostic Checklist. This list has specially 
been constructed to select the 10% of children with classical early 
infantile autism (Kanner's syndrome) from the 1 arger group of children 
with autistic characteristics. Rimland argues that Yuwiler•s investiga-
tion group can be compared with Boullin's control group. In a collabora-
tive study Boullin, Yuwiler, Rimland and others (Boullin et al., 1982) 
have most recently reported that the serotonin efflux of blood platelets 
in autistic subjects is nonnal. 
In our investigation (Anderson et al., 1984, Appendix No. IV) the 
imipramine binding of blood platelets was investigated. The imipramine 
binding sites are supposed to play a role in the regulation of the 
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serotonin uptake of blood platelets and recently low molecular weight 
substances in plasma have been detected that inhibit both high-affinity 
imipramine receptor binding and serotonin uptake in platelets (Brusov et 
al., 1g85). The imipramine binding of blood platelets in 11 autistics 
without medication appeared not to differ from that of a control group. 
Therefore, this finding lends no support to alterations in the serotonin 
uptake of blood platelets in autistics. 
Hanley et al. (1977) studied the effect of reserpine on the serotonin 
values of the blood in 4 hyperserotonemic autistics and 5 slightly 
retarded children with normal serotonin levels.. Reserpine expels 
serotonin from the storage vesicles in the blood platelets so that the 
serotonin level in the blood is strongly reduced. In both groups the 
serotonin percentage was not to be measured any longer after some days. 
In both groups the recovery developed at the same rate. After 17 days 
the serotonin values were back to baseline levels. This finding is not in 
favour of a disturbance existing in the ability of blood platelets to 
store 5-HT. 
Platelets have been reported to contain a neurone-specific enolase 
(Marangos et al., 1980; Campbell et al., 1980,1981). This enzyme was 
previously found only in neurones and in cells of the APUD-system (amine 
precursor uptake and decarboxilation system). Its presence in platelets 
suggests that platelets, like the argentaffine cells in the gut that 
produce serotonin, may belong to the Diffuse Neuroendocrine System 
(ONES). The ONES, the somatic and the autonomic nervous system are judged 
as the three devisions of the mammal ian nervous sytem (Pearse, 1977) .. 
This might mean that ontogenetically the blood platelet and the 
argentaffine cell in the gut are related to each other. With Campbell 
(1983) we state that were this to be the case, conceptual problems 
concerning the relationship of various aspects of platelet function, 
argentaffine cell function and psychopathology might better be understood 
in the future .. 
4.5 PLASMA CYCLIC AMP 
Cyclic AMP (adenosine 3'5'-monophosphate, cAMP) is supposed to be a 
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"second messenger" for neurotransmitters such as serotonin in the brain. 
These neurotransmitters elevate intracellular cAMP after interacting with 
the membrane receptors. Winsberg et al. (1980) reported that levels of 
ck~P in cerebrospinal fluid of autistic children were elevated after 
probenecid administration. However, no control group was used in this 
study. Hoshino et al. (1979b) measured the concentration of plasma cAMP 
in a group of 20 autistic children. They found the percentage of ckMP in 
plasma significantly higher than in the control children. At the same 
time, they, found a positive correlation of this value with the serotonin 
percentage in serum. There also existed a correlation of cyclic AMP 
concentration with the hyperactivity scores of the autistic children. The 
more active these children were, the higher the cAMP concentration in 
plasma. 
Goldberg et al. (1984) reported plasma cyclic P-MP significantly elevated 
by over 100% in 18 patients with childhood autism and in 7 patients with 
pervasive developmental disorders compared to 12 age- and sex-matched 
normal controls. Plasma guanine monophosphate (cGMP) was normal in these 
groups. The origin of plasma cAMP remains unclear. The compound has been 
assumed to be derived from peripheral organs, such as the liver, kidney, 
lung and adrenal glands, as well as the brain (Anderson et al., 1g85b). 
So, the relation between plasma cAMP and whole blood serotonin is 
uncertain. 
4.6 ATP AND ATPASE ACTIVITY 
Boullin et al. (l97la) found the concentration of ATP in blood platelets 
in autistics not changed in comparison with controls. But the range 
appeared to be greater. However, Sankar (1971) found significant 
differences in ATPase activity before and after lysis of the blood. He 
concluded from this that a difference possibly existed in membrane 
function of the red cells between autistic and normal children. 
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4.7 MONOAMINE OX!OASE ACTIVITY IN BLOOO PLATELETS 
Research on monoamine oxidase (MAO) in blood patelets is reported in 
various studies. MAO degrades serotonin (in addition to other amines) and 
decreased MAO-activity could be a cause of the elevated serotonin levels. 
However, the MAO activity in blood platelets of autistic children, 
measured under a variety of conditions, has appeared to be normal 
(Boull in et al ., 1976; Campbell et al ., 1976a; Cohen et al ., 1977d; Lake 
et a1., 1977; Roth et a1., 1976). No correlation was found between MAO 
activity and the serotonin concentration in autistics (Cohen et al., 
1977d). 
4.8 TRYPTOPHAN 
Hoshi no et al. (1979b) measured free tryptophan in serum in 10 autistic 
children and found no differences with a control group of adults. Two 
children had a remarkably high free tryptophan level. These children were 
very hyperactive and showed aggressive behavio.r. However, in the whole 
group of autistics there was no connection between the free tryptophan 
level in serum and scores of degree of active behavior. The same research 
group recently compared 37 autistics with 76 control children (Hoshino et 
al ., 1984c). The plasma free tryptophan level was significantly higher in 
autistic children than in normal control subjects. No differences were 
found for total TRP levels. There tended to be a significant positive 
correlation between the plasma free tryptophan level and scores of 
clinical symptoms and signs of autism at the Children's Psychiatric 
Rating Scale and at the Werry-Weiss-Peters Activity Scale and a negative 
correlation between plasma free tryptophan level and the Developmental 
Quotient. No correlation was found between 5-HT levels and behavior 
scores or between 5-HT levels and free tryptophan levels. 
Yamamoto et al. (1982) treated autistic children during six months with 
haloperidol and showed that during this treatment plasma free levels of 
TRP normalised concomitant with clinical improvement. 
In our first study (Anderson et al ., 1985b, Appendix No. l) we found 
slight differences in total tryptophan levels in the blood of 40 autis-
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tics in comparison with an age-matched control group. The tryptophan 
level in the autistics was lower. However, this difference was only 
significant for the medicated autistics. Takatsu et al. (1965) reported 
that the total TRP level was at the lower limit of normal or lower in 
atypical autism. Sylvester et al. (1970) reported that young psychotic 
children excreted significantly lower amounts of urinary TRP compared to 
normal controls. 
In our second study (Minderaa et al., 1985d, Appendix No. ll) no differ-
ences were found in total TRP between unmedicated autistics and control 
subjects. Hoshino et al. (1979b) found no differences either of total TRP 
levels between autistics and controls. It can be concluded from these 
several studies that the total TRP levels in the blood of autistics are 
normal. 
Several investigators have experimented with a tryptophan loading test in 
autistic children. Schain and Freedman (1961) gave an oral tryptophan 
loading in 4 autistic children. This did not lead to consistent changes 
in the serotonin level of the blood. After an oral loading with 3 g of 
tryptophan Shaw et al. (1959) saw no difference in the increase of 
5-hydroxyindoleacetic acid (5HIAA) excretion in the urine between 11 
schizophrenic children and 10 non-schizophrenic children with different 
psychiatric problems. Sutton et al. (1958) described an 18 months old 
autistic girl with a decreased ability to convert tryptophan into 5-HIAA. 
After oral tryptophan loading (0.25 g/kg) there was found decreased 
concentration of indoleacetic acid, indolelactic acid and 5-hydroxy-
indoleacetic acid in the urine. Without loading the excretion of these 
metabolites was normal. No deviations were found in the excretion of 
metabolites of the kynurenine pathway such as xanthurenic acid and 
kynurenic acid. 
Finally Hanley et al. (1977) administered an oral dose of tryptophan to 4 
hyperserotonemi c a uti sti cs and 4 mildly mentally retarded children with 
normal serotonin levels during a period of 3 days. Both before and after 
the tryptophan loading the serotonin values in the blood and the urine 
excretion of serotonin and 5-HIAA were higher in the autistics. 
Tryptophan loading caused a slight fall in the serotonin values in the 
blood in both groups, while the urine 5-H!AA excretion doubled. After 
loading the serotonin excretion via the urine increased in the hyper-
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serotonemic autistics, but decreased in the retarded children. The 
investigators concluded that in hyperserotonemic autistics 5-HT can be 
converted adequately into 5-HIAA via the MAO dehydrogenase enzymes. 
Furthennore they concluded that it is unlikely that there exists a 
serious blockade in the kynurenine pathway, as the 5-HIAA rise after TRP 
loading was proportionally equal in both groups. Finally, they concluded 
that the uptake of TRP by the APUD cells in the gut, and the different 
steps to convert TRP to 5-HTP and 5-HT were not greatly altered in 
autism. 
Heeley and Roberts (1965) investigated the tryptophan metabolism in 16 
psychotic children. They studied in particular the ratio between the 
excretion of 3-hydroxy kynurenine (HK) and 3-hydroxyanthranilic acid (HA) 
after tryptophan loading (0.1 g/kg). This HK-HA ratio was elevated in 9 
out of 16 children, which points to a decreased kynureninase- activity. 
As kynureninase is very pyridoxine sensitive, this is interpreted as an 
indication for a dietary or functional pyridoxine deficiency .. There were 
no other indications for diet deficiency of pyridoxine in these children. 
Four children with deviating values were treated with oral pyridoxine 
suppletion. After a week the HK-HA ratio had been nonnalised after 
tryptophan loading .. Consequently, according to the authors, there are 
indications for a decreased availability of pyridoxine, for the 
kynureninase step. There are investigators who also claim a favourable 
result of administrating Vitamine B6 in regard to the behavior of some 
autistic children (Rimland et al ., 1978; Martineau et al ., 1981). 
Hoshi no et al. (1983, 1984b) administered L-5-hydroxytryptophan (5-HTP) 
to 6 autistic children and nine nonnal controls. Although the baseline 
values of blood 5-HT were significantly increased in the autistics, blood 
serotonin showed a suppressed increase after 5-HTP, compared with normal 
controls. 
4.9 5-HYDRDXYINDOLEACET!C ACID IN URINE 
5-HIAA is the main metabolite of serotonin and can be measured in urine. 
The urine excretion of 5-HIAA seemed mainly derived from peripherely 
produced serotonin. Shaw et al. (1g59) found no difference in absolute 
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values of 5-HIAA in urine between a group of 11 "schizophrenic children" 
and 10 non-schizophrenic psychiatrically disturbed children. Partington 
et al. (1973) also found a normal 5-HIAA excretion in mentally retarded 
children with elevated 5-HT values in blood. 
Schain and Freedman (1961) did find significant higher 5-HIAA values in 
24-hours urine in a group of autistics compared with a group of mildly 
mentally retarded children~ if it was expressed per mg creatinine. 
However, the creatinine concentration in the autistics was much lower 
than in the mentally retarded children, so that the results concerning 
the 5-HIAA excretion can not be considered to be deviating. However, 
Hanley et al. (1977) found significantly elevated 5-HIAA values (mg/day) 
in 4 autistics with hyperserotonemia compared with a control group of 4 
slightly mentally retarded children with normal serotonin values. This 
elevated 5-HIAA excretion increased further after an oral TRP loading, at 
the same rate as in the slightly mentally retarded children. 
We assessed urinary 5-HIAA excretion in a group of 16 unmedicated 
autistic individuals (Minderaa et al., 1985a, Appendix No. III). No 
significant differences were found between unmedicated autistics and 
normal controls. Furthermore, a lack of correlations between urinary 
5-HIAA and whole blood 5-HT was observed for the autistics as well as for 
the control subjects. These findings suggested that elevation of whole 
blood 5-HT is not due to differences in 5-HT gut production in the 
intestine. However, urinary 5-HIAA excretion was significantly greater in 
hyperserotonemic autistic subjects compared to normal controls and tended 
to be higher compared to normoserotonemic autistics. These findings might 
suggest that some relationship between gut 5-HT production and increased 
blood 5-HT levels do exist in hyperserotonemic autistic individuals. 
4.10 5-HYDROXYINDOLEACETIC ACID IN SPINAL FLUID 
Up to the present only a few research groups have done spinal taps in 
autistic children in order to measure metabolites of monoamine metabo-
lites. Cohen et al. (1977c) found in a group of 18 autistic children 
after administering probenecid the CSF concentration of 5-HIAA increased 
1 ess than in a contrast group coosi sting of non-autistic psychotic 
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children. Within the group of autistic children there is searched for 
corre 1 ati ons between metabo1 i te concentrations in the CSF and behavior 
scores. Autistic children who scored better as to soci a 1 responsiveness 
and the ability to concentrate had higher 5-HIAA concentrations in the 
CSF. This also held true when a larger group of neuropsychiatrically 
disturbed children was examined. So~ a greater turnover of serotonin, as 
measured via the metabolite concentrations after probenecid loading, was 
correlated with less disturbance in social functioning and attention 
functioning in autistic children and in a larger group of neuropsy-
chiatrically disturbed children. Winsberg et al. (1980) found in a few 
autistic patients no increase in CSF 5-HIAA after probenecid adminis-
tration. However, in this study, no control group was used. In a recent 
investigation Gillberg et al. (1983a) compared a group of 13 autistic 
children with a group of 22 children with other psychoses and with an 
age-matched control group. They also examined, among others, a group of 8 
children with "simple" mental retardation. The CSF baseline 5-HIAA values 
of the autistics were not significantly higher than those of the control 
children. The same held true for the non-autistic psychotic children and 
the mentally retarded children. Of these 3 groups of children the 5-HIAA 
values were the highest in the last group. However, neither in the group 
with autistic children, nor in the group with other psychoses did there 
exist a significant correlation between IQ and metabolite values. 
So, although the findings with respect to CSF 5-HIAA are inconclusive, 
there might be some suggestion of decreased values in autistic patients. 
4.11 BUFOTENIN EXCRETION IN URINE 
Perhaps prompted by the interest in the transmethylation hypothesis of 
schizophrenia~ there also existed an interest in the bufotenine excretion 
(N, N-dimethylserotonin) with regard to psychotic children. Bufotenin is 
a dimethylated derivate of serotonin and was considered to have an 
hallucinogenic effect. Related compounds with hallucinogenic effects are 
N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine 
( 5-MeODMT) • 
Perry (1963) found that 2 out of 18 "juvenile psychotics" excreted 
bufotenin, while they were medicated with a MAO blocker. The bufotenin 
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concentrations did not differ from those of the control children, of whom 
4 out of 6, with MAO blockers, excreted bufotenin. Himwich et al. (1972} 
compared 6 children suspected of autism with 6 nonnal children, under 
dietary circumstances. Five of the autistics and none of the control 
chi 1 dren sporadically excreted bufoteni n. None of the patients excreted 
OMT of 5-MeOOMT. 
Finally, Narashimharchari and Himwich (1975) reported three out of six 
autistic patients excreted DMT compared to none of their 13 controls. 
Urinary bufotenin was detected in five out of six autistic individuals 
compared to one out of 13 of the control subjects. 
As far as is known, methyldonors, as methionine, has never been 
administered to autistics. 
Nicotinic acid or nicotinamide can serve as methylgroupacceptors. Their 
effect on autistic children are much disputed, as will be discussed in 
the following section. 
So it might be suggested that unusual methylated metabolites of indole-
amines are present more often in autistic individuals. The significance 
of these findings is unknown, at present they require replication. 
4.12 MEDICATION WHICH HAS AN IMPACT ON THE SEROTONERG!C SYSTEM 
Until recently medication which was primarily directed to the serotoner-
gic system was applied only sporadically. Campbell et al. (1971} treated 
10 autistic and schizophrenic children with imipramine. This resulted in 
a mixture of stimulating~ tranquilizing and deteriorating effects. Three 
children functioned obviously better, five worse. In these 5 children 
there was an increase in the serotonin levels in blood. Sverd et al. 
(1978} treated 3 autistic children with the precursor of serotonin, 
L-5-hydroxytryptophan, in combination with Carbidopa, according to a 
double blind design. Changes in behavior were observed which~ however~ 
were not correlated with the treatment. Zarcone et al. (1973) adminis-
tered L-5-HTP orally to 2 autistic boys, 7 and 8 years old, during a 
period of 8 days. Except the increase in REM-sleep no changes in behavior 
were observed. 
Furthermore, in the 1960's several investigators tested the effect of LSD 
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on the symptomatology of autistics. Bender (1966) gave LSD (1-methyl-D-
lysergine acid butonalamide bimaleate) to 26 schizophrenic children and a 
methylderivate of LSD, methysergide, to 28 schizophrenic children during 
the period of about a year. This resulted in an overall improvement in 
behavior~ in particular with regard to the social responsiveness. 
However, in some children an increase of anxiety and chaotic behavior was 
observed. 
Simmons et al. (1966) obtained variable or negative results with LSD. 
Finally, Fish et al. (1969) administered methysergide to ll mentally 
retarded children. Only 2 children showed some symptom-improvement. 
Ritvo et al. (1971b) investigated, in 4 autistic children, whether the 
serotonin values in the blood would decrease with oral L-Dopa therapy. In 
the youngest three children a fall of the serotonin levels were observed. 
However, no symptom-improvement appeared. 
In a double-blind crossover study Campbell et al. (1976b) gave L-Dopa to 
12 psychotic children in the age varying from 3 to 6 , in daily doses of 
900 to 2250 mg. Five out of 12 children improved, in particular by 
decreasing negativism, an increase in playing, energy and motor 
i ni ti at ive. Four children showed progress in speaking, affective 
responsiveness and a decrease in irritability. These differences were not 
significant and there was no correlation with changes in the serotonin 
values. The -four children with decreased serotonin values did not 
improve. In three children there were no changes in the serotonin levels, 
five of them showed a rise in serotonin levels. 
A great number of American centers have lately started an investigation 
on the effect of fenfl uramine. These activities started after publica-
tions by Ritvo et al. (1983) and are led by him: he treated 14 autistics 
with fenfluramine in a double-blind ABA crossover design. Fenfluramine 
depletes the blood platelets of serotonin and thus decreased the 
serotonin concentration in the blood .. After one month of treatment the 
serotonin concentration did decrease to an average of 50 % of the 
starting value. It nonnalized again within a month after stopping the 
therapy .. Both in autistics with normal and with elevated serotonin levels 
it was true that certain symptoms decreased with medication and returned 
on placebo. August et al. (1984) found after 4 months fenfl uramine 
medication in autistic children an average reduction of 5-HT values of 
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60% which was coupled with significant decrease of certain symptoms such 
as dlstractability, motor activity and mood disturbances. 
In the 1960's the therapeutic effect of a number of substances was inves-
tigated which are normally present in the organism, but which in some 
disorders may be functionally deficient in certain brain areas. Research 
within this "Orthomolecular Psychiatry" (Pauling, 1968) focussed its 
attention on schizophrenia in particular. Substances investigated were 
for example ascorbic acid, thiamine, pyridoxine, folic acid, glutamic 
acid and also nicotinic acid and nicotinamide. A number of these 
substances have a 1 so been administered t.o children and influence, among 
other things, the tryptophan and serotonin metabolism. 
Hoffer (1970) found nicotinamide and ascorbic acid effective in psychotic 
children in comparison with a placebo. 
However, Greenbaum (1970) could not confirm these results. He saw no 
difference in a double-blind investigation in which 17 children received 
nicotinamide and 24 a placebo. In a big survey with 190 children treated 
as outpatients Rimland (1973) investigated the effect of vitamines in 
high doses. Thirty seven of these 190 children were· described as 
autistic. Nicotinamide, ascorbic acid, pyridoxine and pantothenic acid, 
were administered according to a fixed scheme. Changes in behavior were 
scored by parents and the medical attendant. The group of classical 
autistic children improved most. The strongest effect was by Vitamin B6 
(150 mg/day), in particular in causing an increase in the intention to 
speak and the total verbal production. At the beginning of the therapy 
side effects such as an inc-reased activity, irritatabil ity and 
sleeplessness were observed in some children, both with nicotinamide 
(more than 1000 mg/day) and with Vitamin B6. These symptoms disappeared 
after some weeks. The overall result of the Vitamin regime was an 
improvement in 45% of the children, a possible improvement in 41%, no 
improvement in 10,5% and a worsening of the symptomatology in 3%. 
In a follow-up study 16 autistic children who had reacted positively on 
Vitamin B6 therapy, were switched over double-blind on either Vitamin B6 
or placebo. Behavior worsened significantly in the children who didn•t 
receive Vitamin B6 (Rimland et al ., 1978). 
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4.13 GENETIC FACTORS AND SEROTONIN 
Recently, Jackson et al. (1984) studied 24 male fragile X patients, 13 of 
them (54%) being autistic. Of these 13 autistic fragile X patients, none 
demonstrated hyperserotonemi a.. They conclude that if blood serotonin 
levels differentiate subgroups of autistic patients, the subgroup with 
hyperserotonemia does not include fragile X autistic patients. 
Finally, Kuperman et al. (1985) examined 30 autistic children and 84 of 
their first-degree relatives for serotonin blood levels and platelet 
counts .. Significant carrel ati ons were found between sets of relatives 
(mother-child, father-child, sib-sib, either probands being included or 
not included) for platelet rich plasma (PRP) serotonin levels. The 
correlations between PRP serotonin levels of mothers and fathers was not 
significant. The authors conclude that there is a strong indication for 
familial resemblance of PRP serotonin levels and that the significant 
positive correlations of PRP serotonin levels between sets of blood 
relatives may be attributed to genetic similarity. So, it might be very 
interesting to trace further 5-HT values in blood in autistic and 
nonautistic families. 
4.14 IMMUNOLOGICAL FACTORS AND SEROTONIN 
Weizman et al. (1g82) reported a cell-mediated autoimmune response to 
human myelin basic protein using a macrophage migration inhibition factor 
test in 13 (76%) of 17 autistic children examined. They conclude that 
their results indicate the existence of a cell-mediated immune response 
to brain tissue in autism. Westall et al. (1983) point to the fact that 
myelin basic protein contains a serotonin binding site in its tryptophan 
peptide region. This region is irrununologically active and responds by 
activating lymphocytes. As one of possible explanations of Weizman's 
findings and reported increased whole blood values in autism they 
formulate that an autoimmune response to the serotonin binding site on 
myelin basic protein might result in an agonistic effect on the serotonin 
system concomitant with dumping of excess serotonin into the blood. A 
second hypothesis they offer is that serotonin binds to myelin basic 
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protein that is released during nonnal protein turnover, stabilizing it 
against proteolytic digestion so that it can be immunologically 
processed, which results in the activated lymphocytes. 
Finally, in an intriguing report, Todd and Ciaranello (lg85) described 
the discovery of autoantibodies against 5-HT binding proteins present in 
the blood and cerebrospinal fluid of an autistic child. These antibodies 
are of the IgG class, discriminate between 5-HT and other 5-HT binding 
lA 
proteins and are specific for human 5-HT sites .. The investigators 
lA 
speculate that a subgroup of autistic patients may be suffering from an 
autoimmune disorder .. In a second study they reported of 13 autistic 
children, 7 have circulating antibodies directed against brain 5-HT 
receptors .. In contrast, these antibodies were not seen in 13 nonnal 
children. 
4.15 CONCLUSION 
Research on neurochemical aspects of infantile autism has been 
unsystematic and incomplete .. Only a very few research groups have done 
consistent investigation on neurochemical variables and their relation to 
the psychopathology of autistic children during a considerable period of 
time .. This results in a series of isolated or often contradictory 
findings .. Accordingly, up to the present, few replicated neurochemical 
differences have been found between autistics and control subjects .. The 
fact that many groups have confirmed the finding of elevated whole blood 
serotonin concentration in autistics is remarkable .. Hyperserotonemia has 
been found in approximately 30% of the autistics. The serotonin concen-
tration in the blood is stable, if measured over a year•s time in 
autistic individuals .. The serotonin concentration is elevated both when 
measured absolutely and expressed per blood platelet. A relation with 
specific behavioral aspects of autistics has not been found .. The finding 
of an elevated serotonin level in the blood in various groups of 
non-autistic mentally retarded children is of importance .. This gives rise 
to the question of the specificity of the finding. 
The cause of hyperserotonemia in autistics is not known .. The increase of 
urinary 5-HIAA excretion in hyperserotonemic autistic subjects seen by us 
suggests that increased 5-HT gut production might play a role in the 
hyperserotonemia observed~ Differences between autistics and controls in 
5-HT uptake, storage or release ability of blood platelets have not 
emerged. However, platelet counts were observed to be increased and 5-HT 
levels (ng/ml) and platelet counts were significantly correlated in 
unmedicated autistics:o so a role for the blood platelet in the 
hyperserotonemia of autism is certainly worth considering. No indications 
have been found for decreased degradation of 5-HT by MAO. Research on the 
tryptophan metabolism in autistics does not permit any conclusion. 
Accurate studies with precisely characterized children while use is being 
made of recent analysis techniques, will have to clarify this subject. 
A number of aspects needs further investigation. More insight is required 
into those factors influencing the production of 5-HT and release of 5-HT 
from the gut into the blood. 
Furthermore, uptake and release of 5-HT in platelets of autistics might 
be better characterized using recently developed, modified assay methods 
(Arora and Meltzer, 1981). 
The relation between hyperserotonemia in autistics and the central 
serotonergic functioning in the brain is unclear. Parallel measuring of 
5-HT and free tryptophan levels in the blood and concentration of the 
other amino acids, and 5-HIAA and tryptophan levels in the spinal fluid 
seems useful. 
Another possible line of research is on the ontogenetic aspects of whole 
blood 5-HT. Measurements in baby's and young chi 1 dren may give more 
insight into the age factor which plays a role in the serotonin concen-
tration of the blood. Also the sex factor in young autistics ought to be 
investigated further. More research could be done on the relation of the 
serotonin concentration in the b 1 ood of hea 1 thy fami 1y members, and 
between the concentrations of autistics and those of their relatives. 
Genetic aspects may have an influence. Furthennore, it is tempting to 
speculate about a possible relationship between the recently described 
auto-antibodies against 5-HT binding proteins present in the blood and 
the spinal fluid of some autistic children and blood 5-HT values. Further 
assessment of this finding is warranted. 
Generally speaking better characterisation will have to be found of the 
various behavioral aspects of autistic children. It is more likely that 
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neurochemical variables, related to the functioning of the central 
neurotransmitter systems, will correlate with psychic and motor function 
disturbances, than with the whole of a syndrome. 
Neuropsychological and neurophysi ol ogi ca 1 research techniques wi 11 be of 
importance in this prospect. Animal models have to be used to assess 
specific target behaviors like stereotyped behavior, attachment, etc., to 
unravel their underlying pathophysiologic mechanisms. At the same time 
one has to search for the human analogue of behavior variables which seem 
to be important on the basis of manipulation of neurochemical systems in 
animal models, like e.g. contact comfort (Panksepp, 1980). 
Modern chemical analytical techniques will have to be used~ in which 
pharmacological manipulations both on the behavioral level and on the 
chemical level are monitored. In the future this will hopefully lead to 
more insight into the pathophysiology of the intriguing syndrome of 
infantile autism. 
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SUMMARY 
Whole blood serotonin (5-HT) and tryptophan (TRP) were measured in 87 
normal children and young adults, and in 40 autistic subjects, (DSM-III 
criteria) having a similar age distribution. Whole blood 5-HT was 
significantly elevated in the drug-free (N•21) autistic group (205::_16 
ng/ml) compared to normal subjects (135::_54 ng/ml). Serotonin values were 
Gaussianly distributed in both the normal and autistic groups. When the 
95th percentile of the normal group was used to define hyperserotonemia, 
38% of the autistic subjects could be termed hyperserotonemic. Autistic 
subjects on anticonvulsants and neuroleptic had significantly lower 5-HT 
levels than drug-free autistic subjects. 
The elevated group mean for whole blood 5-HT seen in autism cannot be 
explained by group differences in age, sex, platelet counts or tryptophan 
levels. 
INTRODUCTION 
A number of investigators have reported, that group means of b 1 ood 
serotonin (5-HT) concentrations are elevated in autistic subjects 
compared to normals (Schain and Freedman, 1961; Ritvo et al., 1970; 
Yuwiler et al., 1971; Campbell et al., 1974; Yuwiler et al., 1975; 
Goldstein et al., 1976; Hanley et al., 1977; Takahashi et al., 1g76; 
Hoshi no et al ., 197ga; Hoshi no et al ., 1984; Coleman et al ., 1973; Young 
et al ., 1982). Research on this 11 hyperserotonemiau of autism, which spans 
nearly 25 years, is reviewed in Table I. 
Although the ten studies listed are consistent in their finding of 
increased 5-HT levels in autism, there is poor agreement as to the 
magnitude of the levels observed and the extent of the difference. While 
differences in the normal and autistic population samples selected for 
study may account for some of the discrepancies, it was felt that a 
number of basic aspects concerning the apparent hyperserotonemia of 
autism required further clarification. 
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Table J 
Author Year Technique Sample Type Autistic Subjects 
SchainandFreedman 1961 bioassay serum 141_!)8 ng/ml, N=23 
Ri tvo et a! 
Yv.-.d Jer et a I 
Campbell et al 
YtMi ler et al 
Goldstein et a! 
Hanley et al 
Takahashi et al 
Hoshino et al 
Anderson et al 
(this study) 
1970 
1971 
1974 
1975 
1976 
1976 
acid 
f 1 uorescence 
acid 
fluorescence 
acid 
fluorescence 
acid 
fluorescence 
acid 
f I uorescence 
acid 
fluorescence 
1976 ninhydrin 
f I uorescence 
1979 acid 
f I uorescence 
~1hole blood 
Hhole blood 
platelet-
rich plasrra 
1·1hole blood 
Hhole blood 
1-1hole blood 
platelet 
pe 11 et 
serum 
263_:!:_63 ng/ml, N=23 
272+53 ng/ml, N=7 
760~112 ng/109 plat., 
~ N=7 
280 ng/ml, N=11 
273+30*ng/ml, N=12 
911~106*ng/J0 9 plat., 
~ N=12 
86_:!:_36 ng/ml, N=72 
135_:!:_57 ng/f'll, N=27 
980_:!)57 ng/rng, N=30 
218_:!:_27 ng/ml, N=IJ2 
HPLC- 1·1hole blood 205+73 ng/ml, N=21 
fluorometric 776:31J8 ng/109 plat 
~ N=16 
Controls 
65.:!:_17 ng/ml, t/=4 normals 
72+33 ng/ml, ~!,12 {mildly 
~ retarded) 
216_:!:_ n.g/ml, N=36 
183+28. 11=4 
4911~42 ng/109 plat., t/=4 
170 ng/ml, N=6 
205+ 17*ng/r;J 1, N=12 
6S0;48*ng/109 plat., NuclZ 
73.:!:_23 ng/ml, N=71 
57_:!:__49 ng/ml, 
97_:!:_38 ng/n I, 
N=6 (normals) 
M=23 (mi Idly 
retarded) 
807_:!:_202 ng/ml, 11=30 
175.:!:_60 ng/ml, N=20 
136+50 ng/ml, N=87 
522~213 ng/10 9 plat., N=67 
Notes 
Mean autistic age 10.8. 
3-8 year old subjects; levels 
dec! i ned vii th age; no group 
differences Hhen expressed per 
platelet. 
8 A.M. sa~ples; similar group 
differences seen at 12 noon. 
No circadian ryth'fl seen. 
mean age autistics 5; rcean age 
noma Is 6, 
Platelet SHT uptake, efflux Slnll-
lar in both groups. Hean autistic 
and normal ages 5 c.nd 8 years 
respectively age-matched children. 
7-22 year old subjects; no age 
effect seen; urinary SHIAA also 
higher in autistics. 
Expressed as ng/mg platelet pro-
tein; Mean age 5 years; no age 
effect from 2-12 years 
Mean age autistic 5.7; mean aye 
normals 9.3. 
Mean age autistlcs 14.5; rcean age 
normals 14.6. 
drugs reduced 5HT levels. 
A major issue involves the influence of age upon the 5-HT levels 
observed. In the few reports (Ritvo et al., 1970; Hanley et al., 1977; 
Takahashi et al., 1976; Hoshino et al., 1984) examining the age-related 
changes~ little agreement exists concerning the presence or magnitude of 
the effect. The present study was designed with large groups so that the 
age-effect could be examined in both the normal and autistic populations. 
Important questions also existed concerning the group means observed for 
platelet counts and blood tryptophan (TRP) levels, and the relation-
ships for these measures to 5-HT 1 evel s. The possi bi 1 ity remained that 
group differences in platelet (storage site of blood 5-HT) counts might 
contribute to, or cause, the reported differences in 5-HT 1 evel s. The 
measurement of TRP is important as it might indicate whether the 
metabolism of this amino acid precursor to 5-HT is altered in autism. 
Two additional aspects which have been only very briefly examined are 
a possible sex-difference and the effect of medications on 5-HT levels. 
The influence of sex is of particular interest because of the increased 
prevalence of autism in males. The possibility of a drug-effect is of 
special concern due to the extensive use of potent neuroleptic and 
anticonvulsant medications in autistic subjects. 
Questions regarding analytical methodology center on the type of blood 
sample used and the 5-HT assay employed in the various studies. For 
several reasons, the studies using serum (Hoshino et al., 1979a), 
platelet-rich-plasma (PRP) (Campbell et al., 1974), or isolated platelets 
(Takahashi et al., 1976) are difficult to compare to the majority of 
studies where whole blood 5-HT was measured (See Table I). The use of 
serum presents difficulties in estimating recovery of native (platelet-
bound) 5-HT and in determining the effective sample volume, while the 
isolation of a platelet pellet or PRP for 5-HT analysis is complicated by 
the heterogeneity of the platelet population and the possibility of 
obtaining varying platelet yields in different subjects. The six studies 
(Ritvo et al., 1970; Yuwiler et al., 1g71; Yuwiler et al., 1975; 
Goldstein et al., 1976; Hanley et al., 1977; Hoshino et al., 1984) of 
whole blood 5-HT avoid these problems; however, a discrepancy in the 
group means reported for whole blood 5-HT levels is evident. Here, 
serotonin was measured in whole blood, rather than in PRP or a platelet 
pellet, for the reasons mentioned above. A high performance liquid 
91 
chromatographic (HPLC) fl uorometric assay for 5-HT (Anderson et al., 
1981) was employed instead of the acid fluorescence assay which had been 
used in nearly all previous studies. While the acid f1 uorescence method 
has been carefully checked, it was thought that an HPLC method might be 
1 ess prone to undetected interferences and waul d, at 1 east, all ow an 
alternative method to be employed. 
METHODS 
Subjects 
All autistic subjects had deficits in social relatedness and communica-
tion sufficient to make a diagnosis of Autism (299.00) according to 
OSM-lll criteria (DSM-I!I, 1980). Nearly all were enrolled in special 
programs specifically designed for autistic individuals. Care was taken 
to exclude aphasic subjects and non-autistic, retarded subjects. 
Unmeditated subjects had been drug-free for at least six months prior to 
blood drawing, while medicated individuals were on an constant drug 
regimen for at least two months. Young normal subjects were recruited 
from subscribers to the Yale University Health Service. All youngsters 
(ages 1-20) who were scheduled for routine "well child" visits were 
eligible for participation. Parents were asked to complete a brief form 
describing their child 1 S general health and any current illnesses or 
medications. Normal, young adult subjects (ages 21-32) were recruited 
from healthy medical students and laboratory staff. Blood was drawn from 
young normals throughout the day (8:00AM-4:00PM), from adult normals 
at 12:00 PM - 2:00 PM, from autistic subjects at 10:00 AM - 11:30 AM. 
Data specifying the age and sex distributions in the populations studied 
are presented in Table II. 
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Table II 
Age and Sex Distributions in Normal and Autistic Groups 
Sex Age (tears) 
f1/F Range Median Mean + SD (SEM) N 
Normals 45/42 2.0-32 14.2 14.6:: 7.47 (0 .80) 87 
Autistics 
Total group 29/11 2.1-27.4 17.8 16.8 + 6.04 (0 .96) 40 
Drug-free 15/6 2.1-27.4 15.0 14.5:: 6.64 ( 1 . 44) 21 
Medicated 14/5 7.5-26.7 18.6 19.3:: 4.20 ( .96) 19 
ANALYSIS 
Whole blood 5-HT and TRP were analyzed using an HPLC-fluorometric method 
(Anderson et al., 1981). Blood (approximately 1 ml) was obtained in 
EDTA-containing Vacutainer tubes~ mixed by gentle inversion~ and kept at 
room temperature for no longer than three hours before preparation. A 1-2 
ml blood sample was obtained at the same time for automated (Clay-Adams 
Ultraflow 100) determination of platelet count. Samples (5-HT) were 
prepared for storage by placing 250 ~1 of mixed whole blood into a 1.5 ml 
polypropylene micro-centrifuge tube. Fifty microliters of 1.5 M ascorbic 
acid, 10 ~1 of 10 ng/ml 5-hydroxytryptophan (5-HTP), and 50 ~1 of 3.4 M 
perchloric acid were added in order. Immediately after the addition of 
the perchloric acid~ the tube was capped and vortex-mixed for 10-15 sec~ 
then placed on ice for 5-15 min. After centrifugation at -13000 x G for 
5-10 min~ the supernate was poured into a micro centrifuge tube and 
0 
stored at -80 C. Thawed samples were briefly centrifuged and 20 ~1 
injected on a .39x30 em u Bondapak C 
18 
reversed-phase HPLC column. A 
mobile phase of 95% pH 4.25 .01 M sodi urn acetate - 5% methanol was 
delivered at a flow-rate of 2.0 ml/min. The compounds were detected using 
an Aminco Fluoromonitor with a low-pressure mercury lamp (254 nm) 
excitation source and a 360 nm peak transmittance emission filter. 
Recoveries of 5-HT ~ TRP ~ and 5-HT average 80% and concentrations are 
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calculated knowing the internal standard concentration (400 ng/ml) and 
the peak height ratios obtained for 5 ng standards. The quality control 
sample analyzed over a two-year period, a span of time within which all 
samples included in this study were run, had a day-to-day coefficient of 
variation (CV) of 7.2% (mean.::_ S.D.: 208+15 ng/ml, N=36). 
RESULTS 
Group Means: 
Group means determined for whole blood 5-HT levels, TRP levels, and 
platelet counts in the normal and unmedicated autistic populations are 
given in Table III and the individual autistic data plotted in Figures la 
and lb. Significantly (p<.DOl) higher levels of 5-HT were observed in the 
unmedicated autistic group when compared to normals. This was true 
9 
whether the 5-HT concentration was expressed as ng/ml or as ng/10 
platelet. When the former units were used, the autistic group mean was 
elevated 51%; within the latter units, a 48% elevation was present. 
Serotonin and TRP concentrations, and platelet counts, were Gaussianly 
distributed in the normal, drugfree autistic, and medicated autistic 
groups. 
Table Ill 
Group Means for Normal and Autistic Subjects 
mean ~ SEM {N) 
Serotonin (5-HT) Platelet Count Tr:;tEtoehan 
(ng/ml) (ng/1 o
9 
(per nl) (ng/ml) platelets) 
Normal Subjects 136:!_5.4(87) 522:!_26 ( 6 7) 281:!_9.4(67) 6820:!_170 (87) 
Autistic Subjects 205:!_15.7(21) 776:!_87(16) 279:!_16 (16) 6120:!_330(21) 
(unmedicated) 
p value from t-test < .001 < .001 <.3 <.01 
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Figure 1A. Whole blood 5-HT levels (ng(ml) versus age in the drug-free 
(N = 21) and medicated (N = 1g) autistic subjects. 
Medicated subjects were being treated with anticonvulsants 
(carbamazepine [4], valproic acid [2], and phenytoin [3]) and 
neuroleptics (thoridizine [5] and haloperidol [2]) in usual 
clinical doses 
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Figure lB. Whole blood 5-HT levels (ng/ml) versus age in normal subjects 
(N = 87) 
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Influence of Age and Platelet Count: 
Although platelet counts were similar in autistic and normal subjects 
and, therefore, presumably not a source of the differences seen between 
groups, several important relationships between platelet count, age, and 
5-HT concentrations were examined in detail (see Table IV). A highly 
significant negative correlation of platelet count with age (r=-.59, 
p<.001) was observed. When the normal population (N = 67) was broken into 
age groups of 1-6, 7-12, 13-16, and over 17, means (.:_SEM [N]) plate let 
counts (per nl) observed in the respective groups were 346.:_21 (16); 
3022:_19 (13), 292.:_23 (9), and 234.:_8.2 (30). An analysis of variance 
(ANOVA) for these groups was significant at the p=.001 1 evel (OF 17, 
F 11,6). 
Table IV 
Correlations* in Normal and Autistic Groups r (p) 
5-HT/m1 
5-HT/10 9 
TRP /m 1 
platelet 
count 
5-HT/109 
Normal Subjects 
TRP/m1 
.17(.028) 
platelet count 
. 198 (. 11) 
-.48(.001) 
-.08 (.52) 
age 
-.05(.66) 
.315(.009) 
.08(.47) 
-.59(.001) 
Autistic Subjects (Drug-Free) 
5-HT/m1 
5-HT/109 
TRP/m1 
platelet 
count 
5-HT/10 9 
.73(.001) 
TRP/m1 
.44 ( .46) 
.134(.62) 
platelet count age 
.27(.31) -.016(.94) 
-.425(.19) . 10 (. 71) 
.224(.40) .09 ( .69) 
-.258(.34) 
* In the normal group, sample size (N) was 67 for correlations involving 
5-HT/109 or platelet count, and 87 for remaining correlations. Sample 
sizes were 16 and 21 for the corresponding correlations in the drug-
free autistic group. 
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Age was significantly positively correlated (r=.32, p=.009) w~th 5-HT 
level when the concentration was expressed in terms of ng/10 platelets. 
This positive relationship, and the negative correlation (r=-.48, 
9 p=-.001) seen between 5-HT expressed as ng/10 platelets and the platelet 
count, apparently result from including the platelet count in the 
denominator of the concentration units. When the partial correlation of 
9 
age and 5-HT (ng/10 platelets) was calculated, with the platelet count 
partialed out, no age-effect was seen (r=.04). Similarly, no significant 
correlation was seen between age and 5-HT concentration expressed as 
ng/ml (r=.05, p=.66). The constancy of 5-HT levels (ng/ml) over a broad 
age range was confirmed by dividing the normal group (N = 87) into 1-12, 
13-16, and over 17 age groups. Means ~ SEM (N) observed in these three 
groups were 140~8.8 (37), 127~10 (15), and 136~8.6 (35), respectively. We 
further examined the relationship of age and 5-HT levels within the 1-12 
age group. An age-related decline was seen in the 1-12 year-old group; 
however, because a sex difference was noted, this finding wi11 be 
discussed in the following section. 
Table V 
Comparison of Sexes in the Normal Population (Mean + SEM (NJ) 
Males 
Females 
Males 
Females 
Serotonin 
(ng/ml) 
144.! 7.0(45) 
127.!8.1(42) 
181 + 15(9)b 
113 .! 15(9)b 
AI I A9es (1-32 Years Old) 
(5-HT) Platelet Count 
(nq/10 9 (per n I) platelets) 
596 .! 36 (32) a 274 .! 15 (32) 
453 .! 35 (35)a 287.! 12(35) 
Young (1-6 Year-Old) Children 
562.! 63(8)c 340 .! 38(8) 
357 .! 54 (8) c 352.! 20(8) 
p values from two-tailed t-test: a .006, b .006, c .020 
Tryptoehan 
(ng/ml) 
7100.! 210(45) 
6520 .! 260 ( 42) 
7110.! 540(9) 
7100.! 950(9) 
Average (~ SD) ages in the groups 1 isted: 1-32 year-old males, 15.2.:t_8.0; 
1-32 year-old females, 14.0~7.1; 1-6 year-old males, 4.9~1.8; 
1-6 year-old females, 4.3~ 1.4. 
Sex Differences: 
In Table V, the normal group has been divided by sex and means presented 
(5-HT, TRP, and platelet count) for all subjects of alle ages and for the 
l-6 year old group. Normal males (all ages) are seen to have signifi-
cant]~ (p=.006) greater levels of 5-HT compared to normal females when 
ng/10 platelet concentration units were used. Serotonin only tended 
(p=.l) to be higher in males when expressed as ng/ml; the difference in 
mean platelet counts was also not significant. When the sexes were 
compared within age subgroups (l-6, 7-12, 13-16, and over 17), signifi~ 
cant sex differences were seen only in the youngest group. Scatter 
9 
diagrams for 5-HT concentrations (ng/ml and ng/10 platelets) in the 1-6 
year-old group are presented in Figure 2. 
Figure 2. Distribution of whole blood 5-HT measures in young (1-6 
years old) male and female normal subjects. Additional data 
concerning tryptophan~ platelet count, and age for the two 
sexes are given in Table V 
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Young normal males were observed to have significantly (p=.006) elevated 
levels of 5-HT compared to young females and compared to older rna l es 
and/or females. However, in the 7-12 year-old male group, the mean 5-HT 
concentration was similar to adult (>17) levels: 129:':11 ng/ml (N=10) vs 
138~12 (N=!l). Within the group of 1-12 year old males, 5-HT (ng/ml) 
levels were only weakly correlated (r=.37, p=.12) with age. Serotonin 
(ng/ml) levels in normal females were similar, and no significant 
correlations with age were observed, in alle age ranges examined. 
Finally, no difference in 5-HT levels was seen between males (204~16 
ng/ml, N = 16) and females (208~37 ng/ml, N = 5) when the sexes were 
compared within the unmedicated autistic group (average ages: males 14.8 
years, females 13.7 years). 
Drug Effect 
The effect of medication on blood measures in the autistic population 
was examined by calculating group means for unmedicated (drug-free) and 
medicated subjects. The medicated group was further divided into 
neuroleptic- and anticonvulsant-treated groups. As seen in Table VI, the 
mean 5-HT levels in the medicated autistic group were significantly lower 
than in the drug-free autistic group. This was true for the combined 
medicated group and for the neuroleptic and anticonvulsant-treated 
subgroups, except ~n the ·neuroleptic group when 5-HT concentration was 
expressed as ng/10 platelets. The individual data has been graphed in 
Figure 1a. It is apparent that most of the medicated autistic subjects 
are older than the mean age (14.5 years) of the drug-free group. (See 
also Table II). Although we observed no significant correlation with age 
in the autistic (or normal) group age-matched controls were used to 
ensure that the finding of lowered 5-HT levels in medicated autistics was 
not due to an age effect. When autistic subjects being treated with 
anti convul sants were age-matched with unmedi cated a uti sti cs, mean 
(~S.D.) ages of 17.4~4.2 (N = g) and 17.9~4.8 (N = 9) years were 
obtained, respectively. Average (~ SEM) levels of whole blood 5-HT in 
these age-matched anticonvulsant and unmedi cated groups were 117,!9 .3 
ng/ml and 21g~g ng/ml. The difference was highly significant (P=.006) 
using a one-tailed t-test. When a similar age-matching was performed with 
neuroleptic-treated and drug-free autistic subjects (N = 7), average ages 
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in the two groups were 20.2.:':_2.4 and 19.8.:':_2.5, while mean (.:':. SEM) 5-HT 
levels were 136.:':_26.5 and 201.:':_31.1 ng/ml, respectively. The difference was 
significant only at the p=.068 level. 
Table VI 
Group Means + SEM (N) for Drug-Free and Medicated Autistic Subjects 
Platelet 
Se raton in (5-HT) Count Tryptophan 
(ng/ml) (ng/J0 9plotelets) (per n 1) (ng/ml) 
Drug-Free 205~15.7(21)abc 776~87(16)def 279~16 (16) 6120~330(21) Autistics 
Medicated 
473~53(19)d Autistics 117~11.9(19). 253~10(19) 5680~340(19) (all drugs) 
Anti-
convu 1 sant- 117~ 9. 3 (9)b treated 463~66(9)e 262~17 (9) 5590~400(9) 
Autistics 
Neuroleptic-
136~26. 4 (7) c 571~111 (7) f treated 239~14 (7) 611 0~660 (7) 
Aut i st i cs 
p values from two-tai Jed t-rest: a:<.OOl; b:<.001; c:<.033; 
d:<.004; d:<.018; f: <0.1 
In order to further test the neuroleptic effect, an additional group of 
a uti sti c subjects was ex ami ned during and after neural epti c treatment. 
The group of nine subjects all had been drug-free or medicated (7 with 
haloperidol, 2 with thioridazine) for at least three months when the 
first blood sample was obtai ned. There was an average time-span of 7.6 
months between an individual 1 S samples, and all were drug-free for at 
least three months before the second sample was obtained. The individual 
data, on and off drug, is presented in Figure 3. The average (.:':. SEM) 
drug-free level of 210.:':_26.3 ng/ml was significantly (p=.009) higher than 
the 120.:':_13.4 ng/ml level seen when the same subjects were treated with 
1 01 
neurol epti cs. When the two subjects who showed the 1 argest change were 
excluded from the comparison, 5-HT means (~ SEM) of 173~11.3 and 130~13.1 
ng/ml were obtained, and the t-test was still significant(p = .025). 
Figure 3. 
Whole blood serotonin (ng/ml) 
of autistic subjects during 
treatment with neuroleptics 
(closed circles haloperidol, 
open circles thoridizine) 
and during a drug-free period 
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While the data confirm the general finding of hyperserotonemia in autism, 
they are at variance with the previous reports in some important ways. 
Most apparent is the poor agreement with a number of the previous 
observations in tenns of the absolute levels of 5-HT seen in autistics 
and normals. Many of the whole blood 5-HT group means previously reported 
for nonnal populations are substantially lower (Schain and Freedman, 
1961; Goldstein et al ., 1976; Hanley et al., 1977) or higher (Ritvo et 
al., 1970; Yuwiler et al., 1975) than those observed in this study. 
Discrepancies are also apparent between the 1 evel s seen here in the 
autistic group and many of the previous reports. This issue is of 
importance in attempting to ascertain the magnitude of the 5-HT elevation 
seen in autism and in defining hyperserotonemi a. Prior studies have 
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indicated that autistic populations have whole blood 5-HT (ng/ml) 
elevations of 137% (Hanley et al., 1977), 117% (Schain and Freedman, 
1961), 49% (Yuwiler et al., 1971), 40% (Hoshino et al., 1984), 33% 
(Yuwiler et al ., 1975), 22% (Ritvo et al ., 1970), and 18% (Goldstein et 
al., 1976), compared to normals. Our finding of a 51% elevation in the 
autistic group falls in the middle of these estimations and agrees most 
closely with two studies of Yuwiler and co-workers (Yuwiler et al., 1971; 
Yuwiler et al ., 1975) and Hoshi no and colleagues (Hoshi no et al ., 1984). 
We have chosen to define hyperserotonemia as a whole blood 5-HT level in 
the upper 5% (mean plus 1.65 S.D.) of the large, Gaussianly distributed, 
normal group studied. An individual having a 5-HT value greater than 220 
ng/ml waul d therefore be considered hyperserotonemi c. Using this crite-
ria, 8 of 21 (38%) of .the unmedicated autistic subjects were hypersero-
tonemic. This percentage is slightly higher than the 30% incidence found 
in the one previous study where a similar definition (upper 5%) was 
employed (Hanley et al ., 1977). 
The Gaussian distribution of 5-HT values in the autistic group strongly 
suggests that the elevated group mean is not due to a subgroup of 
autistic subjects. Rather, it appears that all values in the autistic 
group have been shifted upward compared to a normal population. Although 
autistic subjects with higher levels might be more fruitfully studied for 
the cause(s) of the hyperserotonemia, it is misleading to consider those 
termed hyperserotonemic as fanning one pole, or subgroup, of a bimodal 
distribution. 
The observation of a remarkable similarity of platelet counts in the 
autistic and normal groups (Table Ill) is in disagreement with a previous 
study (Ritvo et al., 1970) which reported significantly higher platelet 
counts in young autistics compared to nonnals. This was an important 
aspect of the study (Ritvo et al., 1970) referred to because the 
elevation observed for whole blood 5-HT (ng/ml) was suggested to be due, 
possibly, to the elevated platelet counts seen in autistics. It should be 
pointed out that a subsequent report from several of the same investi-
gators (Yuwiler er al., 1975) found no difference in platelet counts 
between groups while continuing to show increased 5-HT in autism. 
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The downward trend for platelet count with age has been reported before 
for autistic and nonnal subjects (Ritvo et al., 1970); however, it has 
been commonly thought that platelet counts do not vary systematically 
with age (Wintrobe, 1974). 
The observation of an a~e-effect and platelet count effect on 5-HT levels 
when expressed as ng/10 platelets, and the relatively constant nature of 
the ngjml value with respect to age and platelet count, indicate the 
latter units are probably to be preferred. Even so, both units should be 
employed when expressing whole blood 5-HT concentrations. 
An age-related decline in 5-HT values in children has been previously 
reported (Ritvo et al ., 1970; Hoshino et al., 1984) without a distinction 
being made between sexesa Here we see a decline with age only in young 
males. The cause of the high group mean observed in young (1-6 year-old) 
males and the reason for the maturational decline are unknown. It is also 
unclear whether these factors are related to those which cause the 
increase in autism; the possibility that hyperserotonemi a reflects a 
maturation a 1 failure needs further study. Our findings, and those of 
other groups (Ritvo et al ., 1970; Hoshi no et al ., 1984), do suggest that, 
at least in younger children, age- and sex-matched controls should be 
used when studying blood 5-HT. Although based on a small group of 
autistic females (N = 5), the similarity of group means in male and 
female autistics (see Results) suggests that the hyperserotonemia of 
autism occurs in both sexes. 
The observation of significant reductions in whole blood 5-HT brought 
about by anti convul sants and neural epti cs is surprising. In previous 
studies of drug-effects on blood 5-HT, neither anti convul sants 
(Partington et al., 1973) nor neuroleptics (Hoshino et al., 1979b; 
Hoshino et al., 1982; Stahl et al ., 1983; Delisi et al., 1981) were 
observed to lower 5-HT in retarded (Partington et al., 1983), autistic 
(Hoshino et al ., 1979b), or schizophrenic (Hoshino et al ., 1982; Stahl et 
al., 1983; Delisi et al., 1981) subjects. The study examining anticon-
vul sants (Partington et al., 1973) was mainly concerned with the effect 
of phenobarbitone, and two drugs common in the autistic group studied 
here, carbamazepine and valproic acid, were not studied. The reported 
(Hoshino et al., 1979) lack of an effect of Haldol on autistics' 5-HT 
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levels might have been due to the acute (2-week) administration and the 
relatively low doses (.3- 1.5 mg/day) employed previously. It is fairly 
clear from our data that neuroleptics do lower whole blood 5-HT levels. 
Neuroleptics are known to occasionally cause thrombocytopenia (Stahl et 
al., 1983; Holt et al., 1984), and a trend (p=.10) to lower mean platelet 
counts (239 vs. 279 per nl -- see Table V) was observed in the 
neuroleptic-treated group. This, coupled with the possible 5-HT 
uptake-inhibiting effects of neuroleptics (Laubscher and Pletscher, 1979; 
Arora and Meltzer, 1983; Hussein et al., 1978; Oxenkrug, 1978), might 
explain the lowering observed. The situation is even less clear with 
respect to the anti convul sants because it cannot be determined from the 
data whether the lower levels observed are a result of the drug treatment 
or a trait of the subgroup of autistic subjects with seizures. 
We have made what we feel to be the most accurate estimation of autistic 
and normal group mean whole blood 5-HT levels. The normal ranges and 
means established are in relatively poor agreement with a number of prior 
reports; however, reasonable agreement with several previous studies 
(Yuwiler et al., 1971; Yuwiler et al., 1975; Hoshino et al., 1984; 
Swanson and Cook, 1977) is noted. The approximate 50% elevation seen here 
in autism, which is intermediate compared to previous estimations, is of 
unknown etiology. 
The possible causes of the hyperserotonemia of autism have been 
considered in detail by several groups (Hanley et al ., 1977; Takahashi et 
al ., 1976; Hoshi no et al ., 1984; Young et al ., 1982). Hypotheses most 
frequently center around the platelet, 5-HT synthesis, and monoamine 
oxidase (MAO) activity. These three possibilities have also been raised 
when attempting to explain the blood 5-HT elevation often seen in 
schizophrenia (Stahl et al ., 1983; Delisi et al ., 1981; Freedman et al ., 
1981). Theorizing is difficult due to uncertainty regarding what 
factor(s) control blood levels of 5-HT in normal subjects. In certain 
situations, alterations in the platelet, in 5-HT synthesis, or in MAO 
activity all have been observed to affect 5-HT levels. For instance, 
pharmacologically inhibited (Marshall et al., 1960; Ross et al., 1976) or 
pathologically decreased (Tu and Partington, 1972) plate 1 et 5-HT uptake 
results in lower 5-HT levels. On the other hand, the increased 5-HT 
synthesis which occurs in carcinoid syndrome (Crawford et al ., 1967) and 
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coeliac disease (Pimpakar et al ., 1961) or after TRP loading (Yuwiler et 
al., 1981) increases blood 5-HT, as does the inhibition of monoamine 
oxidase (Marshall et al., 1960; Weisbach et al., 1961). Unfortunately, 
these and other related studies do not point to which factor usually 
predominates in setting levels in normal or autistic subjects. The 
picture has been clarified somewhat~ with respect to autism, since 
Hanley, Stahl and Freedman's complete survey of the field (Hanley et al ., 
1977). 
It now seems less likely that an alteration in the platelet accounts for 
the hyperserotonemia. No group differences have been seen in the platelet 
count, in platelet uptake or efflux of 5-HT (Yuwiler et al., 1975; 
Boullin et al., 1971; Sankar et al., 1962; Boullin et al., 1982), or in 
the regulatory site for platelet 5-HT uptake (Anderson et al., 1984). 
Although several aspects of platelet structure and function, including 
size, shape, aggregation response, and intracellular compartmentaliza-
tion of 5-HT remain poorly studied, the platelet studies performed to 
date are generally consistent in finding no differences between autistic 
and normal subjects. 
The possibility of increased synthesis of 5-HT in autism is probably best 
approached by urinary measurements of the end-point metabolite, 
5-hydroxyindoleacetic acid (5-HIAA). It is well established that most 
5-HT is metabolized to, and excreted as, 5-HIAA (Davis et al., 1966; 
Udenfriend et al., 1959). Previously, it had appeared that autistic 
subjects excreted greater amounts of 5-HIAA (Hanley et al., 1977). 
However, we have recently observed no difference in urinary concentration 
or excretion rate of 5-HIAA between autistic and age-matched normal 
individuals (Minderaa~ Anderson~ Volkmar~ Akkerhuis~ Cohen~ submitted, 
1985). Data presented here (see Table III) suggest, in a simplistic way, 
that if 5-HT synthesis is increased in autism it is not a result of 
increased precursor availability as whole blood TRP levels tended, in 
fact, to be slightly lower in the autistic group. It should be noted that 
this finding is at variance with that of Hoshino et al. (1984), 
who found elevated plasma TRP levels in autistics. Because nearly all 
5-HT is synthesized in the enterochromaffin (EC) cell of the intestine 
(Toh, 1954; Erspamer and Testini, 1959), further investigation might be 
aimed toward attempting to assess more directly turnover of gut 5-HT in 
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autistic subjects. It is not clear what measurements, short of those made 
in gut biopsies, would serve this purpose. Measurement of plasma levels 
of gut peptides might be a step in this direction. In particular, the 
determination of plasma levels of Substance P, which is co-localized with 
5-HT in certain EC cells (Sandler et al., 1977), should allow a more 
definite statement to be made regarding the function of the EC cell in 
autism .. 
A decrease in the in-vivo activity of MAO is the least well examined of 
the possi bil i ties mentioned. A number of groups have reported that 
platelet MAO is not lowered in autism (Roth et al., 1976; Boullin et al., 
1976; Takahashi et al., 1977; Lake et al., 1977; Cohen et al., 1977). 
However, it has been recognized that, because platelet MAO is of the 
A-type while 5-HT is a better B-type substrate, the relevance of the 
measurements to the hyperserotonemia of autism is not clear .. The in-vivo 
oxidation of 5-HT is thought to occur principally in the lung and liver 
(Thomas and Vane, 1967; Junod, 1972), and obvious difficulties have 
prevented an estimation of the MAO acitivity of these sites in human 
subjects .. 
This area might be studied further by determining plasma kinetics of 
other amines also catabolized by MAO. Studies of plasma levels and 
half-lives of selected amines and their metabolites should be 
informative. Most substrates of MAO, unlike 5-HT, would not be taken up 
by the platelet, allowing their kinetics to be studied without this 
confounding variable. 
The search for the etiology of the 5-HT increase seen in autism should 
also take into account the fact that 5-HT is elevated in mental 
retardation (as well as in schizophrenia, coeliac disease, and other 
disorders). It is possible that the elevation seen in retarded and 
autistic groups is a reflection of behavioral similarities between the 
groups. Inverse correlations between 5-HT levels and IQ (Campbell et al., 
1974; Hanley et al ., 1977), and between 5-HT and activity levels 
(Campbell et al., 1974; Takahashi et al ., 1976), have been observed 
previously in autistic and retarded populations. In recent studies of the 
relationships of IQ and specific behavior to blood 5-HT levels in 
unmedicated autistic individuals we have not observed a correlation of 
5-HT with IQ. However, negative correlations have been observed with 
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several of the behaviors examined, including stereotypies, echolalia, and 
self-injurious behavior. A detailed report of the behavioral observations 
in unmedicated and medicated autistic subjects is in preparation 
(Volkmar, Minderaa, Anderson, Hader, and Cohen, 1985). 
In summary, although the hyperserotonemia of autism and some of the 
factors which might contribute to it have been well studied since Schain 
and Freedman's original observation (Schain and Freedman, 1961), the 
cause(s) remains elusive. It can be pointed out that the basic finding 
has been characterized better and, at 1 east to some extent, the fie 1 d o.f 
possible causes, narrowed. 
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SUMMARY 
Whole blood serotonin (5-HT) levels, tryptophan (TRP) levels and platelet 
counts were determined in a large group of unmedicated autistic subjects 
(N=17) and compared to an age- and sex-matched control group (N=20). The 
effects of neuroleptic and anticonvulsant medication were examined by 
measuring the species in a group of medicated autistics (N=23). The 
temporal stability of the measures was examined by making repeated 
determinations in a smaller group of medicated (N=16) and drugfree_(N=10) 
autistic subjects. 
Whole blood 5-HT was significantly increased in the drugfree autistic 
group compared to the normal controls, however TRP values and platelet 
counts were similar in unmedicated autistics and normal subjects .. No 
significant differences of 5-HT values were seen between medicated and 
unmedicated groups of autistic individuals. TRP concentrations were 
significantly lower in the medicated group compared to unmedicated 
autistics and a significant negative correlation was found between dose 
of neuroleptic medication and TRP values. 
Highly significant intraclass correlation coefficients and low mean 
percent differences were found for the repeated measures of 5-HT and the 
platelet count in the unmedicated group. In contrast, autistic subjects 
on fixed doses of neuroleptics or anticonvulsants and autistics for whom 
drug treatment was initiated or increased during the study exhibited 
significantly greater variability in 5-HT levels and platelet counts. TRP 
values were highly variable over time in both the medicated and drugfree 
autistic groups. 
INTRODUCTION 
Schain and Freedman (1961) were the first to describe increased group 
values of whole blood serotonin (5-HT) in autism. Since then, this 
finding has been confirmed by many investigators (Ritvo et al., 1970; 
Yuwiler et al., 1975; Goldstein et al., 1976; Takahashi et al., 1976; 
Hanley et al., 1977; Hoshino et al., 1979; Hoshino et al., 1984; Anderson 
et al ., 1985b). The cause and significance of the elevation is unclear. 
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Assessment of tryptophan levels in blood or tryptophan metabolism 
(Hoshi no et al. 1979; Schain and Freedman, 1961; Shaw et al ., 1959; 
Heeley et al., 1965; Anderson et al., 1985b; Hoshi no et al ., 1984), 
assessment of 5-HT serotonin uptake and release and other membrane 
properties of blood platelets (Sankar, 1970; Boullin et al ., 1971; Lucas 
et al., 1971; Yuwiler et al., 1975; Anderson et al., 1984) and of 
catabolism of serotonin (Campbell et al ., 1976; Cohen et al ., 1977) did 
not result in clear insight into the causes of increased blood 5-HT 
values in autistics. 
Furthermore it is not clear if the "hyperserotonemia" observed is related 
to possible dysfunctions of the central serotonergic system, although 
recently blood 5-HT 1 evel has been used as a target phenomenon for 
pharmacological treatment of autistics with fenfluramine (Ritvo et al., 
1983; August et al ., 1984,1985). 
Besides these unanswered questions several other issues require further 
clarification. An important point considered in several reports is 
whether platelet count is increased in autistics and whether hyper-
serotonemia could be due to elevated platelet counts. Ritvo et al. (1970) 
found significantly increased platelet counts in 24 autistic children 
compared to an age-matched control group. Although the mean 5-HT values 
per ml blood were significantly higher in autistics compared to the 
controls, no differences were reported if 5-HT was expressed per number 
of platelets. However, the same group (Ritvo et al., 1977) found in a 
later study that 5-HT values in autistics were increased whether 
concentration was expressed as ng/platelets or as ng/ml. When Hanley 
(1977) compared 4 hyperserotonemic autistic subjects with 4 normo-
serotonemic retardeds, no substantial difference was found in platelet 
count. Anderson et al. (1985b) recently found similar platelet counts in 
autistic and normal groups. 
A related issue involves the question whether serotonin (ng/ml) values 
are correlated with platelet count in autistic groups. A correlation 
between 5-HT ng/ml levels and platelet count might give support to the 
hypothesis that platelet number, and/or platelet function, might play a 
role in the regulation of 5-HT levels in blood. Hanley et al. (1977) 
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found a positive correlation between 5-HT values (ng/ml) and platelet 
counts in autistic individuals. Anderson et al. (1985b) found no such 
correlation in a group of unmedicated autistics, nor in the control 
group. 
Furthermore in the literature there is some disagreement as to the effect 
of different kinds of antiepileptic or neuroleptic medication on mean 
values of whole blood 5-HT. Recently Anderson et al. (1985b) found 
significantly decreased serotonin levels in autistic patients on anti-
psychotic or anti conv u 1 sant medication~ wh i1 e severa 1 previa us reports 
have indicated the drugs have little effect on 5-HT levels (Schain et 
al., 1961; Hoshino et al., 1979; Stahl et al., 1983; Jackman et al., 
1983). 
Only a few studies have dealt with the stability of serotonin values over 
time. In normal controls blood serotonin levels were relatively constant 
over a period of a week (Ritvo et al., 1970). Yuwiler et al. (1981) 
described small intraindividual variance in values obtained from six 
determinations in normal male volunteers. The same conclusion could be 
drawn from five and twentythree samples respectively of two males over 
the period of about a year. Wirz-Justice et al. (1976, 1977, 1979) found 
a pronounced diurnal pattern of 5-HT and a bimodal seasonal rythm in 
normal volunteers. Yuwiler et al. (1971) did not find a circadian 
rhythmicity in normal and autistic children. The stability of whole blood 
serotonin over a longer period of time and the effect of medication on 
this stability in autistic children has not been previously assessed. 
SUBJECTS AND METHODS 
The autistic group was comprised of 40 students enrolled in a school for 
autistic individuals. A diagnosis was made by several child psychiatrists 
and confirmed for this study by another child psychiatrist (RM) based on 
psychiatric evaluation, anamnestic information and observations by the 
school staff before the data were known. Thirty eight individuals 
received the diagnosis of autism, full syndrome present, according to 
OSM-lll criteria (299.00). Two received the diagnosis of infantile 
autism, residual state (299.01). Blood was drawn from 10 AM - 11 AM. 
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Table lA 
Subjects Characteristics Total Sample 
Subjects N Sex Age (years) 
M/F Mean :': so Range 
Norma 1 cont ro 1 s 20 15/5 22.0:':_7-5 9.2 - 36.1 
Autistics unmed i cated 17 11/6 19.4 :':5-3 10.3- 28.7 
Autistics a II medicated 23 17/6 19.4 :': 4.5 8. 9 - 26.4 
phenothiazines 7 6/1 22.0 :': 3-1 18. 1 - 26.4 
haloperidol 7 4/3 17.6 :': 4. 0 10.5 - 22.8 
anticonvulsants 9 712 18.7 :': 4.3 8.9 - 23.4 
Table IB 
Subject Ci1aracteristics Temporal Stability Subsample 
Subjects N Sex Age (years) 
M/F Hean + so Range 
Unmedicated group 10 6/4 19.5 :': 6.0 10.3 - 23.7 
Medicated group* 10 6/4 19.7 :': 4.9 3.9 - 26.4 
Group with changed 6 5/1 20.1 :': 2.8 16.7- 23.3 
medication** 
* 5 used phenothiazines, 1 used haloperidol and 4 used antivonculsant 
medication (carbamazepine and valproic acid) 
** 2 started haloperidol medication 7 1 increased dose of haloperidol 
(2 + 6 mg per day), 1 increased dose of thioridazine (100-+ 400 mg 
per day), 2 started with valproic acid, while medicated with 
thioridazine 
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Whole b 1 ood 5-HT and TRP were ana lysed using a HPLC-fl uorometri c method 
as described elsewhere (Anderson et al., 1981). 
Seventeen of the autistic subjects were unmedicated for at least 6 months 
before the b 1 ood drawing. Seven of the 23 unmedi cated a uti sti cs used 
phenothi azi nes ~ seven used ha 1 do 1 and nine used anticonvulsant 
medication. These medicated subjects used their medication in a constant 
manner for more than 3 months before the blood was drawn. A control group 
was comprised of 20 high school students, teachers and hospital 
employees, comparable in sex and age. All reported being in good physical 
health and using no medication. The group sex and age data for the 
different groups are given in Table IA. 
In a subgroup (N=26) of the autistic subjects two blood samples were 
obtained approximately one year apart in order to test long term 
stability. These subjects were divided into further subgroups according 
to their medication history. Ten were unmedicated for at least 6 months 
before the first blood drawing and remain unmedicated throughout the 
study period. Another ten were medicated with a fixed dose for the period 
extending from at least 3 months before the first blood drawing through 
the time of the second drawing. A final subgroup was comprised of six 
autistic subjects who started or increased the dose of the medication 
between the first and the second blood drawing. Group, sex and age data 
for the subjects of the temporal stability study are given in Table 18. 
The mean time span (.:':. S.D.) between the two blood drawings for the 
unmedicated group, the medicated (fixed dose) group and the group with 
changed medication was 12.7 (_: 0.7) months, 11.4 (_: 4.9) months and 12.3 
(.:':. 1.6) months respectively. Blood was drawn from all subjects at 10 AM -
11 AM. 
RESULTS 
Group means and correlations of blood~5-HT, TRP and platelet count 
Group means of 5-HT ng/ml, 5-HT ng/10 platelets, platelet count and TRP 
are given in Table II. A one tailed t-test comparing unmedicated autis-
tics with normal controls showed significantly higher values of 5-HT in 
the unmedicated autistic individuals if expressed as ng/ml (p = .01) as 
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well as expressed as ng/10 platelets (p = .02). When the control group 
is used to describe a normal range for 5-HT ng/ml an individual having a 
5-HT value of greater than 174 ng/ml would be in the upper 5% (mean + 
1.65 SO) and could be termed hyperserotonemic. By this criteria 29% of 
the unmedicated autistics (5 out of 17) and 30% of the total group of 
medicated autistics (1 out of 9 using anticonvulsive medication, 2 out of 
7 using phenothiazines and 4 out of 7 using haloperidol) could be judged 
hyperserotonemic. 
No significant differences were found for whole blood tryptophan levels 
or platelet count between unmedicated autistics and nonnal controls .. 
However, hyperserotonemic unmedicated autistics showed significantly 
higher platelet counts (308+86.1 per nl) using a one-tailed t-test 
compared to normoserotonemic autistics (249~53.7 per nl, p = .05). 
Table ! J 
Whole blood serotonin and tryptophan in autistic and normal subjects 
(Mean ::': SD) 
Platelet Tryptophan 
Subjects N Serotonin (S-HT) count (TRP) 
n9/m1 n9/109 per n l ~9/m1 
platelets 
Normal controls 20 116!.35.0a 465.=: 162b 258::':_47.7 5-73::':_1.18 
Autistics unmedicated 17 163 ::': 31. f 9 620 ::': 303b 267 ::': 67. ~9 5-38 ::': 1. d::df 
Autistics a 11 medicated 23 146::':_53.2 569 ::': 192 265::':_72.7 4.71 + 1.14d 
phenothiazines 7 128::':_ 45.89 561::':_223 234+42.89 5.21 + 1.25 
haloperidol 7 176::':_75-5 550 ::': 197 324; 73.5e 4.52; 1.19f 
anticonvulsants 9 136+26.9 591 ::': 163 242+68.0 4.48+ 1.02c 
One tailed t-test unmedicated autistics versus normal controls: 
a: p = .01 b:p=.02 
One tailed t-test medicated groups versus unmedicated autistics: 
c:p=.03 d: p = • 04 e: p = . 05 f:p=.07 9' p = .09 
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Table I I I 
Pearson product-moment correlation coefficients in normal and unmedicated 
autistic groups 
5-HT ng/10 9 platelet 
Normal controls (N = 20) elatelets count TRP ~ 
5-HT ng/ml 0 .86** 0.07 0. 07 0.12 
5·HT ng/109 platelets 
-0.45 * -o. 18 0. 13 
platelet count 0.48* 0.07 
TRP 
-0.19 
5-HT ng/10 9 platelet 
Unmedicated autistics (N 17) elatelets count TRP ~ 
5-HT ng/ml 0. 75** 0 .49* 
-0.33 -0.30 
5-HT ng/109 platelets 
-0.14 -0.32 -o. 17 
platelet count 0. 10 -0.20 
TRP 
-0.21 
5-HT ng/ l 09 platelet 
All medicated autistics (N 23) elate lets count TRP ~ 
5-HT ng/ml 0 .61** o.45* 0 .14 0.29 
5-HT ng/10 9 platelets 
-0.40 0.10 0.20 
platelet count 
-0.03 -0.52* 
TRP 0.17 
* p < 0.05 
** p < 0.005 
In Table Ill the Pearson Product-Moment carrel ati on coefficients are 
9 
shown for the values of 5-HT ng/ml, 5-HT ng/10 platelets, platelet 
count, TRP and age in the normal controls, the unmedicated autistics and 
the total medicated group. A hi~hly significant correlation was found 
between 5-HT ng/ml and 5-HT ng/10 platelets in all groups. In the group 
of normal controls no correlation was found between 5-HT ng/ml and 
platelet count. Fugthermore a significant negative correlation was found 
between 5-HT ng/10 platelets and platelet count (r = -0.45 p = 0.04). On 
the contrary, in the unmedicated autistics 5-HT ng/ml values were 
significantly correlated with platelet count (r =90.49 p = .04). In this 
group no correlation was found between 5-HT ng/10 platelets and platelet 
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count. In the total medicated group a significant correlation has been 
observed between 5-HT ng/ml and platelet count (r = 0.45 p = 0.03). A 
9 
trend for a negative correlation between 5-HT ng/10 platelets and 
platelet count did not reach the level of significance (r = -0.40 p = 
0.06). 
In the control group TRP was significantly correlated with platelet 
count, (r=0.48 p=0.04). 
No corre1 ati on has been observed between age and any of the measures 
except for a negative correlation in the total medicated group between 
platelet count and age (r = -0.52 p = 0.01). At-test did not show 
significant differences between males and females for any of the measures 
in the control group or the group of unmedicated autistics. 
Effect of medication on group means 
Group means for 5-HT levels, TRP levels and platelet counts in 
neuroleptic-treated, anticonvulsant treated and unmedicated autistics are 
presented in Table II. A one tailed t-test comparing medicated groups 
with unmedicated autistic individuals did not show significant 
differences for 5-HT values. Only a nonsignificant trend was seen for 
lower 5-HT values if expressed as ng/ml for the autistics on 
phenothiazines (p=.09). 
TRP concentrations were significantly lower in the total medicated group 
compared to the unmedicated autistics (p=0.04). In the medicated 
subgroups this medication effect was greatest in 
vulsants (p=0.03) and the group on haloperidol 
the group on anti con-
(p=0.07). To assess 
further this medication effect on TRP levels, we recalculated the 
neuroleptic dose for the groups on haloperidol and phenothiazine 
medication in equivalents of 100 mg chlorpromazine. For the total group 
on neuroleptic medication (N=l4) a significant negative correlation was 
found between dose of medication and TRP values (r=-0.57 p=0.003). 
In the total medicated group the platelet counts were similar to those of 
the unmedicated autistics, however the platelet counts of the medicated 
hyperserotonemic autistics (314_:!:_73.7 per nl) were significantly higher 
(t=2.38 p=.01) compared to the medicated autistics with normal 5-HT 
levels (243!62.7 per nl). The platelet count of the autistics on 
haloperidol was significantly higher (p=.05) compared to the unmedicated 
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autistics while a trend for lower values was seen in the group on 
phenothiazines (p=.09). 
In the medicated group a significant correlation was found between 5-HT 
ng/ml and platelet count. Furthermore, an almost significant negative 
9 
correlation was observed between 5-HT ng/10 platelets and platelet count 
(r = -0.40 p = 0.06). However, platelet count was significantly 
correlated with age (r = -0.52 p = 0.01). When the partial correlations 
9 
of 5-HT (ng/ml and ng/10 platelets) and platelet count was calculated 
with age partialled out, no significant correlations were seen (r = 0.37 
p = 0.09 and r = -0.35 p = 0.11 respectively). 
Figure 1. Whole blood 5-HT values (ng/ml) first blood drawing versus 
second blood drawing in unmedicated autistics (r=.92 p<.01) 
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Long term stability 
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The mean values of 5-HT (ng/ml, and ng/10 platelets), the platelet 
count, and TRP ~g/ml obtained 12 months apart are given in Table IVA. 
A within-group paired t-test showed no significant differences between 
the values of the first and the second blood drawing in the drugfree 
group of autistic individuals for any of the measures. In the medicated 
9 
group values of 5-HT (ng/10 platelets) of the second blood drawing were 
significantly increased compared to the first drawing (p=.05). With 
respect to 5-HT values expressed as ng/ml this difference was close to 
the level of significance (p=.06). In the group with initiated or 
increased medication TRP values of the second blood drawing were 
significantly lower compared to the first blood drawing (p=0.01). 
Table 1\.;A 
Serotonin and related measures between initial sampling ~nd 12 months 
follow-up 
5-HT ng/ml initial 
follow-up 
5-HT ng/109 pl. initial 
fo 11 ow-up 
Platelet count initial 
follow-up 
TRP Jlg/ml initial 
follow-up 
Drugf ree Medicated 
aroun (N= 10) group, fixed ~ dose (N=10) 
Mean + SD Mean + SO 
167::_81.8 104 + 36.9a 
177::. 91.9 136 ::_ 30.8a 
542 ::. 170 431 .:: 178b 
581 + 218 562 .:: 188b 
281 ::. 65.9 248 + 42. 1 
289 + 68. 1 255 ::. 61.9 
6.36.::1.55 5.61 + 1. 36 
5.67.:: 1.24 5.02::. 0.84 
p values from paired t-test: a: .06 
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b: .05 
c; .0 l 
Group with 
chanqed medi-
cation (N 6) 
Mean + SD 
201 ::. 86.3 
130 ::. 50.2 
783 .:: 337 
533 ::. 242 
258 .:: 74. 1 
261 + 68.8 
6. 72::. 1.01 c 
3-95.:: 1.56 c 
Table IVB 
lntraclass correlations (R) and mean percentage (t.%) of change for 
serotonin and related measures between initial sampling and 12 months 
follow-up 
Druqfree Medicated Medicated 
group 
-m7e grou~ {changed R( 6 %) d dose) medication) R( 6 %) R ( 6 %) 
5-HT ng/ml . 92* (15%) -.05(33%) -.51 (54%) 
5-HT ng/10 9 platelets .86*(14%) .35(42%) -.61 (68%) 
Platelet count .9/( 7%) . 43 (20%) .07(19%) 
TRP .04 (28%) -. 09 (25%) -.43(51%) 
* p < .01 
A one-tailed t-test did show significantly lower 5-HT values (ng/ml) in 
the medicated group (fixed dose) compared to the unmedicated group for 
the first blood drawing (t = 2.22 p = 0.02). For the second blood 
drawing only a trend was. found for lower 5-HT values ( ng/ml) in the 
medicated group compared to the unmedicated autistics (t = 1.34 p = 
0.10). For this reason and because of the observed tendency for increased 
5-HT levels (ng/ml) in the second blood drawing compared to the first 
blood drawing in the medicated group (fixed dose) we determined if a 
group-time effect was present using a MANOVA procedure. No significant 
effect was found (F = 1.21 p ~ 0.12). 
Intraclass correlation coefficients (Bartko, 1976) and the mean 
percentages of change between the variables of the first and the second 
blood drawing of the three experimental groups are shown in Table !VB. 
Highly significant intraclass correlations were found between the values 
of the first and the second blood drawing for 5-HT ng/ml (r=.92 p<.01) 
9 (Figure 1), 5-HT ng/10 platelets (r=.86 p<.01), and the platelet count 
(r=.93 p<.01) in the unmedicated group. In the unmedicated group there 
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was no significant correlation between the values of the first and the 
second blood drawing for TRP. No significant correlation for any of the 
measures were found in the medicated group, or in the group with changed 
medication. 
DISCUSSION 
Group differences and correlation in blood 5-HT, TRP and platelet count 
As expected we confirmed the finding of elevated mean 5-HT values in 
unmedicated autistic subjects compared to normal controls as reported in 
many previous studies (Schain and Freedman, 1961; Ritvo et al., 1970; 
Yuwiler et al., 1971; Campbell et al., 1974; Yuwiler et al., 1975; 
Goldstein et al., 1976; Hanley et al., 1977; Takahashi et al., 1976; 
Hoshi no et al., 1979; Anderson et al., 1985b~ Hoshi no et al., 1984). This 
5-HT elevation of 41% (ng/ml) and 33% (ng/10 platelets) is in agreement 
with our previous findings (Anderson et al ., 1985b) and those of others 
(Yuwiler et al., 1971; Yuwiler et al., 1975). Other groups have found 
smaller (Goldstein et al., 1976; Ritvo et al., 1970) or larger (Schain 
and Freedman, 1961; Hanley et al ., 1977) elevations of whole blood 5-HT, 
compared to normals. 
Using a criteria of hyperserotonemia as a whole blood 5-HT level in the 
upper 5% of the control group, 29 percent of the unmedicated autistic 
subjects were judged as hyperserotonemic. This percentage is similar to 
that found in one previous study (Hanley et al ., 1977) and slightly lower 
than our previous findings (Anderson et al ., 1985b). However, the small 
size of the control group might limit the accuracy of the estimation of 
hyperserotonemia. 
Platelet count in the normal controls and the unmeditated autistics are 
very similar. This finding is in agreement with that of two previous 
reports (Anderson et al., 1985b; Hanley et al., 1977) while one study 
reported significantly higher platelet counts in autistic subjects 
compared to normals (Ritvo et al ., 1970). The finding of normal platelet 
9 
counts and the significantly increased 5-HT values expressed as ng/10 
platelets strongly suggest that the elevation observed for whole blood 
5-HT (ng/ml) is not due to elevated platelet counts. 
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To approach further the question of a possible role of platelet count or 
function in hyperserotonemi a we 1 ooked at the difference between the 
hyperserotonemic (5-HT level greater than 174 ng/ml) and the normo-
serotonemic autistics in terms of platelet count and at correlations 
between 5-HT values and platelet counts. Platelet counts in unmedicated 
hyperserotonemic autistics were significantly higher compared to the 
normoserotonemic autistics~ This is in contrast to the findings of Hanley 
et al. (1977), who reported that platelet counts were similar in 4 hyper-
serotonemic autistic individuals compared to 4 retarded subjects with 
normal 5-HT values. Furthermore, in the group of normal controls we found 
a lack of correlation between platelet count and 5-HT ng/ml and a 
9 
significant negative correlation between platelet count and 5-HT ng/10 
platelets. These two findings are similar to those of a previous study 
(Anderson et al., 1985b). In contrast, in the unmedicated autistic 
subjects a significant correlation is seen between 5-HT ng/ml and 
plate~et count and no correlation of platelet count and 5-HT expressed as 
ng/10 platelets is found. These findings, the increased platelet count 
in hyperserotonemic unmedicated autistics, the significant correlation 
between 5-HT ng/m~ and platelet count, and the lack of correlation 
between 5-HT ng/10 platelets and platelet count, would suggest that in 
these unmedicated autistics platelet number or function might play a role 
in the 5-HT elevation observed. 
Blood total TRP values were similar in unmeditated autistics and in 
nonnal controls. This is in general agreement with the findings of 
Hoshino et al. (1979, 1984) and Anderson et al. (1985b) where no 
differences were found between groups of unmeditated autistic subjects 
and normal controls. On the basis of these studies and the data presented 
here, it might be concluded that total TRP blood levels in autistics are 
normal. However, Hoshi no et al. (1984) did find free (non protein bound) 
plasma TRP was significantly higher in autistic children than in nonnal 
control subjects. There tended to be a si gni fi cant carrel ati on between 
the free plasma TRP level and several clinical rating scales in autistic 
children, but no correlation between blood 5-HT and free TRP levels. 
The question of whether increased precursor availability might contribute 
to increased 5-HT levels in autism remains open, further study of free 
TRP levels appears warranted. 
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Effect of medication 
No si gni fi cant differences of 5-HT values were found between medicated 
and unmedicated groups of autistic individuals. A tendency toward lower 
5-HT values was observed in the total medicated group and in two of the 
three medicated subgroups. However~ the differences were not as marked or 
as consistent as seen in the previous study of Anderson et al. (1985b). 
Several other studies have not observed an effect of neuroleptic or anti-
convu 1 sant medication on b 1 ood 5-HT 1 eve 1 s in retarded ( Partington et 
al., 1983), autistic (Schain and Freedman, 1961; Hoshino et al., 1979;) 
or schizophrenic (Stahl et al., 1983; Jackman et al., 1983) subjects. 
A problem in interpreting these data is the fact that the original 5-HT 
values before the start of the medication are unknown. Medicated subjects 
might be comprised of a group with 5-HT values different from the mean 
values of unmedicated autistics. 
Increased platelet counts were observed in medicated hyperserotonemic 
autistic subjects compared to medicated nonnoserotonemic subjects. This 
increase was also observed in unmedicated hyperserotonemic autistics and~ 
as discussed, might play a role in the increased blood 5-HT levels 
observed. 
The finding of significantly lower TRP levels in medicated autistic 
subjects is consistent with those of a previous report (Anderson et al ., 
1985b), where a nonsignificant trend for lower TRP values in neuroleptic 
and anticonvulsant medicated autistics have been observed. These 
findings, together with the observed negative correlation between dose of 
neural epti cs and TRP va 1 ues, strongly suggest that neural epti cs and 
anticonvulsant medication lowers blood total TRP levels in autistics. 
Long term stability 
The highly significant intraclass cog-relation coefficients for the two 
observations of 5-HT (ng/ml and ng/10 platelets) and platelet count, and 
the relatively low mean percentage of change of these values (Table !VB) 
show that these variables are stable in unmedicated autistics over a time 
span of more than a year. For these variables one can say that if they 
are low, they stay low and if they are high, they stay high over a years 
time. For the 5-HT values this is more true if expressed as ng/ml 
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compared to 
5-HT being 
9 
ng/10 platelets, the intraclass correlation coefficients for 
9 
higher than for 5-HT ng/10 platelets. With respect to 
stability over time it therefore seems preferable to express 5-HT levels 
9 
as ng/ml rather than as ng/10 platelets. 
In the medicated group and the group with changed medication no 
significant correlations were found between any of the variables for the 
first and second blood drawing. Furthermore rather high mean percentages 
9 
of change of 5-HT values (ng/ml and ng/10 platelets} and platelet counts 
were observed in the medicated groups (Table !VB}. It appears that 
anticonvulsant, phenothiazine- and haloperidol medication have a large 
negative influence on the temporal stability of 5-HT levels and the 
platelet count. These findings are in agreement with those of Jackman et 
al. (1983). They found significant shifts, either upwards or downwards, 
of platelet 5-HT levels in schizophrenic patients determined after 2 to 8 
weeks of treatment with haloperidol or chlorpromazine. 
One possibility to look at influences of medication on 5-HT ng/ml levels 
is given by the group that changed medication. Neuroleptic medication 
caused in the group that started medication or. increased the dose, a 
decrease of 5-HT values in all cases (N = 4}. For this subgroup using a 
paired t-test the values of s9HT (ng/ml} were almost significantly (p = 
0.06} and those of 5-HT ng/10 platelets significantly lower (p = 0.02} 
for the second drawing compared to the first drawing. Although no firm 
conclusions can be made on the basis of these data, they might indicate 
that the initiation of neuroleptic medication or a robust increase in 
dose of neuro1eptics result in a drop of 5-HT values. This is in 
agreement with the 1 oweri ng of 5-HT values in neural epti c medicated 
groups previously reported (Anderson et al., 198Sb}. 
An increase in dose of depakine did not show a decrease of 5-HT levels. 
However, the baseline values might we 11 have been suppressed by the 
previous neuroleptic medication. So for the total group that started 
medication or increased the dose, the difference in 5-HT levels did not 
reach the level of significance. 
However, as discussed above, most studies of medication effects have not 
observed significant decreases in whole blood 5-HT levels after neuro-
leptic treatment. In most cases the acute effects of medication have been 
studied; in this sense the studygroups are probably more comparable to 
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the group reported here with initiated or increased medication. It is not 
clear why the data are not more consistent, however the increased 
variability in 5-HT values which occurs after administration of neuro-
leptic (or anticonvulsant) medication has probably hindered studies in 
this area. 
Because of the observed tendency for increased 5-HT (ng/ml} levels for 
the second blooddrawing compared to the first blooddrawing in the 
medicated group (fixed dose), we considered the possibility that, after 
an extended period of medication, compensating mechanisms might be 
triggered which could counter the 1 owe ring effect of medication on the 
5-HT values. However, using a MANOVA procedure only a nonsignificant 
trend for a group-time effect was found. 
No significant intraclass correlatlons were found between the TRP values 
of the first and second blood drawing for any of the three groups. 
Furthermore, relatively high mean percentages of change were seen in all 
groups. This means that TRP values are not very stable over a years 
period of time in both unmedicated and medicated autistic subjects. A 
paired t-test showed a. significant intra-individual difference (p=.Ol) 
between the two TRP values for the group with changed medication, with 
the values of the second blood drawing being lower than the values of the 
first blood drawing. This gives further support to the conclusion made 
above that neuroleptic (and anticonvulsant) medication lowers blood 5-HT 
values in autistic subjects. 
This study on the temporal stability and the effects of medication on 
whole blood 5-HT, TRP and platelet counts has indicated, to some extent, 
what precautions and directions might be taken in research on the hyper-
serotonemia of autism. 
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SUMMARY 
Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion in two consecutive 
collection periods (5 PM - 11 PM and 11 PM - 8 AM) and whole blood 
serotonin (5-HT) and tryptophan (TRP) were measured in groups of 
unmedicated autistics (N = 16), medicated autistics (N = 20) and normal 
controls (N = 27). Whole blood 5-HT values were significantly higher in 
unmedicated autistics compared to normal controls. No significant 
differences were found in 5-HIAA excretion (~g/mg creatinine, mean ~SO) 
between unmedicated autistics (4.07 ~ 1.52) and normal controls (3.50 ~ 
1.07), nor beteen medicated (5.35 ~ 2.93) and dru9free autistic 
individuals. 
No correlations were found between 5-HT values and urinary 5-HIAA 
excretion. Urinary 5-HIAA (~9/mg creatinine, mean~ SO) was significantly 
greater in hyperserotonemic autistic subjects (4.88 ~ 0.87) compared to 
normal controls (3.50 ~ 1.07, total collection period, p = 0.002). A 
slight trend (p = 0.10) to higher overnight (11 PM - 8 AM) 5-HIAA 
excretion (~g/mg creatinine~ mean ~ SO) was observed for unmedicated 
hyperserotonemic autistic subjects (5.12 ~ 1.06) when compared to 
unmedicated autistics with normal whole blood 5-HT levels (3.86 ~ 1.78). 
In the medicated autistic group significantly higher overnight and total 
excretion of 5-HIAA was observed in subjects with elevated whole blood 
levels. The relevance of these findings to the possibility that increased 
gut production of 5-HT might cause the elevated whole blood 5-HT levels 
seen in autism is discussed. 
INTRODUCTION 
In 1961 Schain and Freedman reported that the mean value of whole blood 
serotonin (5-HT) in a group of 23 autistic children was increased 
compared to a contrast group of mildly retarded children without autistic 
features. Since then the finding of elevated serotonin levels in 
autistics has been replicated by a number of researchers {Ritvo et al ·~ 
1970; Yuwiler et al., 1975; Goldstein et al., 1976; Takahashi et al., 
1976; Hanley et al., 1977; Hoshino et al., 1979; Hoshino et al., 1984; 
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Anderson et al., 1985b; Minderaa et al., 1985). Group mean elevations 
ranging from 18% (Goldstein et al., 1976) to 137% (Hanley et al., 1977) 
above group means of normal controls have been observed. The cause of 
this hyperserotonemia in autistic children is unknown. 
A number of factors have been investigated as possible cause of the 5-HT 
elevation including precursor availability~ platelet uptake and release 
of 5-HT, and catabolism by monoamine oxidase (MAO). Hoshino et al. (1977) 
found normal levels of serum tryptophan, the precursor of serotonin, in 
10 autistic children, while Anderson et al. (1985b) found slightly lower 
tryptophan levels in a group of 40 autistic individuals. By some 
investigators (Sankar et al., 1962; Sankar, 1970, 1971, 1977) the in 
vitro uptake of serotonin by blood platelets has been reported to be 
decreased, by others to be increased (Rotman et al ., 1980) or unchanged 
(Lucas et al., 1971; Boullin et al., 1972; Yuwiler et al., 1975). The 
same can be said about the in vitro release of serotonin by blood 
platelets. Initial reports indicated the capacity of autistics' platelets 
to retain serotonin in vitro was decreased (Boullin et al., 1970; Boullin 
et al., 1971). However, it now appears this aspect of platelet 
functioning is normal in autism {Yuwiler et al., 1975; Boul1in et al., 
1982). Finally, Anderson et al. (1984) found the imipramine binding of 
blood platelets of autistic children was normal. Thus, as yet, no 
definite deficiencies in platelet membrane functions in respect to 
serotonin uptake, storage or release have been detected. Furthermore some 
investigators assessed the catabolism of serotonin by monoamine oxidase 
(MAO). The MAO activity in autistics appeared to be normal (Boullin et 
al., 1976; Campbell et al., 1976; Cohen et al., 1977; Roth et al., 1976) 
and no correlation between MAO activity and serotonin levels was found 
(Cohen et al., 1977). 
Of all 5-HT in the human body, about 90% is found in the gut, about 8% in 
the bloodplatelets and 1 or 2% in the brain. The 5-HT found in the blood 
is produced in the enterochromaffi n cells in the mucosa of the gut, 
released into the plasma, from where it is actively taken up by the blood 
platelets. As a possible cause of the elevated group means seen in 
autism, several workers (Hanley et al., 1977; Anderson et al., 1985b) 
have suggested that the 5-HT production in these enterochromaffin cells 
in the gut might be increased. 5-Hydroxyindoleacetic acid (5-HIAA) is the 
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major metabolite of serotonin and urinary 5-HIAA excretion is seen as a 
measure of total body 5-HT turnover (Udenfriend et al., 1959). With 
almost all 5-HT being produced in the gut, 5HJAA excretion can be 
considered a measure of gut 5-HT production, assuming the catabolism of 
5-HT is nonnal. If the production of 5-HT in the intestine of autistic 
subjects is increased~ it seems reasonable to expect that the urinary 
5-HJAA would also be increased. 
In order to test this hypothesis and to study the relationship between 
urine 5-HIAA and blood 5-HT, we have measured these species in 36 
autistic and 27 normal subjects. 
SUBJECTS AND METHODS 
The experimental group was comprised of 36 students enrolled in a school 
for autistic individuals. A diagnosis was made by a child psychiatrist 
(RM) based on psychiatric evaluation~ anamnestic information and 
observations made by the school staff, before the data were known .. 
Thirtyfour individuals received the diagnosis of infantile autism~ full 
syndrome present, according to DSM-111 criteria (DSM-IIJ, 1980, 299.00). 
Two subjects received the diagnosis of infantile autism, residual state 
(299 .01). Urine was call ected for two consecutive call ect ion peri ads, 
namely from 5 PM - 11 PM and from 11 PM up to 8 AM. During collection the 
0 
urine was kept at 3 C. Urinary 5-HJAA was analysed using a high perfor-
mance liquid chromatographic method (HPLC) (Anderson et al., 1985a). 
Sixteen of the autistics were unmedicated for at least six months before 
the urine collection. Out a total of 20 medicated autistic subjects, 6 
used phenothiazines, 6 used haloperidol and 8 used anticonvulsant 
medication .. These subjects were medicated in a constant manner for more 
than 3 months before the urine collection .. A control group was comprised 
of 28 high school students, teachers, and hospital employees, comparable 
in age and sex. All reported being in good physical health and using no 
medication .. 
The group sex and age data for the different groups are given in Table I. 
Blood was drawn between 10 - 11 AM from a 11 but two of the unmedi cated 
autistics and all but one of the medicated autistic individuals. 
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Table 1 
Sex and Age Data of Study Subjects 
Subjects N Sex Ase C:tears) 
M/F Mean + SD Range 
Normal controls 27 19/8 20.3 :':. 6.9 9. I - 36. I 
Autistics unmedicated 16 11/6 20.6 + 4.6 14.3 
- 28.7 
Aut is tics a II medicated 20 16/4 19.4 :':. 4. 1 8.9 - 26.4 
phenothiazines 6 6/0 22.5 :':. 3.2 18.3 - 26.4 
haloperidol 6 4/2 17.8 :':. 4.9 10.5 - 23.7 
anticonvulsants 8 6/2 18.1 + 4.2 8.9 - 23.4 
Whole blood 5-HT and TRP were analysed using a HPLC-fluorometric method 
described previously (Anderson et al., 1981). A control group was 
comprised of 20 subjects of similar age and sex. Both blood and urine was 
obtained from seventeen of the normal control subjects. 
For the autistics~ the mean time span between blood drawing and urine 
collection was 22 days (range 1-252 days). Within this time span there 
was no change in medication for any of the autistics. For the control 
group the blood drawing was done the morning following the urine 
collection procedure. 
STATISTICAL ANALYSIS AND RESULTS 
Urinary 5-HIAA excretion 
Group means of urinary 5-HIAA for the separate and combined collection 
periods in the control group, the unmedicated autistic group and the 
medicated autistic groups are given in Table II. 
The individual data for the excretion of 5HIAA (~g/hr and ~g/mg 
creatinine) are also presented in Figure lA and lB. 
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Table I I 
Urinary 5-HIAA excretion during evening (5 Pi~- 11 PM) and 
overnight (11 PM- 8 AM) collection periods in normal and 
autistic subjects 
Subjects N 
Normal controls 27 
5-HIAA ug/hr 
5-HIAA ~g/mg creatinine 
Autistics unmedicated 16 
5-HIAA ug/hr 
5-HIAA ~g/mg creatinine 
Autistics all medicated 20 
5-HIAA ug/hr 
5-H IAA ug/mg creatinine 
Phenothiazine-treated 6 
5-H IAA ug/hr 
5-H IAA ug/mg creatinine 
Haloperidol-treated 6 
5-H I AA ug/h r 
5-HIAA ~g/mg creatinine 
Anticonvulsant-treated 8 
5-H I AA Ug/h r 
5-H I AA ug/mg creatinine 
5 PM- 11 PM 11 PM- 8 AM 
174 ~ 117 175 ~ 66.5 
3-53 ~ 1.62 3.44 ~ 1.06a 
203 ~ 75-3c 
4.00 + 1.58 
333 ~ 243c 
5-77~4.10 
374 ~ 224 
4.76 ~ 1.98 
370 ~ 369 
7.91 + 6.48 
246 + 120 
4.73~2-74 
208 + 89.9 
4.16: 1. 70ad 
225 ~ 94.0 
5.05 ~ 2.58 
238 ~ 87.7 
4.92 ~ 3.26 
249 + 76.3 
- d 
6. 02 ~ 2.25 
201 ~ 117 
4.19 ~ 2.29 
Unmedicated autistics versus normal controls: 
one-tailed t-test: a: p 0.07 
Medicated groups versus unmed i cated aut i st i cs: 
two-tailed t-test: c: p 0.07 
e: p 0.09 
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5 PM- 8 AM 
174 + 72.5 
- b 
3.50 ~ 1. 07 
205 + 69.8e 
- bf 
4.07 ~ 1.52 
263 + 125e 
- f 
5-35 ~ 2.93 
280 ~ 87. 0 
4.82 ~ 2.39 
294 ~ 179 
7.04~3.85 
222 + 103 
4.44 + 2.10 
b: p 
d: p 
f: p 
0. 1 
0.08 
0.1 
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Using a one-tailed t-test, 5-HIAA excretion rates in drugfree autistics 
and in normal controls were not significantly different. A nonsignificant 
trend (p • .07) was observed for slightly higher overnight 5-HIAA 
excretion (f.lg/mg creatinine) in unmedicated autistics when compared to 
normal subjects .. 
Two-tailed t-tests comparing 5-HIAA excretion in medicated autistics with 
unmedicated autistics did not show significant differences for any of the 
collection periods. Nonsignificant trends were observed for increased 
5-HIAA excretion in several of the medicated subgroups examined (see 
Table II). 
Several methodological issues of urinary 5-HIAA excretion were examined 
in detail. Highly significant correlations were found between urinary 
5-HIAA excretion expressed as f.lg/hr and urinary creatinine excretion 
expressed as mg/hr for the evening (r • 0.61, p • 0.001), the overnight 
(r • 0.74, p < 0.0005) and the combined (r • 0.61, P < 0.0005) collection 
periods of the control group and for the overnight collection period 
(r • 0.50, p • 0.04) of the unmedicated autistics. 
No significant correlation was found between urinary 5-HIAA excretion 
(vg/hr) and body surface area or the collection volume. 
No significant differences were observed in urine volumes or creatinine 
excretion between unmed i cated a uti sti cs and normal controls and between 
medicated and unmedicated autistic individuals. 
No correlations have been found between urinary 5-HIAA excretion (llg/mg 
creatinine or f.lg/hr) and age in the nonnal controls, the unmedicated 
group or the medicated group of autistics over the range examined .. A 
t-test did not show any significant differences in urinary 5-HIAA 
excretion between males and females in the normal controls or the 
unmedicated autistics .. 
A paired t-test comparing 5-HIAA values of the first and the second 
collection period did not show significant differences for any of the 
groups being expressed either as l19/hr or as l19/mg creatinine .. However, 
in the total group of medicated autistics a tendency (p • 0.06) for lower 
5-HIAA values (vg/hr) was found for the overnight collection period. So, 
urinary 5-HIAA excretion seems to be stable over the periods examined in 
unmedicated autistic subjects and normal controls. 
Pearson product-moment correlation coefficients computed for the 5-HIAA 
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values (~g/mg creatinine) of the first and second urine collection showed 
a significant correlation in the normal controls (r = 0.38, p = 0.05), 
the unmedicated autistics (r = 0.66, p = 0.005), the medicated autistics 
(r = 0.66, p = 0.005) and the total group (r = 0.5g, P < 0.0005). 
However~ if the urinary 5-HIAA excretion was expressed as f.lg/hr no 
significant correlations were observed between the two collections in the 
normal controls or any of the autistic subgroups, although the 
relationship approaches significance (r = 0.36, p = 0.06) in the normal 
control group and was highly significant (r = .34, P = 0.006) in the 
total group. 
5-HT and TRP values in blood 
Group means of whole blood 5-HT, platelet count and TRP in the control 
group, the unmedicated autistic group and the medicated autistic groups 
are given in Table III. 
Table J I I 
Whole blood serotonin and tryptophan in autistic and normal subjects 
(Mean :':_ S D) 
Platelet Tryptophan 
Subjects Serotonin (5-HT) count (TRP) 
ng/m] ng/1 o9 (per nl) (~g/ml) 
platelets 
Normal controls 17 113 :':_ 24. 6a 443:':_ 112b 261 :':_50.4 5.85:':_ 1.24 
Autistics unmedicated 14 163 :':_ 86.3a 630 :':_ 333b 262:':_58.7c 5.35:':_1.23 
Aut i st i cs a II medicated 19 147:':_56.0 586:':_191 261 :':_ 77.2 4.70:':_1.15 
phenothiazines 6 132:':_ 48.7 599 :':_ 21 7 222 :':_ 29.3 5.03:':_ 1.27 
ha loperi do 1 6 1 85 :':_ 85. 7 569 :':_ 227 332 :':_ 86. 7c 4.41 + 1.42 
anticonvulsants 8 136:':_28.7 586 :':_ 173 245 :':_ 72.1 4.63 :':_ 0.99 
one tailed t-test: a: p . 01 b: p .03 
two tailed t-test: c: p .03 
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A one-tailed t-test was used to assess differences of 5-HT values between 
the group of unmedicated ~utistics and the control group. The values of 
5-HT ng/ml and 5-HT ng/10 platelets for the unmedicated autistics were 
significantly higher than those for the controls (t value = 2.39, p = 
0.01 and t value= 2.02, p = 0.03 respectively). 
Using a two-tailed t-test no significant differences were found for the 
platelet count and TRP values between the unmedicated autistics and the 
normal controls. 
Two-tailed t-tests between medicated groups and unmedicated autistics 
showed no differences for 5-HT values, platelet counts and TRP values 
except for significantly higher platelet counts in the group of autistics 
on haldol compared to the unmedicated group (p = 0.03). 
Relationship of urinary 5-H!AA and whole blood 5-HT 
A scatter diagram of urinary 5-HIAA excretion (~g/mg creatinine and whole 
blood 5-HT (ng/ml) levels is presented in Figure 2. 
No significant correlations between urinary 5-HIAA and blood 5-HT were 
found for any of the groups (normal controls: r = -0.38, p = 0.13, 
unmedicated autistics: r = 0.17, p = 0.57 if urinary 5-HIAA expressed as 
~g/hr; normal controls: r = -0.25, p = 0.21, unmedicated autistics: r = 
0.28, p = 0.29 if urinary 5-HIAA expressed as ~g/mg creatinine). 
There were also -no significant correlations found between blood TRP 
values and urinary 5-HIAA excretion measures in any of the groups 
studied. 
When the control group (N = 20) is used to describe a normal range of 
5-HT ng/ml, an individual having a 5-HT value of greater than 174 ng/ml 
(mean + 1.65 SD) would be in the upper 5% and could be termed hyper-
serotonemic. 8y this criteria 25% of the unmedicated autistics (4 out of 
16) and 25% of the total group of medicated autistics (1 out of 8 using 
anticonvulsive medication, 2 out of 6 using haldol and 2 out of 6 using 
phenothi azi nes) could be judged hyperserotonemic. The urinary 5-H!AA 
values of the hyperserotonemic autistics were compared with those of the 
autistic subjects with normal whole blood 5-HT ng/ml values and with 
those of the normal controls. 
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Figure 2. Urinary 5-H!AA excretion [~g/mg creatinine) during combined 
collection periods [5 PM- 8 AM) versus whole blood 5-HT 
[ng/ml) in normal controls [N = 17) and in drugfree [N = 14) 
and medicated [N = 19) autistic subjects 
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Table IV 
Urinary 5-HIAA excretion in hyperserotonemic autistic individuals 
A 
Unmedicated autistics 
N 
5 PM - 11 PM 
hyper 5-HT 4 
norma 5-HT 12 
normal controls 27 
11 PM - 8 AM 
hyper 5-HT 4 
norma 5-HT 12 
normal controls 27 
5 PM - 8 AM 
hyper 5-HT 4 
norma 5-HT 12 
normal controls 27 
a,b,c p 0. I 
d p 0.08 
e p 0.02 
f p 0.006 
5-H IAA ~g/hr 
Mean + SD 
208 .:':. 75 
206 + 82 
174 .:':. 117 
229 .:':. 70d 
206 + 102 
175; 66.5d 
221 .:':. 71 
200 .:':. 74 
174 .:':. 72.5 
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5-HIAA ~g/mg creatinine 
Mean + SO 
a 4.57 .:':. 0.68 
3.80 .:':. 1. 77 
3-53 .:':. 1 .62a 
bf 5.12 + 1.06 
- b 
3. 86 + 1. 78 
- f 
3.44 .:':. 1.06 
4.88 .:':. 0.87ce 
3.89 .:':. 1.62° 
3.50 .:':. 1.07e 
B 
Medicated autistics 
N 
5 PM- JJ PM 
hyper 5-HT 5 
norma 5-HT 13 
normal controls 27 
11 PM- 8 AM 
hyper 5-HT 5 
norma 5-HT 13 
normal controls 27 
5 PM - 8 AM 
hyper 5-HT 
norma 5-HT 
norma 1 cant ro 1 s 
5 
13 
27 
5-H I AA ].lg/h r 
Mean + SD 
437 2: 416e 
270 :':: 103 
174 2: 1 J 7e 
222 :':: 95.0b 
225 + 101 
175; 66.5b 
291 2: 197c 
249 :':: 85.8 
174:':: 72.5c 
a p 0.1 e,f p 0.05 
b p 0. 09 g p 0.02 
c,d p 0.07 h p 0 .OJ 
p 0.003 
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5-HIAA ~g/mg creatinine 
Mean + SD 
8.40 2: 6.57ad 
4.38:'::1.34. 
3.53 :':: J.62d 
7.48 :':: 3-339h 
3.87 :':: 1.239 
3.44 2: 1 .o6h 
f" 7.73 :':: 4.22 I 
4.09 :':: J.04f 
3.50 :':: J .07; 
The unmedicated hyperserotonemic autistics showed significantly greater 
5-HIAA excretion (~g/mg creatinine) compared to the normal controls 
(p = 0.02) (see Table IV). In the unmedicated autistics a nonsignificant 
trend was found for higher urinary 5-HIAA excretion (~g/mg creatinine) in 
the hyperserotonemic autistics compared to the normoserotonemic autistics 
in the overnight collection period (p = 0.10) and in the combined 
collection period (p = 0.11). When 5-HIAA excretion was expressed as 
~g/hr no differences were seen between the hyperserotonemic autistics and 
the nonnoserotonemic autistics or the normal controls. In the group of 
unmedicated hyperserotonemic autistics a high correlation was observed 
(r = 0.86) between urinary 5-HIAA excretion (~gjmg creatinine) and blood 
5-HT (ng/ml) that tended to be significant (p = 0.1). 
In the medicated autistic subjects significantly greater 5-HIAA excretion 
(1Jg/mg creatinine) was observed in the hyperserotonemic subgroup during 
the overnight collection period (p = 0.02) and the total collection 
period (p = 0.05) compared to the normoserotonemic autistic subgroup. 
The medicated autistic subgroup also excreted significantly more 5-HIAA 
(~g/mg creatinine) compared to normal controls (p = 0.003). 
DISCUSSION 
The mean urinary 5-HIAA values in the control group are in agreement with 
those of others (Wiesel et al., 1982; Markianos et al., 1982; Challacombe 
et al ., 1981; Anderson et al., 1985a). 
Although the normal control and unmedicated autistic groups were well 
matched with respect to sex and age, and the expected hyperserotonemia 
was clearly observed in the group of unmedi cated a uti sti cs, no 
significant differences were found in urinary 5-HIAA excretion (expressed 
as ug/hr of ug/mg creatinine). This is in agreement with the findings of 
several previous reports. Shaw et al. (1959) did not observe any 
difference in 5-HIAA excretion between a group of 11 schizophrenic 
children and a group of 10 psychiatrically disturbed children. Schain and 
Freedman (1961) did not find increased urinary 5-HIAA excretion in 
autistic subjects compared to mentally retarded children. 
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We did observe greater urinary 5-HIAA excretion (~g/mg creatinine) in a 
subgroup of autistic individuals with increased blood 5-HT values 
compared to normoserotonemi c a uti sti c subjects or nonnal controls. The 
difference between hyperserotonemic a uti sti cs and nonnoserotonemi c 
autistics was not significant, however differences between hyperseroto-
nemic autistics and normal controls were hightly significant. 
These differences were more marked in medicated autistics and medicated 
autistics excreted greater amounts of 5-HIAA than unmedicated autistics. 
These findings are in agreement with those of Hanley et al. (1977) who 
reported increased urinary 5-HIAA excretion in 4 autistic subjects with 
increased whole b 1 ood serotonin values compared to 4 nonnoserotonemic 
mentally retarded children before and after oral tryptophan loading. 
Some discussion of the 1 arge positive carrel ati ons observed between the 
hourly excretion of 5-HIAA and creatinine is called for. No significant 
correlations were observed between hourly 5-HIAA excretion and body 
surface area or urine collection val umes. The correlations between hourly 
rates of 5-HIAA and creatinine excretion remained significant after 
parti a 11 i ng out body surface area. These facts suggest the corre 1 ati on 
was not simply due to larger subjects excreting greater amounts of both 
compounds, or to incomplete collections. The puzzling correlations 
between 5-HIAA and creatinine excretion remain unexplained and warrant 
further investigation, particularly since similar correlations were seen 
between other catecholamine metabolites and creatinine (Minderaa, 
unpublished). In the mean time it would appear advisable to express 
metabolite excretion using both units (per hour and per mg of 
creatinine). 
No significant correlation was found between the urinary 5-HIAA excretion 
and whole blood 5-HT values in the normal groups, nor in any of the 
autistic groups. However, in unmedicated hyperserotonemic subjects a high 
correlation was found between these two measures that tended to be 
significant. These correlation data obtained in the autistic groups 
should be judged with caution because of the time span between the blood 
drawing and the urine collection. However, whole blood 5-HT values have 
been found to be very stable measures over a years time in unmedicated 
autistics (Minderaa et al., 1985) and in normal subjects (Yuwiler et al., 
1971). 
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The lack of correlation between 5-HIAA excretion and whole blood levels 
of 5-HT in the autistic and normal groups is difficult to explain. 
As Anderson et al. (1985c) pointed out, it is not clear which aspect of 
5-HT physiology is most important in setting blood 5-HT levels in normal 
subjects. The rates of gut production, platelet uptake and storage, and 
catabolism by monoamine oxidase (MAO) might all play a role. In some 
pathological circumstances like carcinoid syndrome (Crawford et al., 
1967) excessively increased 5-HT production does lead to increased blood 
5-HT values and increased urinary 5-HIAA excretion. However, it appears 
that under most circumstances, gut production of 5-HT, to the extent 
which it can be assessed by measuring urinary 5-HIAA, does not play a 
predominant role in setting blood 5-HT levels in either normal, or 
autistic subjects. 
Although the bulk of the data presented indicate similar gut production 
of 5-HT in autistic and normal individuals, the increase of urinary 
5-HIAA excretion and the high correlation between urinary 5-HIAA 
excretion and blood 5-HT seen in hyperserotonemic autistic subjects 
suggests that, in fact, some rel ati onshi p between gut production and 
blood levels might exist in these subjects. 
While the increase seen in urinary 5-HIAA excretion is relatively small 
(ca. 35%) compared to the more than 2x fold elevation in whole blood 
5-HT, its potential importance should not be overlooked. It has been 
estimated that only a small proportion of the total gut 5-HT production 
is ever taken up by the platelets. Because the platelet, or whole blood, 
pool of 5-HT is small compared to total gut production, one could 
speculate that a small increase in gut synthesis might have a relatively 
large effect on blood levels of 5-HT. 
SUMMARY 
One can say fairly confidently that the increased whole blood 5-HT values 
seen in autism are not due to a large increase in gut production of 5-HT. 
However, the possibility remains that the significant, but relatively 
small, examined increase in gut production seen in the hyperserotonemic 
autistic subjects might contribute to elevated whole blood 5-HT levels. 
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Further assessment of urinary 5-HIAA excretion in larger groups of 
hyperserotonemic autistic subjects might throw more light on this issue. 
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SUMMARY 
Previous reports of elevated platelet serotonin (5-HT) concentrations in 
autistic subjects suggest that platelet 5-HT uptake might be altered in 
3 
autism. Parameters of H-imipramine (IMI) binding were measured in ll 
drug-free autistic subjects and 10 nonnal volunteers. Similar means (! 
SD) forB (autistics, 1350 + 171 fmole/mg protein; normals 1590 + 206 
max - -
fmol e/mg protein and K (autistics, 0.98 + 0.10 nM; normals 0.94 + 0.13 
d - -
nM) were found in the two groups. The normal number (B ) and affinitity 
max (K ) of the IMI binding site in autistic subjects suggest that the 
d 
regulation of 5-HT uptake is not different in autism. 
INTRODUCTION 
Binding sites for the tricyclic antidepressant, imipramine (IM!), have 
been observed in brain tissue and platelets of humans and rats (Briley et 
al., 1979; Raisman et al., 1979; Wennogle et al., 1981; Langer et al., 
1981). In brain, the site is distributed similarly to serotonin (5-HT) 
neurons (Langer et al., 1981; Palkovits et al., 1981; Sette et al., 
1981), and in both brain and platelets, the site is involved with the 
regulation of 5-HT uptake (Langer et al ., 1980; Paul et al ., 1981a; 
Rehavi et al ., 1981; Raisman et al ., 1982; Sette et al ., 1983). The IMI 
binding site is apparently distinct from, though in close proximity to, 
the 5-HT uptake site (Talvenheimo et al., 1979; Ahtee et al., 1981; 
Barbaccia et al ., 1983). The importance of the site and the existence of 
an endogenous ligand remain to be established. Clinical relevance is 
suggested by studies showing a positive correlation between mean clinical 
doses of tricyclic antidepressants and their dissociation constants (K) 
d 
at the IMI site (Wennogle et al ., 1981; Paul et al ., 1981b). 
Platelet IMI binding has been studied extensively in human depression. 
A number of groups have observed lower numbers (B ) of platelet IMI 
max 
binding sites in depressed patients compared to normals (Asarch et al., 
1980; Briley et al., 1980; Paul et al ., 1981b; Raisman et al., 1981, 
1982; Wood et al., 1983). A lower B for !Ml binding has also been 
max 
observed in post-mortem brain (frontal cortex) tissue of suicides 
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(Stanley et al., 1982). However, several recent studies of IMI binding in 
platelets have not observed lower group means for B values in 
max 
depression compared to normal controls (Berrettini et al ., 1982; Mellerup 
et al., 1982; Whitaker et al., 1983). The discrepancy between studies 
might be a result of an apparently large seasonal variation in the B 
max 
measure (Whitaker et al ., 1983). 
The consistent finding of elevated platelet 5-HT concentration in autism 
(Young et al., 1982) suggests an alteration in 5-HT uptake might be 
present in autistic subjects. Studies of 5-HT uptake in platelets of 
autistic subjects have not demonstrated a difference in rates or 
affinities of uptake (Boullin et al., 1982). We have measured IM! binding 
in drug-free autistic subjects and in normals, in order to ascertain 
whether this aspect of the platelet 5-HT system is altered in autism. 
METHODS 
Subjects 
The control group consisted of 10 normal, healthy children and young 
adults with an age range (8-32 years) and distribution (mean~ SO • 14.0 
~ 2.5) similar to that found in the autistic group (10-24; 17.3 ~ 4.4). 
Subjects were determined to be in good mental health and to be 
unmedicated. The autistic population was composed of 11 individuals 
diagnosed as having infantile autism (299.0) as defined by DSM-lll 
criteria (American Psychiatric Association, 1980). All were enrolled in 
special programs designed for autistic individuals. Care was taken to 
exclude aphasic and nonautistic retarded subjects. All autistic subjects 
had been drug-free for at least 6 months before blood drawing. Blood was 
obtained from normal and autistic subjects over a 4-month period 
(December-April); blood drawing was performed between 10 and 11 A.M. 
Platelet Preparation 
Thirty-five ml of blood were collected in six tubes containing 0.5 ml of 
0.15 M disodium ethylenediaminotetraacetate (EDTA). The blood was pooled 
0 
and spun in polypropylene tubes at 250g for 10 minutes (20 C) using a 
swinging-bucket rotor. The platelet-rich plasma (PRP) was carefully 
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measured and transferred to two additional plastic tubes. A 100 wl 
aliquot was removed from each tube for automated platelet counting (Clay 
Adams, Ultra-Flo 100) and the PRP was then centrifuged at 10,000g for 15 
minutes using a fixed angle rotor. The plasma was decanted off the 
resulting platelet pellet, and each pellet washed with 3 ml of pH 7.0 
0 (20 C), 0.05 M Tris buffer containing o.11 M sodium chloride and 0.02 M 
disodium EDTA (solution 1). The pellets were washed and resuspended by 
filling and emptying a plastic disposable pipette for 2 to 3 minutes. The 
pipette was finally rinsed with an additional 2 ml of solution 1, the 5 
ml platelet resuspensions centrifuged at lO,OOOg for 15 minutes, and the 
wash procedured repeated. The twice-washed pellets were then resuspended, 
lysed, and homogenized by sonicating on ice in 2 ml of 0.005 M Tris 
containing 0.005 M disodium EDTA (pH 6.3). Pellets were sonicated for two 
10-second periods using a Branson Polytron Sonicator (Bridgeport, CT) at 
a setting of 3.5; care was taken to avoid frothing of the sample. The 
sonicates were pooled and 100 wl removed for protein assay (Lowry et al ., 
0 
1951). The membrane protein was pelleted at 39,000g (15 minutes, 4 C), 
0 
the supernate decanted, and the membrane pellet stored at -80 C. 
Binding Assay 
The platelet membrane pellet was resuspended in 5 ml of pH 7.5, 0.05 M 
Tris buffer (containing 0.12 M NaCl, 0.005 M Kcl) by brief sonication 
{setting 3.5, 5 seconds on ice). Tubes,3prepared in duplicate, contained 
0.5, 1.0, 2.0, 4.0, 8.0, and 12.0 nM H-IM! (55 Ci/nmole, New England 
Nuclear, Boston MA), with or without 10 wM desimipramine (OM!) in a total 
incubation volume of 300 wl. Both IMI and OM! were dissolved or diluted 
in assay buffer. Following the addition of 100 wl of platelet membrane 
resuspensi on (approximately 40-80 wg protein), the tubes were incubated 
0 
for 45 minutes with gentle shaking at 0 C. Samples were then individually 
filtered through Whatman GF/C glass fiber filters after the addition of 5 
ml of ice-cold assay buffer. Filters were washed with three 5 ml portions 
of cold buffer first added to the sample tube. The filtration procedure 
was typically performed in 17 minutes for 28 samples. After a 2-hour 
digestion in 1 ml Protosol, 9 ml of Econofluor (New England Nuclear, 
Boston MA) was added and the radioactivity determined by liquid 
scintillation counting. Specific binding was determined by subtracting 
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counts (cpm) observed in samples containing 10 ~M DMI (blocked) from 
those observed in the cor responding unblocked tubes. Duplicated vials 
typically differed by less than 10%; values were discarded i~ agreement 
was not within 15%. The apparent specific activity (cpm/pmole H-I~!) was 
determined for each experiment by counting 10 ~l aliquots of the H-IM! 
solution in similarly prepared vials. Values for receptor number (B ) 
and affinity (K ) 
d binding data. 
max 
were calculated from Scatchard analysis of the specific 
RESULTS AND DISCUSSION 
Methodological Findings 
Saturable~ specific binding was observed in the platelet membranes 
examined, whether isolated from whole blood or obtained from blood bank 
supplies of platelet concentrate. Nonspecific binding was linearly 
3 
related to the concentration of added H-IM! and was approximately 20% of 
the total binding at a concentration of 2nM. As has been reported 
(Mellerup et al ., 1982~, over 90% of the nonspecific binding observed at 
all concentrations of H-IM! was due to binding to the filter. Attempts 
to eliminate this binding by silanizing the filters were unsuccessful due 
to large decreases in filter porosity. To test the effect of incubate 
protein concentration on the binding parameters (B and K ) , assays 
max d 
were performed using protein concentrations of 0.13-0.33 mg/ml. No 
systematic effect on either B of K was observed. The effect of 
max d 
endogenous and exogenous serotonin was also studied. Native serotonin 
concentrations determined (Anderson et al., 1981) in sonicated membrane 
suspensions were found to decline after washing of the sonicated 
membranes (Table I). No difference inK was seen for platelets analyzed 
d 
after 0, 1, or 2 washes; however, the B for the unwashed membranes was 
max 
lower. This difference is attributed to a purification of binding site 
protein (as will be discussed). When 5-HT was added to twice-washed mem-
branes, a decrease in B and an increase in K was apparent {see Table 
max 3 d I). Complex inhibition of H-IM! binding by serotonin has been reported 
previously (Sette et al., 1983) and remains to be clarified. We are 
confident that after the one wash of sonicated membranes used in our 
160 
standard procedure the effects of 5-HT are negligible. 
Table I 
Effect of 5-HT concentration on platelet 3H-IMI binding 
5-HT levels and IMI binding after washing of sonicated membranes 
No. of washes 
Endogenous 5-HT 1 
concentration (~M) 
0 2.04 
0.21 
2 0.03 
Effect of added 5-HT on B and Kd 
max 
Concentration 2 
added 5-HT(~M) 
0 
2 
7.5 
23 
B (fmole/mg) 
max 
690 
1450 
1300 
B (fmole/mg) 
max 
1930 
1455 
1600 
1210 
I .I 
0.69 
1.0 
I. 52 
4.35 
11.2 
12.0 
1. 5-HT concentration measured in 5 ml total resuspension volume 
2. Concentration of 5-HT in incubated assay tube A2).lM concentration 
is equivalent to 6)1M 5-HT in the resuspension 
Measurements of B made in platelets isolated from whole blood or from 
max platelet concentrate were consistently elevated compared to previous 
reports. A mean of approximately 1500 fmol e(mg protein was observed 
compared to typically reported means of 500-600 fmole(mg. The difference 
is probably due in part to the use of sonication rather than of shearing 
homogenization for platelet membrane preparation. Sonication apparently 
results in the preferential isolation of binding site-containing membrane 
protein relative to other cellular proteins. Approximately one half of 
the platelet protein is eliminated after the sonication procedure 
described. When the B is expressed in terms of the protein present 
max 
after the initial sonication (total unpurified platelet protein), values 
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calculated are in better agreement with previous results. This increase 
in B , observed in sonicated rat cerebral cortex (Arora et al ., 1983), 
max 
recently has been reported for platelet membraned prepared by freeze-
thawing ( fri edl et al., 1983). Because of the 1 ow ( <10%) recovery of 
freeze-thaw or sonicated membrane protein, and the lower number of 
binding sites observed per platelet in freeze-thaw membranes, it was 
3 
suggested that H-IM! binding is measured best in intact platelets 
(Friedl et al., 1983). However, we have observed good recovery of 
platelet protein (-60%), and B values (sites/platelet) are similar to 
max 
those obtai ned for intact platelets. The disadvantages of using intact 
platelets remain; possible aggregation and/or shape change, possible 5-HT 
release, and a requirement for immediate assay. We do suggest that B 
max 
values be expressed as fmole/mg total platelet protein, fmole/mg isolated 
protein (if app~icable), and sites/platelet. The reporting of protein per 
platelet (mg/10 ), protein yields, and whole blood and PRP platelet count 
would further facilitate comparisons between studies. 
The reproducibility of the method was assessed by each day running a 
stored aliquot of platelet membranes prepared from platelet concen~rate. 
The total nonspecific and specific binding was determined for a H-IM! 
concentration of 1.0 nM (in duplicate, blocked and unblocked). A day-to-
day coefficient of variation of 20% (n = 17) was observed in this four-
tube quality assessment sample. Full saturation curves of the stored 
aliquots were run every few weeks, and B and K values were 
max d 
calculated .. Coefficients of variation for these measures were 20% and 
18%, respectively, when determined over a period of 2.5 months (n = 4). 
Clinical study 
Mean values of B and K in nonnal control and autistic subjects are 
max d 
shown in Table II, along with related measures. The individual data for 
B and K in the two groups are shown in Figure 1.. The 8 values 
- d -tended to be lower in the autistic group, but the difference was 
significant (p= 0.048) only when B was expressed as fmole/mg of total 
max 
initial platelet protein .. Smaller and insignificant differences were 
observed when B was expressed in the more meaningful units 
max (sites/platelet and fmole/mg isolated protein). As mentioned, the B 
means are elevated relative to most previous reports. 
max 
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Table ! I 
Platelet 3H-IMI binding and related measures in autistic and normal 
subjects (mean ~ SO) 
Measures 
Bmax (fmole/mg isolated 
platelet protein) 
Bmax (fmole/mg total 
platelet protein) 
Bmax (fmo1e/109 
platelets 
Bmax {sites/platelet) 
Kd (nM) 
Platelet count (10 9/ml) in 
platelet-rich plasma (PRP) 
Whole blood platelet 
count (109/ml) 
Total TRP platelet 
protein (mg/109 
platelets) 
Total PRP platelet 
protein (mg) 
Isolated platelet 
protein (mg) 
Serotonin (ng/ml) 
Serotonin (ng/1 o9) 
Autistic subjects 
(n = 1 1) 
1350 2: 568 
616 2: 350 1 
568 2: 275 
342 2: 166 
0.98 2:0.33 
0 . 466 2: 0. 1 70 
0.268 2: 0.085 
0.99::0.39 
5.83 2: 2.43 
2.97 2:1.34 
176 2: 97.1 
681 2: 380 
1. p = 0.048, by two-tailed t-test 
Normal controls 
(n = 1 0) 
1590 2: 650 
973 2: 383 
783 2: 368 
471 2: 222 
0.94 2: 0.42 
0.589 2: 0.109 
0.260 2: 0.053 
0.80+0.16 
5.34 2: 1.40 
3.37 2: 0.96 
123 2: 43.5 
488 
While the membrane preparation method probably accounts for much of the 
elevation, a recently reported seasonal variation may also contribute to 
the increase (Whitaker et al., 1983). The values forK are similar in 
d 
the two groups and are somewhat lower than most prior determinations. No 
significant differences were seen between the groups for the whole blood 
or PRP platelet counts, or for the various protein measures. The expected 
trend to higher 5-HT levels was observed in the autistic group; however i 
the difference was not significant (p = 0.12). 
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0' ,. 
Table I I I 
Correlation cross-table for combined population I 
Variable 2 
Variable I 2 3 4 5 6 7 8 9 10 
I. Bmax(fmole/mg 0. 85 f 0. 78 f 0. 76 * 0. II 0.27 o .so 0.34 0.00 I 0.004 
isolated protein) (0.001 (0.001 (0.001) (0.63) (0. 24) (0. 74) (0. 13) (0 .99) (0.98) 
2. Bmax{fmole/mg total - 0. 89 * 0. 78 t 0. 39 0.22 0.09 0.44 0.05 0.40 
PRP platelet protein) (0.001) (0.001 (0.88) (0. 27) (0. 71) ( 0 . 06) ( 0 . 85) (0. 09) 
3. Bmax ( fmo I e/1 o9 0. 78 * 0. II 0.32 0. 17 0. 19 0.25 0.42 
platelets (0 .00 I) (0 .67) (0 . 19) (0. 50) (0 .43) ( 0 . 31) (0 .07) 
4. Kd (nM) 0.07 0.28 0. 17 0. 18 0.30 0. 15 
(0. 76) (0.23) (0. 48) (0. 43) (0.22) (0.90) 
5. 5-HT (ng/ml) 0. 79 * 0. 38 0. 17 0. 30 0.03 
(0.001) (0.10) (0.47) (0. 22) (0. 90) 
6. 5-HT (ng/10 9 - 0. 19 0. 18 0.03 0. II 
platelets) ( 0 . 41 ) (0 .45) (0 .90) (0 .63) 
7. Platelet count 0.62 * 0.64 t 0.47* 
(whole blood) (0.003) (0.005 (0.04) 
8. Platelet count (PRP) - - 0.07 0.26 
(0. 78) (0. 25) 
9. Total PRP platelet 0. 73 * 
(0.001) 
10. Isolated platelet 
protein 
1. The r values are listed along \·lith p value in parentheses; significant correlations (p<0.05} are 
indicated by an asterisk. 
2. See variable column on left for variable number 
Figure 1. Data presented are mean ~ SEM. Autistic subjects~ n = 11; 
normal subjects, n = 10. B is expressed as fmole/mg of 
max isolated platelet protein. See Table II for additional 
measures of platelet binding and composition in the two 
groups 
Bmax (fmol/mg prot.) K~ !nMJ 
autistic normal autistic normal 
(drug-free) (drug-free) 
2500 2.5 
2000 2.0 
fmol/mg 
• 
nM 
1500 ...... 1.5 
: 
1000 : : • 1.0 ~ ~
• 
500 0.5 
1350~171 1590~06 .96~ 11 .94~42 
Shown in Table III is the correlation cross-table for the measures of 
interest in the combined population. The expressions of B are all 
highly correlated with one another and with K • The signific~~£ positive 
d 
correlation of B with K has been observed previously (Asarch et al ., 
max d 
1980) and might reflect a compensating increase in affinity when fewer 
binding sites are present. Alternatively, it simply may be an artifact of 
Scatchard analyses. The B of K values were not carrel ated with 
max d 
platelet counts, platelet protein, or platelet 5-HT. The lack of a 
correlation of B and K with platelet 5-HT suggests that the state of 
max d 
the IM! binding site does not normally control blood 5-HT levels. Means 
(+ SD) forB (1312 + 375 fmole/mg protein) and K (0.80 + 0.27 nM) in 
- max - d -
a subgroup (n = 3) of autistic subjects with elevated whole blood 5-HT 
(241, 267, and 401 ng/ml) were similar to control values. The absence of 
group differences between normal controls and autistic subjects, the lack 
of a relationship between !MI binding parameters and whole blood 5-HT 
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levels, and the normality of IMI binding in the few hyperserotonemic 
autistic subjects examined all indicate that the site is not altered in 
autism. Hence, the regulation of platelet 5-HT uptake, in addition to 
measures of 5-HT efflux and uptake rates and affinities, appears normal 
in autism. It remains to be determined if some other aspect of platelet 
functioning is responsible for the elevation of whole blood 5-HT in 
autism. 
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ABSTRACT 
A group of 42 autistic individuals and a normal control group matched for 
sex and age were assessed for the presence of a series of primitive 
reflexes: the snout reflex, the sucking reflex, the tactile rooting 
reflex, the visual rooting reflex, the grasp reflex, the palmomental 
reflex, the glabellar tap reflex, and the nuchocephalic reflex. The snout 
reflex and the visual rooting reflex were significantly more cormnon in 
the autistic group. The visual rooting reflex was significantly less 
common in older autistic individuals. 
INTRODUCTION 
Physical and neurological assessments of autistic children have yielded 
an array of neurological findings, including hyperactive tendon reflexes, 
hypotonia, and spasticity (Gubbay, Lobascher, and Kingerlee, 1g7Q). 
So-called minor physical anomalies have also been reported, such as 
low-set ears, partial syndactyly, hypertelorism, high arched palate, 
curving of the fifth finger, and increased distance between the first and 
second toes (Walker, 1977; Campbell, Geller, Small, Petti, and Ferris, 
1978). Individually, none of these symptoms are found in a majority of 
autistic individuals. We have recently conducted extensive neurologic 
evaluations of 42 autistic individuals and were surprised to discover a 
consistently positive snout reflex in most of these patients. We were 
also struck by the difficulty of assessing the snout reflex as the 
subjects often made mouthing of pouting movements just before the reflex 
hammer touched the face. Sometimes a subject bent his/her head toward the 
reflex hammer and touched it with his/her mouth, nose, or forehead, a 
phenomenon suggestive of visual rooting. Based on these findings, we 
reassessed the group for a series of "primitive" reflexes, elicited, 
organized motor patterns which often are seen as normal phenomena in 
newborn infants and disappear in the first months of life but which 
reappear in several pathological conditions and then are interpreted as 
signs of diffuse cortical brain damage (Tweedy et al ., 1982). 
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SUBJECTS 
The parents of 42 of 52 students of a special university-affiliated 
school for autistic individuals gave written consent for the neurologic 
evaluations. Forty of these students satisfied DSM-I I I criteria for the 
diagnosis of infantile autism, full syndrome present (DSM-III, 1980). In 
two cases, the diagnosis was atypical pervasive developmental disorder. 
In five cases, an associated medical condition was present: e.g., 
meningitis in the second year of life, congenital rubella, kernicterus, 
Wa 11 en berg's syndrome, and tuberous sclerosis. Fifteen of the students 
1 ived at home; 27 were enrolled in a residential program. The control 
group was composed of 42 normal individuals, matched for sex and age to 
the autistic population. Data about sex, age, and medication for both 
groups are given in Table I. 
Table J 
Number, Sex, Age, and Medication of Autistic Subjects and Normal Controls 
Autistic 
Control 
METHODS 
N 
of Subjects 
42 
42 
Sex 
M/F 
31/11 
30/12 
A e 
X so Range 
19.5 4.5 8.9-28.9 
19.6 6.2 7.4-29.9 
Medication 
no yes 
15 27 
42 0 
As a part of a thorough neurological assessment, each subject was 
systematically assessed for the presence of a range of so-called 
"primitive" reflexes. These reflexes included the following: the snout 
(elicited by tapping with a reflex hammer and by firm pressure), sucking, 
tactile rooting, visual root-ing, grasp, palmomental, glabellar, and 
nuchocephalic reflexes. 
Details of the elicitation of these reflexes are presented in the, 
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Appendix. 
A11 reflexes in both groups were elicited and rated by the same examiner 
(RBM). 
RESULTS 
Comparative numbers and percentages of the reflexes elicited in the 
autistic subjects and the normal controls are given in Table II. 
Table II 
Number and Percentage of 11 Primitive 11 Reflexes in Autistic Subjects and 
Norma 1 Controls 
Aut i sti cs (N=42) Controls (N=42) 
N percentage N percen:age 
Snout reflex 32 76.2 5 11.9 (p<O. 0001) 
to tapping 
Snout reflex to 10 23.8 2 4.8 (p<0.01) 
manua 1 pressure 
Overall snout reflex 34 81 6 14.3 (p<O .001) 
Visual rooting ref 1 ex 28 66.7 0 0 (p<0.0001) 
to waving hammer 
Vi sua 1 rooting reflex 31 73.8 0 0 (p<o.oool) 
to waving hand 
Overall visual 33 78.6 0 0 (p<0.0001) 
rooting reflex 
Sucking reflex 2.4 0 0 (ns) 
Tactile rooting reflex 2 4.8 0 0 (ns) 
Palmomental reflex 2 4.8 0 0 (ns) 
Grasp reflex 0 0 0 0 (ns) 
Nuchocephal ic reflex 5 11 .9 5 11.9 (ns) 
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Differences between the autistic and the control group were tested with 
2 
the X statistic. Significant differences (p<.Ol or less) were found for 
the snout reflex to tapping, the snout reflex to manual pressure and the 
overall snout reflex, as well as the visual rooting reflex to the hammer, 
the visual rooting reflex to the hand and the overall visual rooting 
reflex. No significant differences were found for the sucking reflex, the 
tactile rooting reflex, the palmomental reflex, the grasp reflex or the 
nuchocephalic reflexes. 
Figure l. Visual rooting reflex to the hand and age (years). 
30 
25 
Age 
[years) 
20 
15 
10 
5 
... 
Present [N-31) Absent (N- J 1) 
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For the autistic group, t-tests were performed by grouping subjects based 
on the presence or absence of the snout reflex to tapping, the snout 
reflex to manual pressure and the visual rooting reflexes using 
chronological age and IQ as dependent measures. Only the age comparison 
for the visual rooting to hand was significant (T • 2.99, df • 40, 
p<.005). The age dependency of the visual rooting reflexes is presented 
in a scattergram in Figure I. Within the autistic group~ no significant 
differences were found between males and females~ or between medicated 
and non-medicated individuals for the snout reflex to tapping or the 
visual rooting reflex to the hand. 
DISCUSSION 
The increased incidence of positive snout reflexes and positive visual 
rooting reflexes in this group of autistic individuals is noteworthy. 
Some difficulty in eliciting these reflexes should be noted. The snout 
reflex!> if present, is most obvious when the subject is relaxed, 
complicating attempts to elicite it in autistic individuals. Problems in 
evaluating this reflex may arise when there is a strong positive rooting 
reflex. Occasionally the patient begins pouting the lips before the 
reflex harruner even touches the face, and sometimes there are such 
prominent kissing-like movements of the lips that it is difficult to tap 
above the upper lip. In these cases, the attention of the subject must be 
diverted, or, as was once the case in this study, the subject must be 
blind-folded. Of the 32 positive reactions to tapping, 12 were associated 
with pouting or protrusion of the mouth. On five occasions there was a 
pursing or puckering movement. And on an additional five occasions there 
was a movement that was considered to be a combination of these two types 
of reactions. In eight cases, there was a short phasic contraction of the 
upper lip. Several times this brief reaction could be observed in 
combination with the longer, more tonic "pout" reaction. 
The snout reflex is known to be a developmental phenomenon. lip 
protrusion is described as a reflex in the nonnal human fetus after 
stimulation of the lip as early as at 14-17 weeks of gestational age 
(Paulson and Gottlieb, 1968). Based on his observations in a group of 
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normal infants, Touwen (1976} described the snout reflex, which he called 
1 i p-tap reflex, as a phenomenon with a very rapid deve 1 opmental course 
that displayed little inter-individual differences. In a group of 51 
normal newborn infants, all showed a tonic protrusion of the lip elicited 
by a brisk tap on the upper or lower lip. In 95% of the infants, this 
protrusion was rated as evident; in 5%, it was evanescent and equivocal. 
The number of subjects evidencing protrusion decreased to 10% when the 
infants were approximately 12 weeks of age. After the age of six months, 
this reaction was not seen except in two cases is which a phasic reaction 
persisted until the age of nine months. 
The incidence of a positive snout reflex in normal youngsters and adults 
is not knOwn. This phenomenon can be observed by electromyography in high 
percentages of normal individuals (Ekbom, Jernelius and Kugelber9, 1952}. 
As a clinical sign and using pressure on the upper lip as a stimulus, 
Jacobs and Gossman (1980) found that the incidence of the reflex was zero 
in the third and fourth decade of life, 12% in the fifth decade and up to 
30% in the ninth decade of life. 
An increased incidence of snout reflexes is described in several clinical 
populations, e.g., demented geriatric patients (Tweedy, Bouchard, Cote, 
and Jus, 1974), patients with severe senile or presenile dementia 
(Paulson and Gottlieb, 1968), and older individuals with 
neuropsychological impairment (Jenkyn, Walsh, Culver and Reeves, 1977}. 
Tweedy et al. (1982} found a significant relationship between the 
occurence of snout reflex and impaired performance on cognitive tests in 
a group of 103 patients referred to a clinic for patients with dementia. 
The visual rooting reflex is clinically very impressive. In our study 
it revealed itself only when the eliciting object attracted the visual 
attention of the autistic individual, provided he was not otherwise 
distracted; on such occasion waving of the hammer or hand from a distance 
of 50 em was enough to elicit the reflex in 5 of our 42 autistic 
subjects. Of the 28 positive rooting reflexes to the waving hammer, six 
subjects exhibited a pouting or pursing of the mouth. In 14 cases, the 
head moved forward as if to touch the object, and in eight cases, a 
combination of these two types of reaction occurred. In contrast to the 
tactile rooting reflex, the visual rooting reflex is not described as a 
developmental phenomenon in infants. 
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Tweedy et al. (1982) described the visual rooting reflex as a sucking 
reflex, elicited by visual stimulation in groups of geriatric patients 
with different types of pathology. If the reflex was positive, the 
patients reacted by opening the mouth in order to seize the object, to 
suck it, or to lick it. Sucking or licking, as part of the reaction, was 
seldom seen in our group of autistic individuals. Jenkyn et al. (1977) 
described the visual rooting reflex as any anticipatory opening of the 
mouth, with or without turning toward the object. In our patients, this 
orienting toward the object became obvious when they were approached- from 
different directions within their visual field .. Paulson and Gottlieb 
(1968}, in their retrospective review of 85 patients with dementia, 
described "patients occasionally pursing the lips or moving forward to 
approach the blade", especially in very deteriorated patients when 
sucking movements also were present.. Unfortunately, no systematic 
assessment of this reflex was done.. The age-dependent nature of the 
visual rooting reflex found in our autistic group suggests that this 
reflex is a developmental phenomenon. 
An intriguing question is whether these phenomena are specifically 
characteristic for autistica11y retarded individuals~ in contrast to 
non-autistic retarded individuals or those with less severe fonns of 
atypical development. The two subjects in our group with atypical 
pervasive develop11ental disorders did not show any of these "primitive" 
reflexes. Correlations between these phenomena and aspects of the symptom 
profiles, e.g., 1 anguage development, IQ sub scores, or behavi ora 1 
phenomena would be of interest. 
The significance of our findings on 11 primitive" reflexes remains to be 
clarified. The neurophysiological basis of these reflexes is not known. 
As developmental symptoms, they are seen as brain stem phenomena that 
disappear with further development of the dendritic arbor and subcortical 
myel i ni zati on in the first months of 1 ife (Ornitz, 1983). The "primitive" 
reflexes may be related to the frequent clinical observation that 
autistic children frequently mouth foreign objects, sometimes leading to 
pica; also, the ease of elicitation of primitive reflexes may be 
associated with the autistic child's continued use or preference for 
proximal sensory receptors (taste, touch) to distal receptors (sight, 
hearing) (Kootz and Cohen, 1981). What may appear as simply mouthing or 
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use of the mouth for sensory input may be a reflection of the engagement 
of reflexes, such as visual rooting .. As pathological reflexes, when they 
fail to disappear, or when they reappear, they are taken as signs of a 
lack of inhibition or disinhibition of brain stem reflexes by "higher'' 
cortical and subcortical centers.. The reflexes, themselves, are all 
integrated in the brain stem and are influenced by cerebra 1 activity, 
without actually requiring such activity .. In this respect, it is 
remarkable that these "oral" reflexes occurred in autistic individuals 
suffering from severe dysfunctions involving speech and language .. Further 
assessment of these primitive reflexes in autistic individuals may 
provide additional insight into the pathophysiology or biological 
correlates of this disorder .. 
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APPENDIX 
Method for elicitation of "primitive11 reflexes. 
1. The snout reflex was elicited by a light tap or touch with the reflex 
hammer beneath the nose on the upper lip or by exerting firm pressure 
with the index finger beneath the nose on the upperlip. Any puckering, 
pursing, protrusion, or pouting of the lips due to contraction of 
upper and lower portions of the orbicularis oris was noted, as were 
contractions of the muscles at the base of the nose. 
2. The sucking reflex was elicited by striking the medial area of the 
upper and lower lip with the index finger. This reflex was judged 
positive if the lips closed around the finger or if sucking of licking 
movements were observed. 
3. The tactile rooting reflex was elicited by striking the corners of the 
mouth and by striking the right and left cheek. Any turning of the 
head and mouth toward the stimulus with or without sucking movements 
was noted. 
4. The visual rooting reflex was elicited by slowly approaching the 
subject•s face with a waving reflex hammer. Any forward movement of 
the head in the direction of the object, as if to touch it, and 
protrusion or opening of the mouth was noted. 
5. The visual rooting reflex was tested by slowly approaching the face 
with a waving, clenched hand. The same reactions as for the waving 
reflex hammer were noted. 
6. The grasp reflex was elicited by stroking the palm of the subject's 
hands with the blade of the reflex hammer. Any flexion of the fingers 
was noted. 
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7. The palmomental reflex was examined by firmly striking the thenar 
eminence of the right and the left hand. This reflex was judged 
positive with any contraction of the ipsilateral mentalis muscle for 
five consecutive times. 
8. The glabellar tap reflex was tested by tapping the glabellar region 
rapidly ten times. The examiner's index finger approached the subject 
from above the forehead outside of the visual field. The normal 
response was inhibition of reflex closure of the eyelids after two to 
three taps with the lids remaining open. The reflex was judged posi-
tive if continuous reflex blinking of either uper or lower lid or both 
occurre'd. 
9. The nuchocephalic reflex was elicited by briskly turning the shoulder 
of the standing subject to the left and to the right. This reflex was 
present if the head did not actively turn in the direction of the 
shoulder movement after an interval of approximately half a second, 
but remained in the original position. 
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SUMMARY 
The relationship between whole blood serotonin (5-HT) and the newly 
observed visual rooting reflex and snout reflex was examined in a group 
of 39 autistic individuals. In the unmedicated group the autistics with a 
visual rooting reflex showed significantly (p = 0.05) higher 5-HT values 
(184~81 pg/ml, N = 13) compared to those without a visual rooting reflex 
(87.4~32.1 ng/ml, N = 3). No difference was found for 5-HT values between 
autistics with a snout reflex (n = 12) and those without a snout refle! 
(N = 4). Further examination of the relationship between these phenomena 
in a greater number of autistic and mentally retarded subjects seems to 
be warranted. 
INTRODUCTION 
Recently the snout reflex and the visual rooting reflex have been found 
to be present in a majority of autistic individuals (Minderaa et al., 
1985a; Minderaa et al., 1985b). These reflexes can be reliably elicited 
and are not correlated with each other in autistic and retarded indi-
viduals (Minderaa et al., 1985b). The visual rooting reflex is correlated 
with aspects of autistic behavior, especially with peculiarities of 
motoric behavior and objects use and is less common in older autistic 
individuals (Minderaa et al ., 1985b). 
These "primitive 11 reflexes occur transitory in the course of normal 
development. The snout reflex is described in normal infants up to the 
age of about 6 months after which the reflex disappeared (Touwen et al ., 
1976). The visual rooting reflex is seen in normal children appearing at 
the age of about 6-8 weeks and disappearing at the age of about 12-18 
months (Minderaa, 1985d; Babkin, 1956). The presence of these reflexes 
in autistic and retarded individuals. fits into a global hypothesis of a 
developmental delay of neuronal brain structures in these subjects. 
Increased values of whole blood serotonin are consistantly found in about 
30% of autistic individuals. Although in normal controls the relationship 
between age and whole blood 5-HT is not totally clear, several groups 
(Ritvo et al., 1971, Anderson et al., 1985a) have reported that whole 
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blood 5-HT levels in children decrease with age. Increased levels of 
whole blood 5-HT might represent a developmental delay in the ontogenesis 
of serotonergic systems. In order to examine the relationship between the 
newly observed primitive reflexes and whole blood 5-HT we have determined 
these behavioral and neurochemical measures in a group of 39 autistic 
individuals. 
METHODS AND RESULTS 
The experimental group was comprised of 39 students (28 males, 11 
females) of a special school for autistic individuals. A diagnosis was 
made by several child psychiatrists and confirmed for this study by 
another child psychiatrist (RM). Thirty-eight of the students satisfied 
DSM-111 criteria for the diagnosis of infantile autism, full syndrome 
present (DSM-III, 1980). In one case the diagnosis was autism, residual 
state. The mean age of the group was 19.2 ~ 5.1 years (range 8.9-28.7). 
Sixteen of the students were drugfree. Twenty-three of the autistic 
subjects used neuroleptic or anticonvulsive medication. 
The snout reflex was elicited by a light tap with the reflex hammer 
beneath the nose on the upperl ip. Any puckering, pursing, protrusion or 
pouting of the lips due to contractions of upper and lower portions of 
the orbicularis oris was noted (Minderaa et al ., 1985a). 
The visual rooting reflex was elicited by slowly approachting the face 
with a waving, clenched hand or with a reflex hammer. Any forward 
movement of the head in the direction of the object, as if to touch it, 
and protrusion or opening of the mouth was noted (Minderaa et al., 
1985a). 
Blood was drawn between 10 AM and ll AM. Whole blood 5-HT was analysed 
using a HPLC-fluorometric method as described elsewhere (Anderson et al ., 
1981, 1985b). Whole blood 5-HT was also measured in a control group 
comprised of 20 highschool students, teachers and hospita 1 employees, 
comparable in sex and age (15 males, 5 females; mean age 22.0 years; age 
range 9.2- 36.1 years). 
In the unmedicated group 12 out of 16 autistic individuals showed a 
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positive snout reflex and 13 out of 16 showed a positive visual rooting 
reflex. In the medicated group these figures were 18 out of 23 and 16 out 
of 23 respectively. 
In the unmedicated autistic group (N = 16) group means of whole blo~d 
5-HT values (mean~ S.D.) were 166 (~ 83.6) ng/ml and 640 (~ 271) ng/10 
plate 1 ets. 
In the medicated autistic group (N = 23) mean whole blood 5-HT values 
9 
were 145 (~ 51.0) ng/ml and 569 (~ 178) ng/10 platelets. 
The mean whole blood 5-HT values of the control group were 116 + 35.0 
ng/ml. The 5-HT values of the unmedicated autistics were significantly 
higher compared to those of the no mal controls, as previously reported 
( Mi nderaa et a 1 • , 1985 c) • No re 1 at i onshi p between b 1 ood 5-HT va 1 ues and 
age was observed in the group studied. 
Table I 
Primitive reflexes and mean 5-HT values in unmedicated autistic subjects 
Subjects 
Autistics 
Visual rooting 
Snout reflex 
Normal controls 
* p<0.05 
** p<0.01 
reflex 
present 
absent 
present 
absent 
N 
13 
3 
12 
4 
Age 
Mean + SD 
17.6 + 4.53 
- ** 25.6 :': 2.90 
18.6 + 4.22 
20.8 :': 8.36 
20 22.0 :': 7.5 
187 
5-HT ng/m I 
184 + 81.0 
* 87.4:<:_32.1 
168 :': 92.1 
161 :': 58.5 
5-HT ng/1 09 
platelets 
699 + 303 
- * 379 :': 95.1 
662 :': 347 
572 :': 86.3 
116 :': 35.0 465 :': 162 
Serotonin values in the groups with and without reflexes were compared 
using a t-test (Table I). In the unmedicated group the autistics with a 
visual rooting reflex showed significantly higher 5-HT values being 
9 
expressed as ng/ml or as ng/10 platelets (p= 0.03 and p= 0.05 
respectively). The mean age (years .:':. SO) of the unmedicated autistics 
without a visual rooting reflex (25.6 .:':. 2.90) was significantly higher 
(p = 0.01) compared to those with a visual rooting reflex (17.6 .:':. 4.53). 
In the unmedicated autistics no difference was found for 5-HT values 
between autistics with snout reflex and autistics without sno-ut reflex. 
In the medicated group no differences were found for any of the 5-HT 
measures between autistics with or without either of the reflexes. 
DISCUSSION 
In the unmedicated autistics the subjects who showed a visual rooting 
reflex did have significantly higher whole blood 5-HT levels than those 
without such a reflex. This does suggest that these phenomena, the 
occurance of a vi sua 1 rooting reflex and hyperserotonemi a in a uti sti cs 
might be related. However, this relationship was not seen in medicated 
subjects. This might have been caused by increased variability of blood 
5-HT values in medicated autistics (Minderaa et al., 1985c). 
No relationship was found between the occurence of a snout reflex and 
whole blood 5-HT levels. This is in agreement with the observed 
di ssoci ati on between the occurence of a snout reflex and the visual 
rooting reflex in autistic and non-autistic retarded individuals 
(Minderaa et al ., 1985b). 
Because of the small numbers in this study, no definite conclusion can be 
drawn. However, it seems interesting to assess further the rel ati onshi p 
between these phenomena in a greater number of autistic and mentally 
retarded subjects. 
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SUMMARY 
Infantile autism is a syndrome defined in terms of behavior, the typical 
symptoms of which exist before the age of thirty months. The most signi-
ficant symptoms are a disturbance in speech- and language development and 
the non-verbal communicative skills, a disorder in the relationship with 
people, objects and events and a disturbance in the reaction on sensory 
stimuli. In general the motor-, socially adaptive and cognitive develop-
ment are seriously retarded, hampered or regressed and the mutual balance 
in the development has been disturbed. There is a serious disturbance of 
the ability of expression, the estimation and appreciation of emotions 
and in the regulation of anxiety and excitement. 
This thesis deals with neurochemical aspects of infantile autism. 
In chapter I the aims of the study are described. The experimental work 
is centered around the finding that group mean whole blood serotonin 
values are increased in autistic populations. 
The study addresses to a number of basic questions in respect of charac-
terization of this 5-HT elevation, and the elucidation of its causes. 
In chapter ll the behavioral and clinical aspects of the syndrome of 
infantile autism are reviewed and genetic and somatic factors that are 
related to the syndrome are outlined. 
In chapter III studies on autistic individuals dealing with the catechol-
amine systems (norepinephrine and dopamine), neuroendocrine systems 
(cortisol, prolactin, growth hormone, luteinizing honnone, follicle-
stimulating hormone and the thyroid hormones, and several hormone-
releasing hormones) and neuropeptide systems are reviewed. 
It is concluded that catecholamine systems in the brain might be involved 
in the syndrome. Indications are the therapeutic effects of medications 
influencing these neurotransmitter systems, increased baseline homo-
vanillic acid values in spinal fluid after probenecid loading, and raised 
norepinephrine levels in plasma. Possibly a subgroup with high spinal 
fluid homovanillic acid concentrations is characterized by a more serious 
degree of stereotypy, repetitive behavior and locomotor activity, and in 
general a more severely disturbed behavior. 
Furthermore, abnormalities have been found in neuroendocrine functioning 
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and in the peptide excretion. The most robust finding of which is an 
increased release of thyroid stimulating hormone after stimulation with 
thyrotropin-releasing hormone. 
In chapter IV studies dealing with the finding of elevated blood 
serotonin levels in autistic subjects are extensively reviewed .. 
"Hyperserotonemia" has been found in approximately 30% of the autistics. 
The serotonin concentration in the blood is stable, if measured over a 
years time in autistic individuals .. The serotonin concentration is 
elevated both when measured absolutely and expressed per blood platelet. 
There exists a negative relation between serotonin level and 
intelligence. The cause of hyperserotonemia in autistics is not known. 
The increase of urinary 5-HIAA excretion seen in hyperserotonemic 
autistic subjects suggest that increased 5-HT gut production might play a 
role in the hyperserotonemia observed. One single interpretation of the 
deviation in the serotonin uptake, storage or release ability of blood 
platelets has not emerged. However, a role of the blood platelet function 
in the explanation of hyperserotonemia is certainly worth considering~ So 
far, no indications have been found for decreased degradation of 
serotonin by monoamine oxidase~ 
The appendix is comprised of papers based on original experimental work 
related to hyperserotonemia in infantile autism. 
In appendix I who 1 e blood serotonin (5-HT) and tryptophan (TRP) were 
measured in 87 nonnal children and young adults, and in 40 autistic 
subjects, (DSM-Ill criteria) having a similar age distribution. Whole 
blood 5-HT was significantly elevated in the drug-free (N=2l) autistic 
group (205.:':_16 ng/ml) compared to normal subjects (135._:':.54 ng/ml). 
Serotonin values were Gaussianly distributed in both the nonnal and 
autistic groups. When the 95th percentile of the normal group was used to 
define hyperserotonemia, 38% of the autistic subjects could be tenned 
hyperserotonemic. Autistic subjects on anti convul sants and neuroleptics 
had significantly lower 5-HT levels than drug-free autistic subjects. 
The elevated group mean for whole blood 5-HT seen in autism cannot be 
explained by group differences in age, sex, platelet counts or tryptophan 
levels. 
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In appendix II whole blood serotonin levels, tryptophan levels and 
platelet counts were determined in a large group of unmedicated autistic 
subjects (N=17) and compared to an age- and sex-matched control group 
(N=20). The effects of neuroleptic and anticonvulsant medication were 
examined by measuring the species in a group of medicated autistics 
(N=23). The temporal stability of the measures was examined by making 
repeated determinations in a smaller group of medicated (N=16) and 
drugfree (N=10) autistic subjects. 
Whole blood 5-HT was significantly increased in the drugfree autistic 
group compared to the normal controls, however TRP values and platelet 
counts were similar in unmedicated autistics and normal subjects. No 
significant differences of 5-HT values were seen between medicated and 
unmedicated groups of autistic individuals. TRP concentrations were 
significantly lower in the medicated group compared to unmedicated 
autistics and a significant negative correlation was found between dose 
of neuroleptic medication and TRP values. 
Highly significant intraclass correlation coefficients and low mean 
percent differences were found for the repeated measures of 5-HT and the 
platelet count in the unmedicated group. In contrast~ autistic subjects 
on fixed doses of neuroleptics or anticonvulsants and autistics for whom 
drug treatment was initiated or increased during the study exhibited 
significantly greater variability in 5-HT levels and platelet counts. TRP 
values were highly variable over time in both the medicated and drugfree 
autistic groups. 
In appendix Ill urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion in 
two consecutive collection periods (5 PM - ll PM and ll PM - 8 AM) and 
whole blood serotonin (5-HT) and tryptophan (TRP) were measured in groups 
of unmedicated autistics (N = 16), medicated autistics (N = 20) and 
normal controls (N = 27). Whole blood 5-HT values were significantly 
higher in unmedicated autistics compared to normal controls. No 
significant differences were found in 5-HIAA excretion (~g/mg creatinine, 
mean .:':. SO) between unmedicated autistics (4.07 .:':. 1.52) and nonnal 
controls (3.50 .:':. 1.07), nor between medicated (5.35 .:':. 2.93) and drugfree 
autistic individuals. 
No correlations were found between 5-HT values and urinary 5-HIAA 
excretion. Urinary 5-HIAA (~g/mg creatinine, mean.:':. SO) was significantly 
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greater in hyperserotonemic autistic subjects (4.88 .:':_ 0.87) compared to 
normal controls (3.50 .:':_ 1.07, total collection period, p = 0.002). A 
slight trend (p = 0.10) to higher overnight (11 PM - 8 AM) 5-HIAA 
excretion (f.lg/mg creatinine, mean !_ SO) was observed for unmedicated 
hyperserotonemic autistic subjects (5.12 .:':_ 1.06) when compared to 
unmedicated autistics with normal whole blood 5-HT levels (3.86 .:':_ 1.78). 
In the medicated autistic group significantly higher overnight and total 
excretion of 5-HIAA was observed in subjects with elevated whole blood 
levels. The relevance of these findings to the possibility that increased 
gut production of 5-HT might cause the elevated whole blood 5-HT levels 
seen in autism is discussed. 
3 
In appendix IV parameters of H-imipramine (IMI) binding were measured in 
11 drug-free autistic subjects and 10 normal volunteers. 
Similar means (+SO) forB (autistics, 1350 + 171 fmole/mg protein; 
- max -
normals 1590 + 206 fmole/mg protein) and K (autistics, 0.98 + 0.10 nM; 
- d -
normals 0.94 ~ 0.13 nM) were found in the two groups. The normal number 
(B ) and affinitity (K ) of the IMI binding site in autistic subjects 
max d 
suggest that the regulation of 5-HT uptake is not different in autism. 
In appendix V a group of 42 autistic individuals and a normal control 
group matched for sex and age were assessed for the presence of a series 
of primitive reflexes: the snout reflex, the sucking reflex, the tactile 
rooting reflex, the visual rooting reflex, the grasp reflex, the 
palmomental reflex, the glabellar tap reflex, and the nuchocephalic 
reflex. The snout reflex and the visual rooting reflex were significantly 
more corrunon in the autistic group. The visual rooting reflex was 
significantly less common in older autistic individuals. 
In appendix VI the relationship between whole blood serotonin (5-HT) and 
the newly observed visual rooting reflex and snout reflex was examined in 
a group of 39 autistic individuals. In the unmedicated group the 
autistics with a visual rooting reflex (N = 13) showed significantly 
higher 5-HT values (p <';0.5) compared to those without a visual rooting 
reflex (N = 3). No difference was found for 5-HT values between autistics 
with a snout reflex (N = 12) and those without a snout reflex (N = 4). 
Further examination of the relationship between these phenomena in a 
greater number of autistic and mentally retarded subjects seems to be 
warranted. 
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SAMENVATTING 
Kinderlijk autisme is een syndroom dat wordt beschreven in termen van 
gedrag. De kenmerkende symptomen zijn aanwezig v66r de leeftijd van 
dertig maanden. De symptomen zijn een stoornis in de ontwikkeling van 
spraak en taa 1 en van de nonverba 1 e communi cati eve vaardi gheden, een 
stoornis in de relatie met mensen, dingen en gebeurtenissen en een 
stoornis in de reactie op sensore prikkels. In het algemeen zijn de 
motore- sociaal- adaptieve en cognitieve ontwikkeling ernstig vertr~agd, 
gestagneerd of geregredieerd en de onderlinge balans in de ontwikkeling 
ervan verstoord. Er is een ernstige stoornis in het vermogen zich uit te 
drukken, in de taxering en waardering van emoties en in de regulatie van 
angst en opwinding. 
Oit proefschrift handelt over neurochemische aspecten van kinderl ijk 
autisme. 
In hoofdstuk I worden de doelstellingen van het onderzoek beschreven. Het 
experimentele onderzoek richt zich op de bevinding dat het gemiddelde 
serotonine gehalte in het bleed van autisten is verhoogd. Het onderzoek 
levert een bijdrage aan de beantwoording van een aantal basale vragen 
betreffende kenmerken van deze serotonineverhoging in het bloed en 
betreffende de opheldering van de oorzaken ervan. 
In hoofdstuk II worden kl i ni sche en gedragsaspecten van het syndroom 
kinderlijk autisme beschreven en een overzicht gegeven van genetische en 
somatische factoren die er mee in verband staan. 
In hoofdstuk Ill wordt een overzicht gegeven van het onderzoek gericht op 
neurochemische aspecten van het syndroom en wel die betreffende de 
catecholamine systemen (noradrena 1 i ne en dopamine)~ neuroendocri ene 
systemen (cortisol~ prolactine~ groeihormoon, luteinizerend hormoon~ 
follikelstimulerend hormoon en de schildklierhormonen~ en verscheidene 
hormoon-releasing hormonen) en neuropeptide systemen. 
Geconcludeerd kan worden dat dysfuncties in catecholamine systemen in de 
hersenen wellicht bij het syndroom zijn betrokken. Aanwijzingen hiervoor 
zijn de therapeutische effecten van medicaties die deze neurotransmitter 
systemen beinv1 oeden ~ verhoogde basal e homovanill i nezuurwaarden in de 
liquor na belasting met probenecid, en verhoogde noradrenalinewaarden in 
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plasma .. Mogelijk bestaat er een subgroup van autisten waarbij verhoogde 
homovanillinezuurwaarden in de liquor gepaard gaan met versterkt 
stereotiep en repetitief gedrag en verhoogde motore activiteit. Deze 
groep is in het algemeen ernstiger gedragsmatig gestoord .. 
Voorts zijn afwijkingen gevonden in functioneren van neuroendocriene 
systemen en in de uitscheiding van neuropeptiden. De meest duidelijke 
bevinding is een verhoogde toename van schildklierstimulerend hormoon na 
stimulatie met thyrotropine-releasing hormoon .. 
In hoofdstuk IV wordt een overzicht gegeven van de studies die gericht 
zijn op de bevinding van verhoogde serotoninewaarden in het bloed van 
aut i sten.. "Hyperserotonemie" wordt gevonden bij ongeveer 30% van de 
autisten .. Het serotoninegehalte in het bloed van autisten is stabiel 
gemeten over de periode van een jaar .. Het serotoninegehalte is verhoogd 
als het wordt uitgedrukt in absolute maat, maar oak indien berekend per 
bloedplaatje. Er is een negatief verband tussen serotoninegehalte in het 
bloed en intelligentie .. De oorzaak van hyperserotonemie bij autisten is 
onbekend. De verhoogde uitscheiding van 5-hydroxyindolazijnzuur (5-HIAZ) 
in de urine in de hyperserotoneme autisten, doet vermoeden dat een 
verhoogde produktie van serotonine in de darm wellicht een rol speelt als 
oorzaak van hyperserotonemie. Ouidelijk te interpreteren afwijkingen van 
de bloedplaatjes in het vermogen tot opnemen, opslaan en vrijmaken van 
serotonine zijn niet gevonden. Echter het is zeker zinvol de rol van het 
functioneren van bloedplaatjes voor een verklaring van de hyperseroto-
nemie verder te onderzoeken. Er zijn geen aanwijzingen gevonden dat de 
afbraak van serotonine door monoamine oxidase afwijkend is. 
De appendix bestaat uit artikelen gebaseerd op experimenteel werk .. De 
artikelen zijn gericht op het probleem van de hyperserotonemie van 
autisten. 
In appendix I werd het gehalte van serotonine (5-HT) en tryptofaan (TRP) 
gemeten bij 87 kinderen en jongvolwassenen, en bij 40 autisten (DSM-!II 
criteria) met een zelfde leeftijdsverdeling. Het serotoninegehalte in het 
bloed was verhoogd in de ongemediceerde (N = 21) autisten (205 .:!: 16 
ng/ml) vergeleken met de controlegroep (135.:!: 54 ng/ml). 
De serotoninewaarden waren zowel in de controle- als in de autistengroep 
normaal verdeeld (Gausse kromme). Indien de 95e percentiel van de 
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controlegroep werd gebruikt om 11 hyperserotonemie" te definH~ren, dan 
b1eek bij 38% van de autisten het serotoninegeha1te verhoogd. 
Autisten met anti-epi1eptica en neuro1eptica a1s medicatie hadden 
si gni fi cant 1 agere serotoni newaarden dan de ongemedi ceerde aut i sten .. De 
verhoging van het gemidde1de serotoninegeha1te van de groep autisten kan 
niet verklaard worden door verschillen in leeftijd, sexe en aantal bloed-
p1aatjes in het b1oed of tryptofaangeha1te in het b1oed. 
In appendix II werden serotoni ne- en tryptofaangehal te, en hoeveel hei d 
b1oedp1aatjes bepaa1d in het b1oed van een grate groep ongemediceerde 
autisten (N = 17) en vergeleken met een in 1eeftijd en sexe overeen-
komende contro1egroep (N = 2D). De effecten van neuro1eptica en anti-
epileptica werden onderzocht door de genoemde variabelen te meten in een 
groep gemediceerde autisten (N = 23). De stabiliteit over de tijd van 
deze variabelen werd onderzocht door herhaalde metingen in een groep van 
gemediceerde (N = 16) en ongemediceerde (N = 1D) autisten. 
Het serotoninegehalte- in het bloed van de ongemediceerde autisten was 
verhoogd verge1eken met dat van de contro1egroep. Echter het tryptofaan-
geha lte en het aanta 1 b 1 oedp1 aatjes in het b 1 oed van ongemedi ceerde 
autisten was niet verschillend van dat van de controlegroep .. Er werden 
geen significante verschi11en gevonden in serotoninegehalte tussen 
gemed i ceerde en ongemed i ceerde a uti sten. Het tryptofaangeha 1 te in het 
bloed was significant lager in de gemediceerde autisten vergeleken met de 
ongemediceerde autisten en er werd een significante negatieve correlatie 
gevonden tussen tryptofaangehalte en de hoogte van de dosis van de neuro-
1eptica. 
Voor de herhaa1de metingen van 5-HT en het aanta1 b1oedp1aatjes werden 
significant hoge intraclass correlaties en een 1aag gemiddeld verschil-
percentage in de ongemediceerde groep gevonden .. De autisten met een vaste 
dosis medicatie met neuroleptica en anti-epi1eptica en die autisten die 
met deze medicatie startten of bij wie deze werd verhoogd gedurende het 
onderzoek, vertoonden een grate mate van variabil iteit in het 5-HT 
geha1te en het aanta1 b1oedp1aatjes in het b1oed. Tryptofaanwaarden in 
het bleed waren zeer variabel over de tijd, zowel in de ongemediceerde 
als in de gemediceerde groep autisten .. 
In appendix III werden de 5-hydroxyindo1azijnzuur (5-HIAZ) uitscheiding 
in de urine in twee aaneensluitende verzamelperiodes (17 uur- 23 uur en 
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van 23 uur tot 8 uur) en het serotonine- en het tryptofaangehalte in het 
bloed gemeten in groepen ongemediceerde (N = 16) en gemediceerde autisten 
(N = 20), en in een controlegroep (N = 27). De serotoninewaarden in het 
bloed waren significant hager in de ongemediceerde groep autisten 
vergel eken met de contra 1 egroep. Er werd geen si gni fi cant verschil 
gevonden in 5-H!AZ uitscheiding (~g/mg creatinine, gemiddelde .::_ SD) 
tussen ongemediceerde autisten (4.07 .::_ 1.52) en controles (3.50 .::_ 1.07), 
noch tussen gemediceerde (5.35 .::_ 2.93) en ongemediceerde autisten. 
Er bestond geen correlatie tussen 5-HT waarden in het bloed en de 5-H!AZ 
uitscheiding in de urine. De uitscheiding van 5-H!AZ (~g/mg creatinine, 
gemidde l de .::_ SD) was significant hoger bij de hyperserotoneme a uti sten 
(4.88 .::_ 0.87) dan bij de controles (3.50 .::_ 1.07, gecombineerde verzamel-
periode, p = 0.002). Een tendens (p = 0.10) tot hogere 5-H!AZ uitschei-
ding (~g/mg creatinine, gemiddelde .::_ SD) gedurende de nacht werd gevonden 
bij de ongemediceerde hyperserotoneme autisten (5.12 .::_ 1.06) indien 
vergeleken met de ongemediceerde autisten met norffiale 5-HT waarden in het 
bloed (3.86 .::_ 1.78). In de groep van gemediceerde autisten werd een sig-
nificant hogere 5-HIAZ uitscheiding waargenomen gedurende de nacht en de 
total e verzamel peri ode bij de a uti sten met de hoge 5-HT waarden in het 
bleed. Het belang van deze bevindingen ten aanzien van de mogel ijkheid 
dat een verhoogde produktie van serotonine in de darm de oorzaak is van 
de verhoogde serotoninewaarde in het bloed bij3autisten wordt besproken. 
In appendix IV werden parameters gemeten van H-imipramine (IMI) binding 
in 11 ongemediceerde autisten en 10 controle-vrijwilligers. 
De gemiddelde (+ SD) waarden voor de B (autisten, 1350 + 171 fmole/mg 
- mqx -
eiwit; controles 1590 + 206 fmole/mg e1Wit) en de K (autisten, 0.98 + 
- d -
1.10 nM; controles 0.94 .::_ 0.13 nM) waren niet verschillend in de twee 
onderzochte groepen. Oeze bevindingen duiden erop dat de regulatie van de 
opname van serotonine door bloedplaatjes niet afwijkend is bij autisten. 
In appendix V werd een groep van 42 a uti sten en een in sexe en leeftijd 
overeenkomende controlegroep onderzocht op de aanwezigheid van een serie 
"primitieve reflexen": de snoutreflex, de zuigreflex, de tactiele rooting 
reflex, de visuele rooting reflex, de grijpreflex, de palmomentaal 
reflex, de glabella tap reflex en de nuchocephaa l reflex. De snoutrefl ex 
en de visuele rooting reflex kwamen significant vaker voor bij de 
autisten dan bij de controles. De visuele rooting reflex kwam minder vaak 
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voor bij de oudere dan bij de jongere autisten. 
In appendix VI werd onderzoek gedaan naar de relatie tussen de serotonine 
waarden in het bloed en de aanwezigheid van de visuele rooting reflex en 
de snoutreflex. In de ongemediceerde groep hadden de autisten met een 
visuele rooting reflex (N = 13) significant hogere serotoninewaarden 
(p <; 0.5) dan die zonder visuele rooting reflex (N = 3). Er werd geen 
verschil in serotoninegehalte gevonden tussen de autisten met (N = 12) en 
die zonder snoutreflex (N = 4). Verder onderzoek naar de relatie tussen 
deze fenomenen bij een grater aantal autisten en mentaal geretardeerde 
kinderen 1ijkt zinvol. 
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ABBREVIATIONS 
ACTH 
ADP 
ATP 
cAMP 
COMT 
CRF 
CSF 
DBH 
DNA 
ENS 
FSH 
GRF 
GTP 
5-HIAA 
HPLC 
5-HT 
5-HTP 
HVA 
L-5-HTP 
LC 
LH 
LH-RH 
MAO 
MHPG 
aMSH 
NAO 
NE 
NMR 
PIF 
PRF 
PRL 
PRP 
SR!F 
T3 
~~ 
TRH 
TRP 
TSH 
UTP 
VIP 
VMA 
Adreno corticotropic hormone 
Adenosine diphosphate 
Adenosine triphosphate 
cyclic Adenosine monophosphate 
Catechol-0-methyltransferase 
Corticotropin-releasing factor 
Cerebro Spinal Fluid 
Dopamine beta-hydroxylase 
Desoxyribonucleinic acid 
Enteric nervous system 
Follicle stimulating hormone 
Growth hormone-releasing factor 
Guanosine triphosphate 
5-Hydroxyindoleacetic acid 
High performance liquid chromatography 
5-Hydroxy tryptamine 
5-Hyd roxy tryptophan 
Homovanillic acid 
L-5-hydroxytryptophan 
Locus coeruleus 
Luteinizing hormone 
Luteinizing hormone-releasing hormone 
Monoamine oxidase 
3-Methoxy-4-hydroxy phenylglycol 
Alpha melatonin stimulating hormone 
Nicotinamide adenine dinucleotide 
Norepinephrine 
high resolution nuclear magnetic resonance spectoscopy 
Prolactin inhibiting factor 
Prolactin releasing factor 
Prolactin 
Platelet rich plasma 
Somatotropin releasing factor 
3~5,3•-Triiodothyronine 
Thyroxine 
Thyroid hormone 
Thyrotropin-releasing hormone 
Tryptophan 
Thyroid stimulating hormone 
Uridine triphosphate 
Vasoactive intestinal peptide 
Vanillyl mandelic acid 
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